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List of frequently used abbreviations
a1-ACT a 1-antichymotrypsin
a2M a2-macroglobulin
AA inflammation-associated amyloid A
Aß amyloid beta
AD Alzheimer's disease
ADAM a disintegrin and metalloprotease
APP amyloid precursor protein
APPswe amyloid precursor protein w ith the Swedish mutation
Aph-1 anterior pharynx defective 1
apoE apolipoprotein E
BACE1 beta-site APP cleavage enzyme
BBB blood brain barrier
CAA cerebral amyloid angiopathy
CD circular dichroism
CdS-Hep N-acetyl-de-O-sulfated (completely desulfated) heparin
CLAC collagenous Alzheimer amyloid plaque component
CR1 complement receptor 1
CS chondroitin sulfate
DAß1-40 amyloid ß containing the Dutch mutation
DeN-Hep de-N-sulfated heparin
DxS dextran sulfate
EM electron microscope
Enox enoxaparin
GAG glycosaminoglycan
HBP human brain pericyte
HCHWA(-D) hereditary cerebral haemorrhage w ith  amyloidosis (of the Dutch type)
HS heparan sulfate
HSPG heparan sulfate proteoglycan
ICAM-1 intercellular adhesion molecule 1
IDE insulin-degrading enzyme
IEM immuno-electron microscopy
LRP lipoprotein receptor-related protein
Nct nicastrin
NEP neprilysin
NFT neurofibrillary tangle
NT non-transgenic
PBS phosphate buffered saline
PS1 presenilin-1
PS1dE9 presenilin-1 w ith a deletion in exon 9
PS2 presenilin-2
Pen-2 presenilin enhancer 2
PG proteoglycan
RAGE receptor for advanced glycation end products
SAP serum amyloid P
sHsp small heat shock protein
9
SP senile plaque
Tg transgenic
TGF-ß1 transforming growth factor-ß1
TgSwDI transgenic mouse model expressing the amyloid precursor protein
w ith the Swedish, Dutch and Iowa mutation 
WT w ildtype
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1Chapter 1
General Introduction
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1Alzheim er's disease
With increasing medical knowledge, life expectancy has greatly increased in the past de­
cades. Therefore, age-related diseases such as Alzheimer's disease (AD) have also become 
more prevalent. It is estimated that in 2050 more than 100 million people w ill suffer from 
AD world-wide, a disease that is clinically characterized by a global loss o f cognitive func­
tions such as memory and language and symptoms such as apathy and depression [209]. 
The very first recognized AD patient, a woman suffering from severe memory failure and 
disorientation, was described by Alois Alzheimer in 1907 [209, 302]. Upon examination of 
her brain, Alzheimer noticed atrophy o f brain cells combined w ith  "clumps o f filaments 
between cells". These clumps are now known to consist o f amyloid ß (Aß). Besides Aß, 
hyperphosphorylated tau protein also accumulates as neurofibrillary tangles (NFT), but 
unlike Aß, which accumulates in the brain parenchyma as senile plaques (SP) or in the 
vasculature as cerebral amyloid angiopathy (CAA), tau accumulates intracellularly.
The most im portant risk factor for AD is age, w ith  sporadic AD cases representing 
>99% o f total AD cases. However, there are other risk factors, such as possession o f the £4 
allele o f apolipoprotein E (apoE). ApoE is a lipoprotein that can exist in several different 
isoforms (i.e. apoE2, apoE3, apoE4). In the general population apoE3 is most common 
[126], but about 65% o f sporadic AD patients carry at least one apoE4 allele [50]. Indeed, 
it has been found that about 50% o f individuals carrying one £4 allele and over 90% of 
individuals carrying tw o alleles were affected by AD, w ith a mean age o f disease onset 
about 10 to 15 years earlier than that o f non-carriers [51]. It is thought that the increased 
risk associated w ith apoE4 is mediated by less efficient binding to Aß [245] or a diminished 
production o f this specific isoform [30]. This, in turn, may reduce clearance o f Aß, as apoE 
is involved in Aß transport across the blood brain barrier (BBB). In contrast, possession of 
the £2 allele seems to be protective, as it is capable o f lowering the risk for AD four-fold 
[50]. However, the £2 allele does seem to be related to an increased risk for CAA-related 
hemorrhages [176]. Besides apoE, several other proteins have recently also been linked to 
an increased risk for AD, i.e. clusterin (CLU), phosphatidylinositol-binding clathrin assem­
bly protein (PICALM) and complement receptor 1 (CR1) [93, 141].
A commonly accepted mechanism that may explain the etiology o f AD is the 
amyloid cascade hypothesis [149]. It suggests that abnormal production and/or clearance 
o f Aß and subsequent fibrillization o f Aß is responsible for AD development. This hypothe­
sis has received much attention in the past decades, based on the fact that Aß deposition 
is such a characteristic part o f AD pathology.
A m ylo id  cascade hypothesis
Production o f Aß
The Aß peptide is a 4 kDa cleavage product o f the amyloid precursor protein (APP), a 
transmembrane protein that can be cleaved into several different products [81, 165, 208] 
(Fig. 1A). In neurons, APP is present in synapses [205], where it may be involved in synapse 
formation and synaptic transmission [186]. Several other functions o f APP have been sug­
gested, including a role in cell-cell interaction, although the exact function o f APP and its 
cleavage products remains elusive [165, 209, 211].
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1Figure 1: Amyloid precursor protein (APP) processing involves proteolytic cleavage by several 
secretases (A). The non-amyloidogenicpathway is initiated by a-secretase cleavage, which oc­
curs in the middle o f the amyloid ß (Aß) sequence (red), and results in the release o f several 
soluble APP fragments. The amyloidogenic pathway releases Aß peptides through cleavage 
by a- and ß-secretases. (B) Part o f the APP amino-acid sequence; mutations associated with 
early-onset Alzheimer's disease have been highlighted. Most mutations are clustered in the 
close vicinity o f secretase-cleavage sites, thereby influencing APP processing, and are named 
after the nationality or location o f the first family in which that specific mutation was demon­
strated. The Aß sequence is indicated in red. Reprinted with permission from Macmillan Publis­
hers Ltd:[Nature Reviews Drug Discovery][247], copyright (2006)
Cleavage o f APP is performed by three proteolytic enzymes: a-, ß- and Y-secretase 
(reviewed in [44]). Most a-secretases are members o f the ADAM (a disintegrin and metal- 
loprotease) family o f proteases and o f this family, ADAM 9, 10, 17 and 19 are known to 
have a-secretase activity [8, 236]. BACE1 (beta-site APP cleavage enzyme) is considered 
the main ß-secretase, while Y-secretase operates as a complex o f four different proteins: a 
presenilin (PS), nicastrin (Nct), anterior pharynx defective 1 (Aph-1) and presenilin enhan­
cer 2 (Pen-2). Presenilin, either presenilin-1 or -2, forms the protease part o f this secretase, 
w ith the other three proteins acting as co-factors, stabilizing presenilin and modifying its 
enzymatic activity [234].
Cleavage by a- and ß-secretase releases tw o soluble extracellular APP fragments, 
sAPPa and sAPPß, respectively. The remaining membrane-embedded fragments, C83 and 
C99 respectively, can subsequently be cleaved by Y-secretase to release p3 from C83 and
13
1Aß from C99. Aß can generally vary in length between 38 and 43 amino acids long, but 
the main Aß species generated are Aß40 and Aß42. Normally, Aß40 makes up 90% o f all 
produced Aß and Aß42 only 10%. However, in both sporadic and familial AD, brain levels 
o f Aß42 are elevated, altering the ratio between Aß40 and Aß42. It is thought that this 
increase in Aß42 leads to deposition o f Aß, as Aß42 is particularly prone to aggregation 
[114]. In patients suffering from familial AD, the cause o f increased production o f Aß42 is 
the presence o f one or more mutations in an AD-related gene, while in sporadic AD cases 
it is believed that impaired removal o f Aß from the brain causes Aß levels to increase.
Familial mutations
Gene mutations in familial cases o f AD explain only a m inority o f AD cases (<1%). Most of 
these are linked to missense mutations in the presenilins that are part o f the Y-secretase 
complex, w ith mutations in PS1 being more frequent than in PS2 [208]. Mutations in 
Y-secretase are known to result in a (partial) loss o f its proteolytic function [19]. As the 
cleavage site for Aß42 seems less affected than the cleavage site for Aß40, this leads to a 
prevalent production o f Aß42 and therefore a (relative) increase in Aß42 levels in familial 
AD cases.
There are also a number o f known APP mutations (Fig. 1B), all named after the 
area in which they were first identified [247]. Mutations near ß-secretase cleavage sites re­
sult in increased production o f both Aß40 and Aß42, while the preferential generation of 
Aß42 seems to occur as a result o f mutations near Y-secretase cleavage sites. Furthermore, 
mutations w ithin the Aß sequence (i.e. Flemish A692G, Dutch E693Q or Iowa D694N) can 
accelerate the aggregation o f Aß into oligomers and ultimately fibrils [81]. Mutations may 
also direct the accumulation o f Aß into specific types o f Aß deposit (i.e. SP or CAA). For 
example, patients carrying APP w ith the Dutch mutation (Glu22Gln amino acid substitu­
tion) specifically develop CAA accompanied by hemorrhages and suffer from a condition 
called hereditary cerebral hemorrhage w ith amyloidosis o f the Dutch type (HCHWA-D) 
[251].
Clearance o f Aß
In healthy individuals, Aß is generally cleared in two different ways, either by proteolytic 
degradation or by transport across the BBB [210, 270, 303]. There are several proteases 
involved in the normal degradation o f Aß, including endothelin converting enzyme (ECE), 
insulin-degrading enzyme (IDE) and neprilysin (NEP), w ith the latter two having received 
most attention [270]. IDE is a th iol metalloendopeptidase o f about 110 kDa that can de­
grade a number o f proteins such as insulin, glucagon and monomeric, but not oligomeric, 
extracellular Aß [188, 210, 261]. The Aß-degrading capacity o f NEP, another metalloen­
dopeptidase, was revealed when inhibition o f this protease suppressed the degradation 
o f intracerebrally injected Aß in rats [109]. Unlike IDE, NEP can degrade both monomeric 
and oligomeric Aß species [120]. With age and in AD, the levels o f IDE and NEP decrease, 
specifically in brain areas that are most vulnerable to Aß pathology (i.e. cortex and hip­
pocampus) [36, 297].
Transport o f Aß across the BBB is mediated by two receptors, the lipoprotein 
receptor-related protein (LRP) and the receptor for advanced glycation end products 
(RAGE). Aß, either alone or complexed w ith  apoE or a2-macroglobulin can be transported 
out o f the brain by LRP [60, 216], while RAGE is considered an influx receptor [59]. In AD, 
the expression o f LRP, but not RAGE, diminishes, perhaps explaining in part the observed
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1increase in brain Aß levels [60, 216, 296]. In contrast, we have previously demonstrated an 
Aß-induced increase o f LRP-1 in cerebrovascular cells [283], which may be a (temporary) 
compensatory mechanism to enhance Aß clearance.
Aggregation and toxicity
When Aß levels increase in the brain, Aß starts to aggregate. To this end, its conformation 
switches from an a-helix to a ß-sheet [23]. Monomeric Aß can assemble into oligomers 
(dimer, trimers, and larger aggregates), protofibrils (4-11 nm in diameter and <200 nm in 
length) and mature fibrils (6-10 nm in diameter, indeterminate length) [81, 128], ultima­
tely form ing the Aß deposits visible in AD brain (Fig. 2). Furthermore, accumulation can 
also occur intracellularly [138].
—
A|i Oligoflners Protofibrils Fibril*
Figure 2: Amyloid ß (Aß) can exist in multiple assembly states —  monomers, oligomers, proto­
fibrils and fibrils. In its monomeric state, Aß does not appear to be neurotoxic. By contrast, o li­
gomeric and protofibrillar species are considered potent blockers o f long-term potentiation, a 
form o f synaptic plasticity. Reprinted with permission from Macmillan Publishers Ltd: [Nature 
Reviews Neuroscience] [138], copyright (2007).
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1It has long been thought that Aß fibrils are the toxic species in AD, but it is now 
known there is little  correlation between dementia and fibrillar amyloid deposits. Indeed, 
there is much more evidence that oligomeric and protofibril species o f Aß are toxic [128, 
168]. This toxicity is in part thought to be mediated by Aß-induced inflammation and/or 
oxidative stress [18, 209]. Furthermore, (oligomeric) Aß species are considered synapto- 
toxic, as they can, for example, reduce long-term potentiation (LTP) (reviewed in [238]). 
Ultimately, Aß-induced toxicity results in the substantial loss o f neurons seen in AD.
In flam m ation  and Aß-associated pro te ins
Aß deposition in AD is accompanied by neuroinflammation, as it activates and attracts 
microglial cells, the innate immune cells o f the brain. Furthermore, astrocytes also be­
come activated and are surrounding Aß deposits (reviewed in [4]). Both these glial cells 
have pro- and anti-inflammatory activities and can therefore enhance brain damage but 
also protect the brain from (Aß-induced) toxicity [207]. In their pro-inflammatory state, 
glial cells release numerous inflammatory factors, including cytokines and complement 
factors [4], that contribute to neurodegeneration. However, glial cells have also been de­
monstrated to phagocytose Aß and in this way may have a protective function against 
Aß-induced toxicity [274].
The inflammatory factors excreted by glial cells, such as complement factors, can 
be found co-deposited w ith Aß [72, 73, 264] and other inflammatory proteins, such as 
acute phase proteins [72, 264] and intercellular adhesion molecule 1 (ICAM-1) [267], are 
also found near or w ithin Aß deposits. In fact, many proteins co-deposit w ith  Aß and some 
o f them, including heparan sulfate proteoglycans [254, 255] and small heat shock proteins 
[280, 284], have been proven to bind Aß w ith high affinity and influence Aß aggregation 
in vitro.
Heparan sulfate proteoglycans (HSPG)
HSPG are part o f a family o f proteoglycans that also include chondroitin sulfate, keratan 
sulfate and dermatan sulfate proteoglycans [91, 256]. In general, proteoglycans consist of 
a glycosaminoglycan (GAG) chain attached to a protein core via a specific serine residue. 
The GAG chains are long sulfated polysaccharide chains synthesized in the Golgi appa­
ratus. The repeating disaccharide units that make up the GAG chains are unique for each 
proteoglycan family member. For HSPG, the disaccharide unit consists o f N-acetylglucosa- 
mine w ith a uronic acid. The type o f uronic acid depends on the enzymatic modifications 
o f the chain that occur during the synthesis process. Various Golgi enzymes modify GAG 
chains to contain highly sulfated regions w ith iduronic acid and relatively unmodified re­
gions w ith  glucuronic acid [22, 256].
There are several different HSPG, each characterized by a different core protein. 
In general, HSPG can divided into two groups: extracellular matrix-associated HSPG, in­
cluding perlecan, agrin [108] and collagen XVIII [88] and various cell surface HSPG, like 
the glypicans and syndecans [22]. The different HSPG have numerous functions, although 
most are involved in developmental processes. For example, functions o f perlecan include 
involvement in cartilage formation and blood vessel development in embryogenesis [89], 
while agrin is involved in organizing synapses in the neuromuscular junction [199] and 
maintaining BBB impermeability [14]. Cell surface HSPG can bind extracellular proteins 
for internalization or act as co-receptors (reviewed in [22]). HSPG have also been linked to 
several pathological conditions, including all types o f amyloidosis [225].
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1In AD, HSPG can be found co-localized w ith Aß deposits. Agrin and the cell surf­
ace HSPG glypican-1 have the most prominent co-deposition, as they can be found asso­
ciated w ith nearly all types o f Aß deposits (i.e. fibrillar and non-fibrillar SP, CAA) [254, 255]. 
Syndecans can only be detected in a m inority o f SP w ith some deposition o f syndecan-2, 
but not the other syndecans, in CAA [255]. Collagen XVIII can be found in all Aß deposits, 
except fibrillar SP [257]. The association o f perlecan w ith Aß deposits is still unclear, as 
some describe this HSPG to have the strongest association [222, 224], whereas we and 
others have been unable to detect perlecan in CAA or SP [254, 255, 263]. There is evidence 
that other proteoglycans can also be found in the vicinity o f Aß deposits, but never to the 
same extent as HSPG [65, 221, 223].
Small heat shock proteins (sHsp)
Small Hsp are chaperone proteins, involved in the proper folding o f proteins [32]. There 
are ten members o f the sHsp family [121], each possessing an a-crystallin domain and all 
ranging between 16-25 kDa in size. Some sHsp are expressed in the eye lens, where they 
help refract incoming light and maintain transparency o f lens flu id  [105]. Many members 
are also expressed in skeletal and cardiac muscle tissues. In AD, Hsp20, Hsp27, HspB2/B3 
and HspB8 co-localize w ith SP, while HspB2/B3 is only associated w ith Aß in CAA [280, 
284]. The only sHsp not co-deposited w ith  Aß is aB-crystallin, although this sHsp can be 
detected in glial cells near Aß deposits [284].
As would be expected from their close association w ith Aß in vivo, both HSPG 
and sHsp can bind Aß w ith high affinity [41, 52, 279] and protect cells against Aß-induced 
cellular toxicity [279, 290]. By binding to Aß, HSPG can stimulate Aß fibrillization [41, 52] 
and protect Aß from proteolytic degradation [52, 87]. In contrast, sHsp, especially aB- 
crystallin, seem to inh ib it Aß fibrillization [279].
Mouse m odels fo r  AD
To investigate disease mechanisms and test new therapeutic interventions, transgenic 
mouse models have been created. There are several different methods for creating trans- 
genics, including homologous recombination and pronuclear injection [74, 97]. Homolo­
gous recombination relies on targeted disruption o f endogenous mouse genes, thereby 
altering gene function or even generating full knockouts. However, as mice do not ne­
cessarily possess the genes responsible for human disease, this technique is not always 
suitable to mimic their pathology. With pronuclear injection, human genes can be inser­
ted into the mouse genome. To accomplish this, the gene o f interest is inserted into a vec­
tor, containing a (tissue-specific) promoter, that is then injected into a pronuclear mouse 
zygote. This results in the development o f a transgenic mouse that w ill (over)express the 
human gene.
Most transgenic mouse models for AD express the human APP gene [67, 74, 80] 
(for a summary o f models mentioned in this thesis: see Table 1). Initial attempts to gene­
rate an APP-expressing model revealed that w ild type APP, although expressed, did not 
generate the (robust) Aß pathology seen in humans [35, 98, 293]. However, inserting APP 
w ith one (or more) o f the pathogenic mutations found in familial AD cases did generate 
mice w ith AD-like pathology. The first model expressing mutated APP, the PDAPP mouse 
expressing APP w ith the Indiana mutation, developed Aß plaques at about 6 months of 
age [79] (Table 1) accompanied by impaired cognition [68].
To facilitate APP cleavage, many models also express (mutated) PS1 [67, 74, 80].
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Table 1 : Characteristics o f the AD mouse models mentioned in this thesis (Adapted from [74])
Mouse model Mutations Promotor Amyloid pathology (age of onset) Reference
APPwe/PSI dE9 APP-Swedish 
PS1 exon 9 deleted
PrP Parenchymal plaques (4-6 months o f age) [82]
TgSwDI APP-Swedish + Dutch + 
Iowa
Thy 1.2 Severe vascular deposition + parenchymal 
plaques (3-6 months o f age)
[55]
PDAPP APP-lndiana PDFG-ß Parenchymal plaques (6-9months o f age) [293]
Tg2576 APP-Swedish PrP Parenchymal plaques (9-12 months o f age) [106]
TgCRND8 APP-Swedish + Indiana PrP Aggressive parenchymal plaques 
(3 months o f age)
[42]
PSAPP PS1M146V
APP-Swedish (Tg2576)
- Earlier and more extensive plaque pathology 
compared toTg2576 mice
[101]
Triple transgenic APP-Swedish 
PS1M146V 
Tau P301L
Thy 1.2 Parenchymal plaques (6 months o f age) + 
tau pathology (12 months o f age)
[181]
1The fastest approach to create double-transgenics is to co-inject both genes, although it 
has long been done by mating the single transgenic mice w ith each other [112]. Generally, 
expression o f PS1 accelerates and exacerbates Aß pathology in models [101]. However, 
even w ith  robust Aß deposition, AD models still do not mimic all (Aß-related) characte­
ristics o f AD, such as neurodegeneration [80], Aß modifications (e.g. N-terminal cleavage) 
[136] and tau pathology. To further model the disease, a trip le  transgenic mouse (3xTg), 
expressing APP, PS1 and a mutated tau protein, has now been created [181]. These 3xTg 
mice accumulate Aß, develop tau tangles and demonstrate synaptic dysfunction.
Therapeutic in te rven tions
Currently, only five drugs are approved for the treatment o f AD [175]. Four o f these drugs 
are acetylcholinesterase inhibitors, including donepezil and rivastigmine. These inhibi­
tors aim to prevent the degradation o f acetylcholine, as levels o f this neurotransmitter 
are severely diminished in AD brains due to the loss o f cholinergic neurons [276]. The 
other drug, memantine, is an antagonist o f the N-methyl-d-aspartate (NMDA) glutamate 
receptor and currently used to treat moderate to severe AD cases [192]. In blocking the 
NMDA receptor, memantine is thought to reduce excitotoxicity triggered by the neuro­
transmitter glutamate. Although all these drugs can at least stabilize the symptoms [90, 
192], they cannot prevent or cure AD. Curing this disease requires addressing the underly­
ing (neurotoxic) causes o f the disease (reviewed in [209]). For example, lowering oxidative 
stress by administering substances w ith  anti-oxidant properties, such as titerpenoids [70], 
can improve memory o f AD mice. It has to be mentioned that effective treatment o f AD 
is hindered by the late diagnosis o f this disease, although advances are being made to 
identify patients at an earlier stage o f AD [47].
Most new therapeutic strategies target Aß directly. For example, Aß production 
can potentially be modulated by inhibition o f ß- or Y-secretase cleavage o f APP [179]. A 
whole number o f ß-secretase inhibitors are now being developed and tested, w ith  GRL- 
8234 lowering plasma and brain Aß40 levels in Tg2576 mice [84]. The potent Y-secretase 
inh ib itor LY411575, a benzodiazepine analogue, was demonstrated to lower brain Aß 
levels in Tg2576 mice [143] and a similar, but slightly less potent, Y-secretase inhibitor, 
LY450139 has now entered clinical trials [217].
Another therapeutic strategy is to inh ib it Aß aggregation. Indeed, scyllo-inositol, 
a known inh ib itor o f Aß aggregation, can significantly improve cognition o f TgCRND8 
mice [77]. Most promising o f all potential new therapeutic strategies, however, is immune 
therapy, aimed at the removal, or clearance, o f Aß. This form o f therapy not only affects 
brain Aß pathology and cognition, it also provides insights into the mechanisms respon­
sible for Aß removal from  the brain.
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1Immune therapy
There are tw o different types o f immune therapy, active and passive immunization. With 
active immunization, Aß or fragments o f Aß are administered, together w ith an adjuvant, 
to trigger an immune response. With passive immunization, antibodies against Aß are in­
jected directly, circumventing the necessity for patients to generate an immune response 
and allowing for a better regulation o f the immune response. In vitro studies have demon­
strated that antibodies may inh ib it Aß aggregation and Aß-induced cellular toxicity [228, 
229] and therefore the feasibility o f in vivo immune therapy was soon investigated in AD 
mouse models.
The first immunization studies were performed in PDAPP mice [16, 203]. When 
actively immunizing these mice, by injecting Aß42 for a number o f months, mice deve­
loped a significant antibody tite r against Aß, which was accompanied by a reduction in 
brain Aß burden [203]. This was not only true when injections started prior to Aß patho­
logy development (11 weeks old), but also when injections were started when severe Aß 
pathology was already prominent (11 months old).
Similar to active immunization, passive immunization o f PDAPP mice w ith anti­
Aß antibodies also reduced brain Aß burden when administered before or during deve­
lopment o f Aß pathology [16]. These antibodies were found associated w ith Aß in the 
brain, apparently having been able to cross the blood brain barrier (BBB), even though in­
tegrity o f the BBB remained intact. In general, it appeared that antibodies directed against 
the N-terminus o f Aß were more effective in reducing brain Aß deposition than those d i­
rected against the C-terminus [15], which is in line w ith the idea that the N-terminus is the 
most accessible part o f the aggregated Aß protein [124]. After these first immunization 
treatments, many more animal studies revealed the promising effects o f both active and 
passive immune therapy on brain Aß levels (reviewed in [83]). Furthermore, immunization 
was also demonstrated to improve cognitive impairment [66, 113, 172] and to reduce pa­
thological features such as gliosis, neuritic dystrophy [203] and loss o f synapses [34]. Ad­
ministration o f anti-Aß antibodies could even facilitate development o f diagnostic tests, 
as it was demonstrated that plasma Aß levels o f PDAPP mice are highly correlated to brain 
Aß levels only after administration o f the m266 antibody [62].
Since immunization protocols had such positive results in different AD mouse 
models [83], human trials started not long after the first mouse results were published. 
In the very first clinical trials, patients were actively immunized using Aß42 w ith the ad­
juvant QS21 (AN1792). AN1792 not only induced production o f anti-Aß antibodies [99], 
but could also reduce brain Aß levels [160, 177] and slow the rate o f cognitive decline 
[100]. Long-term effects o f AN1792 however were minimal [102]. Six years after receiving 
AN1792, brain Aß levels were lower in immunized patients than in unimmunized controls, 
but there was no sign o f an attenuation o f cognitive decline. Furthermore, in a Phase II 
trial, immunization w ith AN1792 resulted in the development o f meningoencephalitis in 
6% o f the enrolled patients, causing the trial to be interrupted [183].
Immunization protocols are now being modified to improve efficacy and ensure 
safety in clinical trials. For example, to minimize negative side-effects, Aß peptides are 
being shortened to create small epitopes specifically recognized by antibodies, but not T- 
cells [158]. Choosing alternative administration routes, such as intranasal administration, 
may also further increase safety o f immunization [145]. In general, passive immunization 
protocols appear to be safer (i.e. associated w ith a low risk o f encephalitis) than active 
immunization and can also be further modified to improve safety. For example, deglyco-
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1sylation o f antibodies diminishes their interaction w ith microglial Fc-receptors and com­
plement factors that can trigger a harmful neuroinflammatory response (i.e. microglial 
and complement activation) [235]. This modification neither affects binding affin ity to Aß 
nor does it reduce the ability to lower brain Aß levels and improve cognition [278].
There are several proposed biological mechanisms Aß antibodies may use to re­
duce brain Aß levels (reviewed in [227, 268]) (Fig. 3). First, antibodies may trigger the up­
take o f Aß by microglia (Fig. 3A) [16]. This process is likely mediated by Fc receptors on m i­
croglial membranes as specific antibodies against these receptors could inh ib it Aß uptake. 
However, experiments w ith  deglycosylated antibodies [235], antibody fragments lacking 
the Fc-binding region [9] and Fc-receptor knockout mice [53] proved that there are also 
non-Fc-mediated mechanisms responsible for antibody-mediated clearance o f Aß. One of 
these alternative mechanisms is inhibition or disruption o f Aß aggregation by antibodies 
that directly associate w ith  Aß in the brain (Fig. 3B), a process that has been demonstrated 
in in vitro studies [228, 229]. For this latter mechanism, antibodies need to enter the brain.
a Microglia mediated b Direct resolution e Peripheral sink
Figure 3: Three biological mechanisms that are not mutually exclusive have been proposed. 
Small amounts o f anti-amyloid antibodies reach amyloid deposits in the brain and trigger a 
phagocytic response by microglia (A). Anti-amyloid antibodies reach amyloid deposits in the 
brain and resolve them directly through interaction o f the antibody with the amyloid depo­
sit (B). Anti-amyloid antibodies act as a peripheral sink for soluble amyloid ß species, leading 
ultimately to the resolution o f brain deposits by mass action (B). BBB, blood-brain barrier. Re­
printed with permission from Macmillan Publishers Ltd: [Nature Reviews Neuroscience] [46], 
copyright (2004).
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1Indeed, peripherally administered antibodies have been found associated w ith brain Aß 
in PDAPP mice, and therefore were apparently able to cross the BBB [16]. However, there 
are also antibodies that can reduce brain Aß levels w ithout entering the brain [61]. These 
antibodies may act as so-called peripheral sink agents (Fig. 3C).
Peripheral s ink hypothesis
The peripheral sink hypothesis was first postulated by DeMattos et al. in 2001 [61], who 
found that passively immunizing PDAPP mice w ith  the monoclonal antibody m266 signi­
ficantly increased plasma Aß levels, while decreasing brain Aß load. They suggested that, 
by binding to plasma Aß, antibodies caused a net efflux o f Aß from the brain. Indeed, 
m266 has been found in complex w ith Aß in CSF and plasma o f PDAPP mice [66]. Aß/ 
antibody complexes can be degraded in peripheral organs such as liver or kidneys [200], 
which disturbs the equilibrium  that is known to exist between brain and peripheral Aß 
pools [63]. To reestablish this equilibrium, soluble Aß is transported from the brain to the 
plasma, explaining the decrease in brain Aß levels. It should be mentioned that fibrillar Aß 
remains in the brain, as it cannot cross the BBB.
After the first description o f the peripheral sink hypothesis [61], a number of 
studies, both immune and non-immune, have been performed that support this hypo­
thesis. For example, actively immunized PSAPP mice demonstrated an increase in se­
rum Aß levels, accompanied by a reduction in brain Aß levels [146]. Furthermore, the 
previously mentioned deglycosylated antibodies also significantly increased plasma 
Aß levels in trip le  transgenic (APP, PS1, tau) AD mice, w ithout entering the brain [235]. 
Immunization o f TgSwDI mice provided additional proof o f the existence o f a perip­
heral sink mechanism. TgSwDI mice produce Aß that, due to the Dutch and Iowa mu­
tations, has less affinity for the receptor that is involved in Aß clearance from the brain 
(i.e. LRP-1) and Aß is retained w ithin the cerebral vascular wall [56, 60]. Indeed, it was 
demonstrated that immunizing TgSwDI mice w ith an antibody against Aß neither redu­
ced the deposition o f Aß in the brain nor dissolved established Aß deposits [259]. Only 
when directly delivered to the brain, this antibody cleared already established deposits.
As previously mentioned, immune therapy can be accompanied by neuroinflam- 
matory responses that are detrimental to AD patients [183]. Therefore, the use o f non­
immune substances as peripheral sink agents has also received attention. To act as perip­
heral sink agents, binding Aß is key. Gelsolin and GM1, a secretory protein and ganglioside 
respectively, can both bind Aß and it was found that both could reduce brain Aß levels of 
PSAPP mice w ithout entering the brain [163]. Furthermore, GM1, but not gelsolin, influen­
ced plasma Aß levels. As it has a high binding affinity to Aß, part o f the Nogo-66 receptor 
(NgR(310)ecto-Fc) has also been tested as a peripheral sink agent [184]. NgR(310)ecto- 
Fc administered to APPswe/PS1dE9 did not enter the brain, but lowered brain Aß levels. 
Furthermore, it reduced the number o f dystrophic neurites and gliosis and improved cog­
nition o f these mice. However, like gelsolin, it d id not alter plasma Aß levels, demonstra­
ting that altered plasma Aß levels may not always be a good measure o f the presence of 
a peripheral sink mechanism. Another potential peripheral sink agent is part o f the LRP-1 
receptor (binding domain LRP-IV) that can reduce brain Aß levels o f APPswe mice while 
increasing plasma Aß levels [200]. Furthermore, a peripheral sink action has also been 
suggested for several Congo red derivates [164] and for an analogue o f heparan sulfate 
proteoglycans, the low-molecular weight heparin enoxaparin [20].
22
1Aim  o f th is  study
As HSPG are such prominent components o f human Aß deposits, we aimed to further 
investigate the interaction between Aß and HSPG. Using cerebrovascular cells and 
the APPswe/PS1dE9 mouse model for AD, we explored the capacity for Aß to trigger 
HSPG expression and GAG chain modification in vitro (Chapters 2 and 3) and in vivo 
(Chapter 4). Furthermore, we reviewed the literature on co-deposition o f HSPG and se­
veral other co-depositing factors (e.g. complement factors and acute phase proteins) 
in different AD mouse models (Chapter 5). Finally, we investigated if a HSPG analogue, 
enoxaparin (Chapter 6 ), and the sHsp aB-crystallin (Chapter 7) could be potential thera­
peutic agents and possibly even act as peripheral sink agents.
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Outline of this thesis
Chapter 2
O f all HSPG, agrin and glypican-1 are most commonly found in association w ith Aß. Howe­
ver, it is still largely unknown what causes the association o f heparan sulfate proteoglycans 
w ith Aß deposits in human brains. Therefore, we examined the role o f Aß in the expression 
and production o f these two HSPG in vitro. Furthermore, using human brain pericytes, 
we studied the cellular location o f agrin and glypican-1 in the absence or presence o f Aß.
Chapter 3
Sulfated glycosaminoglycan chains o f HSPG are not only found in association w ith paren­
chymal Aß deposits, they can also be detected in CAA, suggesting a role for GAGs in vas­
cular Aß deposition. Their sulfate moieties in particular are said to be key in the interaction 
o f GAGs w ith Aß in plaques. We investigated if sulfate moieties have a similar role in GAG 
association w ith  vascular Aß. Furthermore, we studied the effect o f several different GAGs 
(heparin, chondroitin sulfate, heparan sulfate) on aggregation o f Aß and Aß-induced toxi­
city o f cerebrovascular cells.
Chapter 4
The close association o f HSPG w ith Aß deposits in human AD patients is well-established 
and proven to influence Aß deposition. We aimed to characterize the association o f HSPG 
w ith Aß deposits in the APPswe/PS1dE9 mouse model for AD in order to get a better 
understanding o f the differences o f mouse and human Aß deposits and to investigate if 
there is a temporal relation between HSPG and Aß deposition.
Chapter 5
In this chapter we reviewed the co-deposition o f several factors w ith  mouse Aß deposits 
that are known to be associated w ith human Aß deposits. These factors include: HSPG, 
apolipoproteins, complement factors, acute phase proteins, ICAM-1, cystatin C and CLAC.
Chapter 6
Enoxaparin is a low molecular weight heparin that is known to reduce brain Aß levels 
when prophylactically administered to a mouse model for AD. We investigated what ef­
fect prophylactic and therapeutic injections o f enoxaparin had on cognition and brain Aß 
levels o f APPswe/PS1dE9 mice.
Chapter 7
According to the peripheral sink hypothesis, Aß can be removed from the body by degra­
dation in peripheral organs after form ing macromolecular complexes, e.g. by binding to 
anti-Aß antibodies in the blood. To restore the balance o f the Aß pool in the blood and 
brain, Aß is then transported out o f the brain. Since aB-crystallin can bind Aß w ith  high af­
finity, we investigated if this sHsp can act as a peripheral sink agent in two mouse models 
for AD.
Chapter 8
In this chapter we summarize and discuss the results o f this thesis and propose future 
research plans.
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2 Abstract
The major component o f senile plaques and vascular amyloid in Alzheimer's disease 
(AD) brains is the amyloid ß protein (Aß). Besides Aß, several other proteins have been 
identified in these lesions, in particular heparan sulfate proteoglycans (HSPG). However, 
it is still unclear, what causes the excessive accumulation o f HSPG in AD brains. There­
fore, we investigated if Aß may influence production and expression o f tw o major Aß- 
associated HSPG species, agrin and glypican-1. When human brain pericytes (HBP) were 
cultured in the presence o f Aß, protein and mRNA expression o f both agrin and glypi­
can-1 were increased and more radioactive sulfate was incorporated in the glycosami- 
noglycan fraction o f Aß-treated HBP. Furthermore, after Aß treatment these HSPG were 
found in association w ith the amyloid fibrils attached to the cell membrane, in contrast 
to the intracellular agrin and glypican-1 staining observed in untreated cells. We con­
clude that Aß can modulate the cellular expression o f agrin and glypican-1, which may 
contribute to the accumulation o f these HSPGs in AD lesions.
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In troduction
The major pathological lesions in Alzheimer's disease (AD) brains comprise neurofibril­
lary tangles (NFT), senile plaques (SP) and cerebral amyloid angiopathy (CAA). NFTs are 
composed o f fibrillar hyperphosphorylated tau protein [159]. The major component of 
SPs and CAA-affected vessels is the amyloid ß protein (Aß), a proteolytic cleavage product 
o f the amyloid precursor protein (APP) [208]. Next to the presence o f these abnormal pro­
tein aggregates, several other proteins accumulate in AD lesions, including inflammatory 
proteins [72, 73, 267], apolipoprotein E [173, 287], small heat shock proteins [280, 284] and 
heparan sulfate proteoglycans (HSPG) [225, 254-257].
HSPG are complex macromolecules involved in a variety o f biological processes, 
such as proliferation, differentiation and cell adhesion [189]. They are composed o f long 
sulfated polysaccharide side-chains covalently attached to a specific serine residue o f the 
core protein. These glycosaminoglycan (GAG) side-chains may undergo a series o f enzy­
matic modifications leading to variable sequences w ith highly sulfated regions alternated 
by relatively unmodified regions [22, 91, 256]. In the sulfated regions o f HSPG, the dis­
accharide units consist o f N-acetylglucosamine in combination w ith  iduronic acid, while 
in the unmodified regions N-acetylglucosamine is combined w ith glucuronic acid. HSPG 
can be divided into two major groups: the extracellular matrix-associated HSPG, including 
perlecan, agrin and collagen XVIII [88, 108], and cell surface HSPG o f the syndecan and 
glypican families [22].
We previously demonstrated a differential expression pattern o f several HSPG 
subtypes in AD lesions [254, 255, 257]. Unlike the syndecans, perlecans and collagen XVIII, 
the HSPG agrin and glypican-1 are the only two HSPG that are expressed in all types of 
AD lesions. Agrin and glypican-1 expression was detected in the majority o f SP present 
in AD patients [254]. In CAA o f AD patients a variable, sometimes weak agrin expression 
was detected [255]. A much stronger association o f agrin w ith Aß in CAA was found in pa­
tients suffering from hereditary cerebral haemorrhage w ith amyloidosis o f the Dutch type 
(HCHWA-D), a rare autosomal dom inant disease characterized by vascular depositions of 
Aß [251]. Of all HSPG, glypican-1 was most predominant, accumulating in CAA-affected 
vessels o f both AD and HCHWA-D patients [255]. Interestingly, glypican-1 could not be de­
tected in normal vessels, suggesting a particular role for this HSPG in CAA pathogenesis.
In AD lesions, HSPG expression not only occurs at the same location, but also 
virtually at the same tim e as Aß deposition [222], which suggests a close association 
between HSPG and Aß. It has indeed been reported that HSPG can bind to Aß w ith high 
affinity [41, 52] through a connection between the GAG side-chains and the Aß protein, 
although the core protein is also involved [219]. The effect o f HSPG on Aß accumulation 
may in fact be caused by their tigh t association. Indeed, HSPG can induce aggregation of 
Aß, stabilize Aß plaques [41, 52] and inh ib it Aß degradation [52, 87]. There is also evidence 
that the heparan sulfate (HS) GAG side-chains can prevent ß-secretase cleavage o f Aß 
from its precursor protein [17, 204]. Since it is well known that Aß, agrin and glypican-1 
are tigh tly  associated in AD brains, we investigated in vitro if Aß directly affects cellular 
expression o f these HSPG and the degree o f sulfation o f GAG side-chains in general. We 
used human brain pericytes (HBP) as an in vitro model system, since these cerebrovascu­
lar cells are tightly  associated w ith one o f the Aß-containing lesions in AD brains, namely 
CAA [262].
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M ateria ls and m ethods
Antibodies
We used primary monoclonal antibodies directed against the core protein o f agrin (JM72) 
[249] and glypican-1 (S1) [57]. For immunocytochemistry we used FITC-labeled sheep an­
ti-mouse as secondary antibody (Vector, Burlingame, CA) and for Western blot analysis we 
used peroxidase-labeled rabbit anti-mouse (Vector, Burlingame, CA).
Aß peptides
We used Aß containing the Dutch mutation (Glu22-->Gln22) as found in HCHWA-D (DAß1- 
40), since this protein is biology active towards cerebrovascular cells [54]. DAß1-40 was 
purchased either from Biosource (89% pure, Etten-Leur, The Netherlands) or from Qua­
lity Controlled Biochemicals (QCB; Hopkinton, Massachusetts, USA, 96% pure). Aß40-1 was 
purchased from QCB (Hopkinton, Massachusetts, USA). In previous experiments it was de­
monstrated that Aß40-1, unlike the DAß1-40 peptide, has no biological activity towards HBPs 
in viability assays [283].
We used two different ways o f preparing stock solutions o f the DAß1-40 pepti­
des: in sterile water (250 ^M) [280] or by dissolving the peptide in hexafluoroisopropanol 
(HFIP), removing the solvent by evaporation and subsequently dissolving it in DMSO (5 
mM). The former procedure yields an DAß1-40 preparation that is in a monomeric state for 
more than 90%; the latter procedure is commonly used by researchers to yield a robust 
solution o f monomeric Aß. Aß40-1 was dissolved in HFIP and DMSO (5 mM). Aliquots were 
stored at -80°C prior to use. Neither the source o f the peptide nor the procedure used to 
dissolve the peptide affected the results in the experiments.
Cell cultures
HBP were isolated and characterized as described previously [265]. For the different ex­
periments HBP were maintained in fibronectin-coated flasks containing Eagle's modified 
essential medium (EMEM; Bio-Whittaker, Verviers, Belgium) w ith L-glutamine containing 
10% human serum, 20% newborn calf serum, 1 ng/m l basic fibroblast growth factor and 
2% penicillin/streptomycin. Prior to experiments, HBP were incubated in EMEM contai­
ning 0.1% bovine serum albumin (EMEM-BSA) and antibiotics for at least 4 hours. Next, 
cells were incubated in fresh EMEM-BSA, either supplemented or not w ith 8-25 ^M syn­
thetic DAß1-40 peptide for 1-3 days depending on the specific assay.
Immunofluorescence staining o f DAß1-40-treated HBP
To study the effects o f DAß1-40 on the expression o f agrin and glypican-1 at the immu- 
nocytochemical level, HBP were cultured in sterile gelatin-coated 8-well chamber slides, 
and incubated either w ith or w ithout 25 ^M DAß1-40 for three days. After fixation w ith  pe- 
riodate-lysine-paraformaldehyde (PLP) for 10 minutes, cells were incubated overnight at 
4°C w ith primary antibodies. Finally, cells were incubated w ith the secondary antibody for
1 hour and mounted in Vectashield (Vector, Burlingame, CA, USA). Between incubation 
steps, cells were thoroughly washed w ith PBS. All antibodies were diluted in PBS contai­
ning 0.1% BSA, which also served as a negative control. Nuclei were stained w ith Topro3 
(Molecular probes, Eugene, Ore., USA, dilution 1:1000). Immunofluorescence staining was 
examined using a confocal laser-scanning microscope (Leica, Wetzlar, Germany).
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Immuno-electron microscopical (IEM) analysis
HBP were cultured on fibronectin-coated foil bottom  dishes (WillCo Wells BV, Amster­
dam, The Netherlands) and subsequently incubated for three days w ith  fresh EMEM-BSA 
w ith or w ithout 12.5 ^M DAß1-40. After washing twice w ith PBS, HBP were fixed in PLP for 
2 hours, followed by washing w ith  PBS and blocking w ith  20% goat serum in PBS with 
0.1% BSA for 1 hour. Cell preparations were pre-treated w ith 0.05% Triton-X in PBS for 
30 minutes to increase permeability o f the cells. Incubation w ith primary antibodies was 
performed overnight at 4°C. After washing four times w ith PBS, samples were incubated 
w ith ultra-small gold conjugated goat anti-mouse antibodies (Aurion, Wageningen, The 
Netherlands) overnight at 4°C. Again, samples were washed w ith  PBS and fixed for 10 m i­
nutes in 2% glutaraldehyde, washed w ith PBS, followed by 10 minutes post-fixation with 
2% osmium tetroxide. After intense washing w ith  PBS and ultrapure water the prepara­
tions were silver-enhanced w ith the Aurion R-Gent SE-EM kit and the reaction was stop­
ped after 20 minutes in ultra pure water. Then, cells were washed in 30% ethanol, en-bloc 
stained w ith 2% uranyl acetate in 30% ethanol for 30 minutes at 4°C and washed again 
in 30% ethanol. Subsequently, samples were dehydrated w ith increasing concentrations 
o f ethanol followed by mixtures o f epon (Agar Scientific, Stansted, England) w ith 100% 
ethanol and finally pure epon resin. The foil was cut w ith a razor blade and embedded in 
pure epon resin. Ultrathin sections were cut on a Leica Ultracut (Leica, Wetzlar, Germany) 
and stained w ith uranyl acetate and lead citrate. Photographs were taken on a Jeol 1200 
EX/II electron microscope at 60 kV (Jeol, Tokyo, Japan).
Western blot analysis
HBP were cultured w ith or w ithout 8-25 ^M DAß1-40 in EMEM-BSA for 3 to 6 days. Cell 
culture medium was removed for Western blot analysis and cells were thoroughly rinsed 
three times w ith 0.9 % NaCl. Subsequently, cells were treated w ith  8 M urea (Sigma-Aldrich 
Chemie, Zwijndrecht, the Netherlands) to lyse the cells. Cell culture medium and cell ly­
sates were diluted 1:1 w ith  reducing sample buffer (2.3 % sodiumdodecylsulfate (SDS), 
12.5 % Tris-HCL (0.5 M, pH 6.8), 77 % glycerol, 3% dith iothreito l (DTT) and bromophenol 
blue in milliQ). This mixture was heated for 5 minutes at 100 °C and equal amounts of 
protein were subsequently separated by SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE). Proteins were electrophoretically transferred onto nitrocellulose membranes (Hy- 
bond; Amersham Corp, Arlington Heights, IL, USA) in b lotting buffer (25 mM Tris pH 8.6, 
192 mM glycine and 20% methanol). Blots were incubated for 15 minutes in blocking 
solution (PBS/0.05% Tween-20 (PBS-T) containing 5% low fat m ilk powder), rinsed three 
times in PBS-T and subsequently incubated overnight at 4°C w ith specific primary anti­
bodies in PBS-T w ith 0.5% low fat m ilk powder. The blots were then rinsed three times 
in PBS-T and incubated w ith  the appropriate secondary antibody in PBS-T w ith 0.5% low 
fat m ilk powder for 1 hour at room temperature. Blots were washed three times in PBS-T 
and finally rinsed in PBS. Detection was performed by chemiluminescence according to 
the manufacturer's protocol (Roche, Basel, Switzerland) and exposed to Kodak X-OMAT-R 
films. Each experiment was repeated three times.
Total RNA isolation
HBP were cultured in 6 well plates and subsequently incubated for 1-3 days w ith  or w it­
hout 8-10 ^M DAß1-40 or Aß40-1 in EMEM-BSA medium. Total RNA was isolated follow ing 
w ith Trizol reagent (1 ml per well; Invitrogen, Carlsbad, CA, USA) follow ing the manufactu­
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rer's instructions. The total RNA pellet was washed w ith 75% ethanol and finally dissolved 
in RNA-free water. A Nanodrop® ND-1000 UV-Vis spectrophotometer (Nanodrop Techno­
logies, W ilm ington, DE, USA) was used to determine amount and purity o f total RNA iso­
lated and a small sample was separated on a 1% agarose gel to check for the presence of 
the characteristic 18S and 28S bands.
cDNA synthesis
To quantify mRNA expression o f agrin and glypican-1, cDNA was synthesized from isola­
ted total RNA. Total RNA (0.5-1.0 ^g) was incubated w ith random primers in a mixture of 
5mM dNTPs, RNAsin, 5x first strand buffer, 0.1 M DTT and M-MLV transcriptase (Invitrogen). 
The samples were incubated for 10 min at room temperature and for one hour at 37°C, 
followed by a 3 m inute M-MLV inactivation at 70°C. A solution containing all components 
o f the mix except M-MLV served as a negative control. A PCR o f the housekeeping gene 
ß-2 m icroglobulin (B2M) was performed to exclude contamination o f the samples with 
genomic DNA. Amount and purity o f cDNA was determined on the Nanodrop® ND-1000 
UV-Vis spectrophotometer (Nanodrop Technologies).
Quantitative PCR
For real-time RT-PCR, 2x Taqman Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA) was used. A 20x Taqman gene expression assay mix o f agrin, glypican-1 or 
lipoprotein-related protein 1 (LRP-1), an Aß receptor, was added to a mixture o f Taqman 
universal mastermix, RNAse-free water and 50 ng o f cDNA. We used LRP-1 expression as 
a positive control as we have previously demonstrated that LRP-1 protein expression is 
upregulated by Aß treatment [283]. Forward (5'-GGCAATGCGGCTGCAA-3') and reverse 
(5'-GGGTACCCACGCGAATCAC-3') primers for the housekeeping gene porphobilinogen 
deaminase (PBGD) and a probe (5'-CTCATCTTTGGGCTGTTTTCTTCCGCC-3') labeled with 
AllGloTM were from Biolegio (Nijmegen, The Netherlands). The PCR was performed using 
the ABI PRISM 7700 sequence detection system. A standard curve o f mRNA expression 
was created w ith mRNA isolated from a 75-cm2 flask o f untreated HBP.
Three separate RT-PCR experiments were performed. In each experiment, cDNA 
samples were analyzed in duplicate and the standard curve method was used to calculate 
the mRNA expression o f agrin, glypican-1 and LRP-1 o f DAß1-40 or Aß40-1 -treated cells. Ex­
pression was normalized to PBGD and an unpaired two-sided t-test was used to compare 
expression levels o f treated and untreated HBP. Data o f one representative experiment are 
presented as mean expression ± standard error relative to untreated cells.
Assessment o f 35S-sulfate incorporation
HBP were cultured for 24 h in EMEM-BSA, in the presence or absence o f 12.5 ^M DAß1-40. 
Transforming growth factor-ß1 (TGF-ß1) increased the production o f various extracellular 
matrix proteins, including HSPG [131], and was therefore used as positive control (2 ng/ 
ml). Subsequently, 35S-labeled sulfate (25 ^Ci/ml) (PerkinElmer, Boston, MA, USA) was ad­
ded to the medium for 24 hours. Then, cells were washed in EMEM three times and dige­
sted for 2 h at 65°C in a papain solution containing a chondroitin sulfate as carrier. Cells 
were centrifuged for 10 minutes at 1,000x g to remove cell debris and 0.2% cetylpyridi- 
nium chloride solution was added to the supernatant in equal amounts and incubated for 
2 h at 37°C to precipitate the GAGs. After incubation, the mixture was centrifuged for 10 
minutes at 10,000x g to collect the precipitate. Finally, the precipitated residue was rinsed
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twice and dissolved in Lumasolve (Omnilabo, Breda, The Netherlands). Subsequently, the 
dissolved precipitated residue was diluted in Optifluor (Packard BioScience, Groningen, 
The Netherlands) and 35S-sulfate incorporation was measured by liquid scintillation coun­
ting (PerkinElmer 1450 Microbeta, Boston, MA, USA) and expressed as counts per minute 
(cpm). One-sided unpaired t-tests were performed to compare the effects o f TGF-ß1 or 
DAß1-40 on 35S-sulfate incorporation. Each experiment was repeated three times. All values 
are expressed as mean ± standard deviation.
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Results
Aß-induced agrin and glypican-1 immunoreactivity
To determine the effects o f Aß on expression o f agrin and glypican-1, DAß1-40-treated 
HBP were immunocytochemically stained. The JM72 antibody, directed against the core 
protein o f agrin, demonstrated increased immunoreactivity after incubation w ith DAß1-40 
(Fig. 1B) when compared to untreated cells (Fig. 1A). The glypican-1 antibody S1, directed 
against the glypican core protein, showed a similar increase o f immunoreactivity after 
DAß1-40 treatment (Fig. 1C and D).
Furthermore, immunocytochemical analyses showed that agrin was confined to 
a perinuclear localization in cultured HBP (Fig. 1A), whereas glypican-1 was distributed 
throughout the cytoplasm (Fig. 1C). DAß1-40 treatment caused a cellular redistribution of 
agrin towards the cell membrane (Fig. 1B).
Figure 1: Immunofluorescence staining o f untreated (A, C) and DAß140-treated (B, D) HBP for 
agrin (A, B) and glypican-1 (C, D). Protein expression o f both agrin and glypican-1 was incre­
ased after treatment. Original magnification 630x.
Subcellular localization o f agrin and glypican-1
To further investigate the cellular localization o f agrin and glypican-1, ultrastructural analy­
sis o f agrin and glypican-1 localization by IEM analysis was performed (Fig. 2). Untreated cells 
demonstrated agrin immunoreactivity in phagosome-like structures (Fig. 2A). Upon DAß1-40 
treatment, agrin was predominantly found in close association w ith DAß1-40 fibrils attached 
to the cell surface (Fig. 2B and E) but also in DAß1-40-containing phagosomes (Fig. 2B and 
F). Glypican-1 immunoreactivity in untreated cells was mainly observed at the cell surface 
and sporadically in the cytoplasm (Fig. 2C). After DAß1-40 treatment glypican-1, like agrin, co­
localized w ith amyloid fibrils attached to the cell surface (Fig. 2D). Additionally, glypican-1 
immunoreactivity was also detected throughout the cytoplasm o f DAß1-40-treated HBP.
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Figure 2: Immuno-electron microscopical analysis o f untreated (A, C) and DAß140-treated (B, 
D, E, F) HBP for localization o f agrin (A, B, E, F) and glypican-1 (C, D). In control HBP, agrin is 
mainly found in phagosomal bodies (A; arrow). After DAß140 treatment, agrin co-localized 
with DAß 140 fibrils on the cell surface (B; arrow; shown at higher magnification in E) and in 
phagosomal bodies (B; arrowhead; shown a t higher magnification in F). In untreated cells, gly- 
pican-1 is closely associated with the cell surface (C) and, after DAß140 treatment, associated 
with Aß fibrils on the cell surface as well as distributed throughout the cytoplasm (D). Original 
magnification A, B, C, D 12.000x and E, F25.000x.
Aß-induced protein expression o f agrin and glypican-1
To determine protein expression and secretion o f agrin and glypican-1 in DAß1-40-treated 
HBP, cell-lysates and cell culture medium were analysed for the presence o f these 
HSPG by Western blot analysis. Both untreated and DAß1-40-treated HBP cell lysates de­
monstrated the typical bands o f the agrin (Fig. 3A; 212 kDa) and glypican-1 (Fig. 3B; 64 
kDa) unglycosylated core protein. The expression o f these core proteins increased after 
DAß1-40-treatment (Fig. 3A and B, lane 2). In addition to the core protein, we observed 
a high molecular weight smear (>>200 kDa) immunoreactive w ith  anti-agrin antibodies 
(Fig. 3A, lane 2) after treatment w ith DAß1-40. A similar smear was observed for glypican-1 
(Fig. 3B, lane 2) in the absence o f DAß1-40, which became more intense after DAß1-40- 
treatment.
Agrin and glypican-1 could not be detected in cell culture medi­
um o f treated and untreated cells by Western b lot analysis (data not shown).
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Figure 3: Western blot analysis o f agrin (A) and glypican-1 (B) extracted from control HBP (lane 
1) and DAß140-treated HBP (lane 2) showed increased expression o f core protein and an incre­
ased high molecular weight smear after DAß140 treatment.
Aß-induced mRNA expression o f agrin and glypican-1
To test whether the increases in agrin and glypican-1 immunoreactivity represent chan­
ges in production o f these HSPG, we analyzed normalized mRNA expression o f agrin, 
glypican-1 and the positive control LRP-1 after 1-3 days o f DAß1-40 treatment relative to 
expression in untreated HBP by quantitative PCR (Fig. 4).
After one day o f treatment w ith DAß1-40, relative LRP-1 expression was signifi­
cantly (p<0.05) increased (1.58 ± 0.03) compared to untreated cells (Fig. 4A). A lower, near 
significant (p<0.10), increase in expression was detected on day 2 (1.42 ± 0.13) w ith an 
unsignificant increase on day 3 (1.21 ± 0.10). Agrin expression on day 1 demonstrated a 
near significant (p<0.10) increase (1.66 ± 0.24; Fig. 4B) w ith an unsignificant increase on 
day 2 (1.53 ± 0.17) and day 3 (1.15 ± 0.20). DAß1-40-induced expression o f glypican-1 was 
increased on day 1 (1.45 ± 0.20; Fig. 4C) and even significantly (p<0.05) increased on day 
2 (1.47 ± 0.04). On day 3, expression o f glypican-1 was unsignificantly increased (1.18 ± 
0.19).
Thedifferencesinagrinorglypican-1expressionbetweenAß-treatedanduntreated 
HBP were consistent in three separate experiments, but did not always reach statistical signi- 
ficance.Aß40-1,anAßpeptidewithaninversesequence,wasusedasanegativecontrolanddid 
not influence mRNA expression o f LRP-1, agrin and glypican-1 (data not shown), indicating 
that the increases in mRNA expression o f both LRP-1 and the HSPGs are specific for DAß1-40.
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Figure 4: Normalized relative mRNA expression o f LRP-1 (A), agrin (B) and glypican-1 (C) in 
untreated (white bars) and 1-3 days DAß1-40 treated HBP (grey bars). Expression o f all three 
genes was increased after treatment with DAß1-40 compared to expression in untreated cells. 
Expression was highest on the first day o f treatment. # p<0.10, * p<0.05
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Aß-induced 35S-sulfate incorporation
The size and composition o f GAG chains influence the biological function o f HSPG [91]. 
Sulfation o f the disaccharide units for example appears to be very selective and depends 
on the specific function o f the HSPG. To investigate the influence o f Aß on sulfation o f the 
GAG chains, incorporation o f radioactively labeled sulfate by HBP was assessed.
The incorporation o f 35S-sulfate was significantly enhanced in TGF-ß1-treated HBP, compa­
red to untreated control HBP (p < 0.01; Fig. 5). Addition o f DAß1-40 resulted in a significant 
3-fold increase in 35S-sulfate incorporation compared to untreated HBP (p < 0.01).
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Figure 5: Effect o f DAß1-40 on 35S-sulfate incorporation in human brain pericytes. TGF-ß1 treat­
ment markedly enhanced35 S-sulfate incorporation (*: p< 0.01) compared to untreated control 
HBP. Incubation with DAß140 resulted in a significant 3-fold increase in 35S-sulfate incorpora­
tion (*: p< 0.01) compared to untreated HBP.
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Discussion
HSPG expression is observed in various pathological lesions in AD brain tissue and the 
tim ing o f HSPG deposition parallels that o f Aß. This suggests a direct relation between 
Aß and HSPG, implying that HSPG may play a role in Aß aggregation and accumulation. 
Binding o f HSPG to Aß does indeed stimulate aggregation o f Aß and may affect cleavage 
o f Aß from its precursor protein [17, 204]. In this study, we demonstrated that Aß increases 
the production o f agrin and glypican-1.
Treatment o f cultured HBP w ith DAß1-40 resulted in increased immunoreactivity 
o f both agrin and glypican-1 (Fig. 1). Furthermore, the immunocytochemical analyses re­
vealed that after treatment o f HBP w ith DAß1-40, agrin could be found in association with 
amyloid fibrils attached to the cell surface, whereas in untreated cells agrin was found in 
the cytosol (phagosomes). This result was confirmed by our IEM analyses (Fig. 2). Binding 
o f agrin to amyloid fibrils is in line w ith earlier findings o f agrin associated w ith Aß in 
vitro and w ith  the presence o f agrin in the different Aß-containing lesions o f Alzheimer's 
disease [52, 69, 254, 255]. After DAß1-40 treatment, some agrin was still present in phagoso­
mal bodies. In these bodies, agrin could be found together w ith Aß, suggesting that both 
Aß and agrin were targeted for degradation, either as individual proteins or in a complex. 
We did not observe glypican-1 in phagosomal bodies.
Glypican-1 is a cell surface HSPG and could, accordingly, be observed at the cell 
membrane o f untreated HBP. After incubation w ith DAß1-40 glypican-1, like agrin, was de­
tected in association w ith Aß fibrils attached to the cell surface as well as in the cytoplasm. 
Our immunocytochemical and IEM studies suggest that the cell surface-associated Aß 
fibrils function as a HSPG retention reservoir. This may also be the molecular basis for ac­
cumulation o f HSPGs in the Aß-containing lesions o f AD brains.
An increased immunoreactivity may reflect enhanced agrin and glypican-1 pro­
duction after Aß treatment. We therefore investigated Aß-induced expression o f these 
HSPG and found that both protein and mRNA expression o f agrin and glypican-1 were 
increased after Aß treatment. Our Western blot analysis demonstrated an Aß-induced 
increase in core protein levels o f glypican-1 and agrin (Fig. 3). Furthermore, a (more pro­
nounced) high molecular weight smear characteristic o f glycosylated proteoglycans ap­
peared after Aß treatment in both HSPG. The presence o f this smear suggests that the 
degree o f glycosylation o f glypican-1 and agrin was altered when HBP were treated with 
DAß1-40, perhaps because Aß triggers the newly synthesized pool o f agrin or glypican-1 to 
become more heavily glycosylated. Since it is known that nitrocellulose membranes have 
a relatively low affinity for highly glycosylated proteoglycans, it is possible that we unde­
restimated the amount o f heavily glycosylated HSPG present in treated and untreated 
HBP. Finally, the absence o f both agrin and glypican-1 in cell culture medium may suggest 
that these HSPGs do not reach the cell culture medium or that the concentration o f these 
HSPG in the medium was too low to be detected in our Western blot.
Together w ith the increased protein levels we found that mRNA levels o f agrin 
and glypican-1 were increased after treatment w ith DAß1-40 , but not w ith the inactivated 
Aß40-1. Although it was already known that Aß can upregulate gene expression in HBP 
[195], to the best o f our knowledge this is the first report o f Aß-induced gene expression 
o f a protein involved in Aß aggregation.
Close examination o f the mRNA expression during three days o f culturing in the 
presence o f DAß1-40 revealed that the highest expression levels were found during the first 
tw o days. On the th ird day, expression levels had returned to control levels, which may
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reflect a negative feedback mechanism. It is unlikely that the decreased expression on the 
third day is a result o f increased cell death, that is observed after several days o f culturing 
w ith DAß1-40 [282], since expression levels o f agrin and glypican-1 were normalized against 
a housekeeping gene that should be similarly affected by this degeneration.
Another way to examine Aß-induced biosynthesis o f (HS)PG is by measuring sul­
fate incorporation into GAG side-chains. We demonstrated that DAß1-40 increased 35S-sul- 
fate incorporation into GAG chains o f HBP (Fig. 4), suggesting that Aß is able to influence 
GAG composition, e.g. by activating or inducing expression o f enzymes involved in the 
synthesis o f (HS) GAG chains, such as sulfotransferases and epimerases [256]. This may 
then contribute to the production o f the highly glycosylated and sulfated forms o f PG 
found in AD brains, but this remains to be investigated. However, it cannot be excluded 
that GAG chains other than HS chains, such as chondroitin sulfate (CS) chains, incorpora­
ted radioactive sulfate as well. Indeed, others [190] have demonstrated that radioactive 
sulfate incorporation into CS chains in the presence o f TGF-ß, our positive control, was 
increased more than 6-fold. Future sulfate incorporation experiments under CS degrading 
conditions may resolve the specific sulfate incorporation into HS chains. Furthermore, sin­
ce Aß fibrils may act as a HSPG reservoir, Aß-treated cells may retain larger amounts of 
GAGs that have incorporated 35S-sulfate, relative to untreated HBP. Finally, it is known that 
Aß can interfere w ith HSPG metabolism by inhibiting the degradation o f HSPG by hepara- 
nases [13], which may contribute to both the relatively high sulfate incorporation and the 
relatively high HSPG expression in Aß-treated cells.
In any case, our data suggest that DAß1-40 not only increases HSPG expression but 
also influences GAG composition. Since it is known that the sulfate moieties o f proteogly­
can GAG chains stimulate Aß fibril formation [40], Aß may indirectly stimulate its own ag­
gregation, by induction o f sulfate incorporation into HSPG.
In summary, we have demonstrated that Aß treatment o f HBP induces an incre­
ased cellular production o f both agrin and glypican-1, which are likely also modified by 
increased sulfate incorporation. Furthermore, after Aß treatment, agrin and glypican-1 
bind the Aß fibrils that attach to the cell surface. Interestingly, agrin and glypican-1 are 
not only the most predominant HSPG species accumulating in senile plaques [263], CAA 
and NFTs in AD brains, they are also the only tw o HSPG that have been demonstrated to 
interact directly w ith Aß [52, 271]. Since HSPG, and particularly the sulfate moieties o f the 
GAG side-chains, stimulate Aß aggregation, our findings suggest that Aß-regulated HSPG 
production may contribute to AD pathogenesis in general and HSPG accumulation in par­
ticular.
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Abstract
Glycosaminoglycans (GAGs), in particular as part o f heparan sulfate proteoglycans, are 
associated w ith cerebral amyloid angiopathy (CAA). Similarly, GAGs are also associated 
w ith the severe CAA found in patients suffering from hereditary cerebral hemorrhage 
w ith amyloidosis o f the Dutch type (HCHWA-D), where the amyloid ß (Aß) peptide con­
tains the Dutch mutation (DAß1-40). This suggests a role for GAGs in vascular Aß aggre­
gation. It was the aim o f this study to investigate the effect o f different GAGs (heparin, 
chondroitin sulfate, heparan sulfate), the macromolecule dextran sulfate and, using 
desulfated heparins, the role o f GAG sulfate moieties on the in vitro aggregation o f CAA- 
associated DAß1-40 and on DAß1-40-induced toxicity o f cultured cerebrovascular cells. We 
also aimed to study the in vivo distribution o f various sulfated heparan sulfate GAG epi­
topes in CAA. Of all GAGs tested, heparin was the strongest inducer o f aggregation of 
DAß1-40 in the different aggregation assays, w ith both heparin and heparan sulfate redu­
cing Aß-induced cellular toxicity. Furthermore, (partial) removal o f the sulfate moieties 
o f heparin partially abolished the effects o f heparin on aggregation and cellular toxicity, 
suggesting an essential role for the sulfate moieties in heparin. Finally, we demonstra­
ted the in vivo association o f sulfated heparan sulfate (HS) GAGs w ith CAA. We conclude 
that sulfate moieties w ithin GAGs, like heparin and HS, have an im portant role in Aß 
aggregation in CAA and in Aß-mediated toxicity o f cerebrovascular cells.
40
In troduction
Accumulation o f the amyloid ß (Aß) protein into senile plaques and cerebral amyloid 
angiopathy (CAA) is one o f the major pathological characteristics o f Alzheimer's disease 
(AD). Aß is a 4 kDa protein that is cleaved from the amyloid precursor protein (APP) by 
Y- and ß-secretases [81, 208]. After its cleavage, Aß can adopt a ß-sheet conformation and 
accumulate as insoluble deposits.
CAA is mostly found in cortical areas [241], w ith the occipital lobe being most 
severely affected. The hippocampus on the other hand, a brain area that is early and ex­
tensively affected by senile plaque formation, is not substantially affected by CAA [193]. 
When Aß is deposited w ithin the vessel walls, degradation o f cerebrovascular cells such as 
smooth muscle cells and human brain pericytes (HBP) is observed w ith subsequent loss 
o f vessel integrity [262]. Severe and widespread CAA is found in patients suffering from 
hereditary cerebral hemorrhage w ith amyloidosis o f the Dutch type (HCHWA-D) [251]. 
HCHWA-D is caused by a Glu-->Gln at amino acid 22 o f the Aß protein leading to extensive 
CAA accompanied by severe secondary pathology (i.e. hemorrhagic stroke).
We have previously demonstrated that several proteins, such as the small heat 
shock protein HspB2 [284], and the heparan sulfate proteoglycans (HSPG) glypican-1 and 
agrin [255] co-deposit w ith  vascular amyloid deposits in AD and HCHWA-D. HSPG are part 
o f a family o f proteoglycans that consist o f sulfated glycosaminoglycan (GAG) chains at­
tached to a core protein [91]. It is known that HSPG via their GAG chains, and to a lesser 
extent via their core protein, bind to Aß w ith  high affinity [219]. In this way they may in­
fluence the formation and stabilization o f Aß plaques [41, 52]. Other members o f the GAG 
family are dermatan sulfate, keratan sulfate and chondroitin sulfate (CS) [256]. Although 
less abundant than HSPG, these proteoglycans can also be found in the vicinity o f some 
Aß deposits [65, 221, 223].
The GAG chains o f proteoglycans are composed o f different disaccharide units, 
each comprising either N-acetylgalactosamine or N-acetylglucosamine in combination 
w ith glucuronic or iduronic acid [91]. In case o f HSPG, this disaccharide unit contains g lu­
curonic or iduronic acid and N-acetylglucosamine. Disaccharide units, in turn, are variably 
N- and O-sulfated, w ith  different GAGs having a different number o f sulfate moieties per 
disaccharide unit (Table 1). Notably, N-sulfates are essential for GAG chains to become 
subsequently sulfated at the 2-O and 6-O positions [201]. It appears that the biological 
function o f proteoglycans is dependent on their level o f sulfation and saccharide sequen­
ce [91].
Given the relation between Aß and cellular degeneration in CAA and the close as­
sociation o f HSPG and GAGs w ith CAA, we aimed to investigate the role o f different GAGs, 
and in particular their sulfate moieties, in DAß1-40 aggregation and DAß1-40-induced cellular 
toxicity o f cultured cerebrovascular cells. In addition, we studied the association o f d iffe­
rently sulfated HS in CAA-affected vessels using different HS domain-specific antibodies.
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M ateria ls and M ethods
GAGs and (desulfated) heparins
Heparin, heparan sulfate (HS) and chondroitin sulfate (CS) as well as N-acetyl-de-O-sul- 
fated (completely desulfated) heparin (CdS-Hep) and de-N-sulfated heparin (DeN-Hep) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in Milli Q water 
(1 mg/m l stock solutions). The different GAGs were chosen based on their level o f sulfation 
(Table 1). Dextran sulfate (DxS), a GAG-related macromolecule (Sigma-Aldrich), was cho­
sen for its high level o f sulfation.
HCHWA-D Aß140-protein
We used Aß containing the Dutch mutation (Glu22-->Gln22) as found in HCHWA-D 
(DAß1-40) as a model peptide, since this peptide has robust and reproducible aggregation 
properties and cytotoxic properties in vitro [54] and is associated w ith conditions o f se­
vere CAA formation in vivo, i.e. HCHWA-D. DAß1-40 was purchased from Quality Controlled 
Biochemicals (QCB; Hopkinton, Massachusetts, USA, 96% pure). We made a stock solution 
by dissolving the peptide in hexafluoroisopropanol, removing the solvent by evaporation 
and subsequently dissolving it in DMSO (5 mM). For circular dichroism analysis, stock so­
lutions o f the peptides were made in sterile water (250 ^M). Aliquots were stored at -80°C 
prior to use.
Thioflavin Tanalysis
DAß1-40 (50 ^M) was incubated up to 48 hours at 37°C w ith or w ithout GAGs or the desulp- 
hated heparins (250 ^g/m l) in Tris/NaCl buffer (50 mM Tris, 150 mM NaCl, 0.01% sodium 
azide pH 7.4). After several time intervals (1, 7, 24 and 48 hours), 20 ^l samples were taken 
from the incubation mixture. These samples were added to 980 ^l Thioflavin-T solution 
(50 mM glycine pH 9.2, 3 ^M Thioflavin-T). Samples were excited at 450 nm (slit w idth 5 
nm) and emission fluorescence was measured tw ice for each sample at 482 nm (slid width 
10 nm). Each experiment was repeated at least three times. Mean emission fluorescence 
o f one representative analysis ± standard error was plotted as a function o f time. At each 
tim e point, an unpaired two-sided t-test was performed to compare aggregation o f DAß1- 
40 w ith and w ithout the different GAGs and desulfated heparins.
Electron microscopy
After 48 hours o f incubation, 3 ^l samples were taken from the Thioflavin-T assay incuba­
tion mixtures to analyse by electron microscope (EM). The samples were diluted 10 times 
in ultra pure water, 5 ^l aliquots were placed on a formvar-coated Ni-grids and grids were 
then left to dry overnight at 37°C. The follow ing day, grids were washed w ith ultra pure 
water and negatively stained for 30 minutes w ith 4% filtered uranyl acetate solution. Fi­
nally, grids were air dried and examined using a Jeol 1200 EX/II electron microscope (Jeol 
Ltd., Tokyo, Japan) at 60 kV.
Circular dichroism (CD) analysis
DAß1-40 (50 ^M) dissolved in sterile water was incubated in Tris/NaCl buffer (50 mM Tris, 
150 mM NaCl, 0.01% sodium azide) w ith or w ithout (desulfated) heparins (250 ^g/m l) or 
GAGs (250 ^g/m l) for 48 hours at 37°C. All samples were kept on ice before measuring far 
UV spectra at 4°C w ith 1 nm intervals (240-195 nm). Measurements were performed on a 
Jasco J-810 spectropolarimeter (Jasco Inc., Easton, MD, USA) using a quartz cuvette (path
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length 1 mm). Spectra are an average of 15 scans recorded at a speed of 20 nm/min with 
5 scans of the Tris/NaCl buffer used as baseline.
Viability assay
HBP were isolated and characterized as previously described [265]. Cells were maintained 
in uncoated culture flasks at 37°C with complete medium containing Eagle's modified 
culture medium (EMEM), 20% fetal calf serum, 10% human serum (Lonza BioWhittaker 
Benelux BV, Breda, the Netherlands), 0.1% basic fibroblast growth factor and antibiotics. 
For the viability assay, HBP were transferred to 8-well chamber slides (Nunc, Roskilde, Den­
mark) coated with gelatin (1%) and cross-linked with glutaraldehyde (0.1%). After one day 
of culturing in complete medium, HBP were incubated with EMEM with 0.1% bovine se­
rum albumin (EMEM-BSA) overnight. The next day, cells were incubated with EMEM-BSA 
containing 10 ^M DAß1-40 with or without either 50 ^g/ml GAGs or desulfated heparins. 
Controls were cells incubated without DAß1-40 and without GAGs or desulfated heparins. 
After six days in culture, cell viability was quantified using a fluorescent Life/Dead® via­
bility kit (Invitrogen Molecular Probes, Eugene, Oregon, USA). Four fields per well were 
counted using a Leica DMI inverted fluorescence microscope (magnification 10x) and the 
percentage dead cells was calculated. Assays were repeated at least twice and data of 
one representative is presented as mean ± standard error. An unpaired two-sided t-test 
was performed to compare the effects of the different GAGs and desulfated heparins on 
DAß1-40-induced cell death.
Table 1: The number of sulfate moieties present in each disaccharide of 
different GAGs and a GAG related macromolecule
Glycosaminoglycan Sulfate moieties
per disaccharide unit 1
Dextran sulfate 2 4 - 6
Heparin 1.6 - 3
Heparan sulfate 0.4 - 2
Chondroitin sulfate 0.1 - 1.3
1 adapted from [94]
2 GAG-related macromolecule
Immunofluorescent staining of Aß on the cell surface of HBP
HBP were cultured for three days in 8-well chamber slides incubated with 10 ^M DAß1-40 
and either 50 ^g/ml GAGs or 50 ^g/ml desulfated heparins. HBP were then fixed for 10 
minutes with periodate-lysine-paraformaldehyde and incubated overnight with rabbit 
anti-Aß antibody 40-4 (1:200; generously provided by Dr. William van Nostrand). Subse­
quently, cells were incubated for one hour with the secondary antibody Alexa 594-labeled 
anti-rabbit (1:200; Invitrogen, Breda, The Netherlands). Topro-3 (1:1000; Vector laborato­
ries, Burlingame, California, USA) was used to stain nuclei. All antibodies were diluted in 
PBS/1% BSA. Staining was analyzed using a confocal laser-scanning microscope (Leica, 
Wetzlar, Germany).
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Human autopsy material
Occipital lobe tissue samples of a female AD patient (age 75 years, NFT Stage (Braak) VI, 
Plaque score (CERAD) C, CAA grade ++) were obtained after a rapid autopsy procedure, 
snap-frozen in liquid nitrogen and stored at -80°C until sectioning. Informed consent was 
obtained according to European guidelines.
Antibodies
The phage display antibodies directed against specific HS GAG motifs and the dilutions 
used are listed in Table 2. Phage antibodies were detected by monoclonal mouse anti-VSV 
(P5D4; Sigma-Aldrich Chemie BV, Zwijndrecht, NL). Anti-VSV was subsequently detected 
with goat anti-mouse 594 Alexa (Invitrogen, Carlsbad, CA, USA).
Immunohistochemistry
Cryosections (4^m) of the occipital neocortex were stained with the different phage dis­
play antibodies (Table 2). In short, sections were air-dried and fixed in 4% paraformalde­
hyde for 10 minutes. Phage display antibodies were diluted in PBS/1% BSA, and incubated 
overnight at 4 °C. Sections were then incubated with anti-VSV antibody (1:200) and sub­
sequently with goat-anti mouse 594 Alexa (1:200) for one hour each. For the detection of 
fibrillar Aß, sections were double stained with Thioflavin S (1% w/v in distilled water) for 
5 minutes at room temperature, in the dark. Then, sections were dehydrated with 70% 
ethanol. Finally, sections were mounted in Vectashield (Vector Laboratories) and staining 
patterns were analyzed using a fluorescence microscope (Leica, Wetzlar, Germany).
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Table 2: Phage display antibodies that recognize different sulfated HS GAG 
motifs
Antibody Moieties involved in binding Dilution 5
AO4B08 1 N-sulfation 
2-O-sulfation 
6-O-sulfation (high) 
C5-epimerization
1:1
EV3C3 2 N-sulfation
2-O-sulfation
C5-epimerization
1:5
HS4C3 3 N-sulfation
2-O-sulfation 
6-O-sulfation
3-O-sulfation
1:2
HS4E4 1 N-sulfation
N-acetylation
C5-epimerization
1:1
RB4EA124 N-sulfation
N-acetylation
6-O-sulfation
1:1
1 [137]
2 unpublished data
3 [239]
4 [277]
5 dilution used in immunohistochemical staining
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Results
GAGs affect Aß aggregation and Aß-mediated cell death
The effect of different GAGs, i.e. chondroitin sulfate (CS), heparan sulfate (HS), and heparin 
and the GAG-related macromolecule dextran sulfate (DxS) on aggregation of Aß was stu­
died using several different aggregation assays, i.e. Thioflavin T assay, electron microscopy 
and circular dichroism. Furthermore, we studied the pathological effects of these GAGs on 
Aß-mediated toxicity of cultured HBP.
In the Thioflavin T assay (Fig. 1), heparin and the highly sulfated DxS incre­
ased DAß1-40 aggregation, although this increase was only measurable after 24 hours 
of incubation. At this time point, heparin and DxS increased DAß1-40 fluorescence emis­
sion significantly (p<0.01 and p<0.05, respectively) three- to four-fold. After 48 hours 
of incubation only heparin significantly (p<0.001) increased DAß1-40 aggregation (3.5- 
fold). HS and CS had no significant effect on DAß1-40 aggregation at any time point.
□
□
□
DAß1-40
Hep + DAfr-40 
DxS + DAß,-40 
HS + DAß,-40 
CS + DAßi-40
Figure 1: Thioflavin-T analysis of DAß140 aggregated up to 48 hours (37°C) with different GAGs. 
heparin treatment significantly increased thioflavin-T fluorescence after 24 and 48 hours of 
incubation. DxS significantly increased fluorescence, but only after 24 hours of incubation. The 
other GAGs had no effect on aggregation. DxS: dextran sulfate; Hep: heparin; HS: heparan sul­
fate; CS: chondroitin sulfate. *p<0.05; **p<0.01, ***p<0.001
Using electron microscopy to visualize aggregation, it was revealed that aggre­
gation of DAß1-40 alone for 48 hours resulted in compact aggregates of Aß, whereas in­
dividual fibrils could hardly be detected (Fig. 2A). It was not possible to dissolve these 
compact aggregates by further dilution of samples either before or after incubation (data 
not shown). When DAß1-40 was co-incubated with heparin, extensive networks of long Aß 
fibrils were observed (Fig. 2B) in between compact aggregates that were much smaller in 
number than observed without heparin incubation. Similar to heparin, incubation with 
DxS induced the formation of an extensive network of Aß fibrils with only a small number 
of compact aggregates (Fig. 2C). Co-incubation with HS (Fig. 2D) or CS (Fig. 2E) resulted in 
an intermediate situation characterized by compact aggregates of DAß1-40 interconnected 
with long, mostly laterally aggregated, Aß fibrils.
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Figure 2: Electron microscopic analysis of DAß140 aggregated up to 48 hours (37°C) with 
different GAGs. Co-incubation with heparin (B) resulted in a network of fibrils in between the 
compact aggregates seen in untreated DAß 1-40 (A). A similar aggregation pattern can be seen 
after co-incubation with DxS treatment (C; compact aggregates present, but not shown). 
After co-incubation with HS (D) and CS (E), compact DAß1-40 aggregates interconnected with 
laterally aggregated fibrils are visible.
Magnification 10.000x;scale bar: 100 pim
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Figure 3: CD analysis of DAß140 aggregated for 0 or 48 hours (37°C) in the presence of different 
GAGs. After 48 hours of incubation DAß140 alone (A) has a conformation in between random 
coil (minimum 197 nm) and ß-sheet (minimum 220 nm, maximum 200 nm). In the presence 
of heparin (B) and CS (E), DAß140 adopts a ß-sheet conformation after 48 hours, whereas in 
the presence of DxS (C) and HS (D) a conformation in between random coil and ß-sheet was 
detected. At 0 hours of incubation DAß140 alone or in combination with the GAGs is in a ran­
dom coil conformation (A-E).
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To determine the conformation (i.e. random coil, ß-sheet) of DAß1-40 when incubated for 
48 hours with or without GAGs, we performed CD analysis (Fig. 3). Before incubation (0 
hours), a typical random coil conformation was observed (minimum at 197 nm) for DAß1-40 
alone or in combination with the different GAGs. After 48 hours of incubation, however, 
the spectrum of DAß1-40 alone demonstrated a conformation that had characteristics of 
both a ß-sheet and random coil conformation (minimum signal between 200 to 220 nm) 
(Fig. 3A). DAß1-40 incubated with heparin (Fig. 3B) resulted in a CD spectrum with a mini­
mum signal at 220 nm and a maximum at 200 nm, basically resembling a ß-sheet confor­
mation. DAß1-40 with either DxS (Fig. 3C) or HS (Fig. 3D) had an intermediate conformation 
(minimum signal at 220 nm and 213 nm, respectively), although a ß-sheet structure was 
more prominent than with DAß1-40 alone. The CD spectrum of DAß1-40 incubated with CS 
(Fig. 3E) demonstrated a minimum around 216 nm, indicative of a ß-sheet conformation.
Figure 4: Viability assay of HBP incubated for 6 days with DAß140 with different GAGs. Incuba­
tion of DAß 1-40 with heparin and HS significantly reduced DAß 1-40 - induced cell death, whereas 
DxS significantly increased HBP cell death. CS had no effect.
DxS: dextran sulfate; Hep: heparin; HS: heparan sulfate; CS: chondroitin sulfate. * p<0.05; 
***p<0.001
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Finally, we examined toxicity of HBP when they were cultured with Aß in com­
bination with the GAGs (Fig. 4). Incubation of HBP with DAß1-40 increased cell death of 
HBP from an average of 4 ± 1% in controls to 33 ± 2%. The GAGs alone had no effect 
on cell death compared to controls (data not shown). Both heparin and HS significant­
ly (p<0.0001) reduced Aß-mediated cell death in cultured HBP (9 ± 1% and 13 ± 2%), 
whereas DxS significantly (p<0.05) increased HBP death ( 44.5 ± 3%) and CS had no effect 
(39.5 ± 2%). To determine whether aggregation of Aß on the cell surface was related to 
the observed cellular toxicity, immunofluorescent imaging of HBP incubated with DAß1-40 
and the GAGs was performed. There were no obvious differences in DAß1-40 aggregation 
on the cell surface when comparing DAß1-40 alone or in combination with heparin (Fig. 5) 
or any of the other GAGs (data not shown). As mentioned earlier, the different GAGs used 
have different levels of sulfation (Table 1). To study the influence of sulfation on Aß aggre­
gation and toxicity, we next used desulfated forms of heparin.
Figure 5: Immunofluorescent staining of confluent cultures of HBP incubated with DAß1-40 al­
one (A) or in combination with heparin (B). No obvious change in the association of Aß (40-4; 
red) with the cultured cells (Topro-3; blue nuclei) was visible when DAß140 was incubated with 
heparin. Magnification 630x. Scale bar: 1 mm
Pathological effects of heparin are dependent on sulfate moieties
We studied the effects heparins with various degrees of sulfation, i.e. fully sulfated he­
parin, deN-sulfated heparin (DeN-Hep) and completely desulfated heparin (CdS-Hep), 
on Aß aggregation by using the same assays as previously mentioned. In the Thiofla­
vin T assay, the influence of sulfated heparin on DAß1-40 aggregation again became 
measurable only after 24 hours of incubation (Fig. 6); from that time point on it signi­
ficantly increased fluorescence emission (p<0.001) four-fold compared to the emis­
sion level seen with DAß1-40 alone. As seen before (Fig. 1) this significant increase 
remained until at least 48 hours of incubation. In contrast, neither DeN-Hep nor CdS- 
Hep affected DAß1-40 fluorescence at any time point between 1 and 48 hours (Fig. 6).
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Figure 6: Thioflavin-T analysis of DAß140 aggregated up to 48 hours (37°C) with different 
(desulfated) heparins. Heparin treatment significantly increased thioflavin-T fluorescence at 
24 and 48 hours of incubation. DeN-Hep and CdS-Hep had no effect on aggregation. DeN- 
Hep: de-N sulfated heparin; CdS-Hep: completely desulfated heparin. ***p<0.001
Electronmicroscopyrevealedthatafterco-incubationwithDeN-Hep(Fig.7C),unlike 
the vast network of fibrils seen when incubated with heparin (Fig. 7B), only a limited number 
of individual fibrils extending from the compact DAß1-40 aggregates were observed. Co-in­
cubation with CdS-Hep demonstrated compact aggregates similar to DAß1-40 alone (Fig. 7D).
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Figure 7: Electron microscopic analysis of DAß1-40 aggregated up to 48 hours (37°C) in the pre­
sence of different (desulfated) heparins. Co-incubation with heparin (B) resulted in a network 
of fibrils between the compact aggregates that were also seen in untreated DAß140 (A). Some 
individual fibrils protruding from compact aggregates are detected after coincubation with 
DeN-Hep (C). Incubation with CdS-Hep had no effect on DAß140 aggregation. Magnification 
10.000x;scale bar: 100 pm
When we examined the conformation of DAß1-40 in the presence of desulfated 
heparins, it was revealed that DAß1-40 incubated with DeN-Hep (Fig. 8C) resulted in a CD 
spectrum with a minimum signal at 220 nm and a maximum at 200 nm, basically res­
embling a ß-sheet conformation. This spectrum is therefore similar to the spectrum of 
DAß1-40 incubated with heparin (Fig. 8B). Incubation with CdS-Hep (Fig. 8D) also resulted 
in an intermediary conformation (minimum at 210 nm, maximum 195 nm), but with rela­
tively more aspects of a random coil structure than DAß1-40 alone (Fig. 8A). Before incubati­
on (0 hours), the conformation of DAß1-40, either with or without the (desulfated) heparins, 
was a typical random coil conformation (minimum at 197 nm) (Fig. 8 A-D).
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Figure 8: CD analysis of DAß1-40 aggregated for 0 or 48 hours (37°C) with different (desulfated) 
heparins. After 48 hours of incubation DAß140 alone (A) has a conformation in between ran­
dom coil (minimum 197 nm) and ß-sheet (minimum 220 nm, maximum 200 nm). After co­
incubation for 48 hours with heparin (B) and DeN-Hep (C), DAß 140 has a ß-sheet conformation, 
whereas co-incubation with CdS-Hep(D) results in an intermediate conformation between 
random coil and ß-sheet. At 0 hours of incubation DAß 140 alone or in combination with the 
heparins is in a random coil conformation (A-D).
In the cell culture experiment, the addition of heparin to DAß1-40 significant­
ly (p<0.05) decreased cell death from 46 ± 6%  to 25 %  ± 5% (Fig. 9). Addition of DeN- 
Hep or CdS-Hep to DAß1-40 resulted in cell death rates of 47 ± 6%  and 37 ± 14% res­
pectively, comparable with that of DAß1-40 alone (46 ± 6%). Incubation of HBP with 
the (desulfated) heparins alone did not influence cell death (data not shown). Con- 
focal imaging of HBP incubated with DAß1-40 and the (desulfated) heparins did not 
show a difference in DAß1-40 accumulation on the cell surface (data not shown).
Sulfated HS are associated with CAA in vivo
CAA-positive vessels were double-stained for Thioflavin-S and a variety of phage display 
antibodies directed against specific sulfated HS motifs (Table 2) to determine if there is 
an in vivo association of sulfated HS with vascular amyloid pathology (Fig. 10). Strong 
staining of Thioflavin-S positive vessels was observed with A04B08, EV3C3, HS4E4 
and HS4C3 (Fig. 10 K-N). RB4E12 showed little staining of Thioflavin-S positive vessels 
(Fig. 10 O).
Notably, whereas Thioflavin-S staining was localized to the outer layers of the 
vessels where Aß is typically deposited (Fig. 10 A-E), sulfated HS were observed in the
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entire vessel wall (Fig. 10 F-J), which also includes basement membranes that surround 
vascular endothelial cells.
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Figure 9: Viability assay of HBP incubated for 6 days with DAß140 with different (desulfated) 
heparins. Incubation of DAß140with heparin significantly reduced DAß140 - induced cell death, 
whereas DeN-Hep and CdS-Hep had no effect.
Hep: heparin; DeN-Hep: deN-sulfated heparin; CdS-Hep: completely desulfated heparin. 
* p<0.05
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Thioflavin-S HS4C3
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Figure 10: Immunofluorescent staining of Thioflavin-S positive cortical vessels of an 
AD patient (A-E) with different phage display antibodies that recognize different HS sul­
fate motives (F-J). In K-O, Thioflavin-S and HS staining is merged. Vessels with fibril­
lar Aß deposits were positive for most antibodies (K-N), but negative for RB4EA12 (O). 
Original magnification 630x.
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Discussion
Aggregated Aß in CAA is predominantly present in a fibrillar form. Since GAGs are abun­
dantly present in CAA of AD and HCHWA-D, it is possible that they contribute to the aggre­
gation of Aß in these vascular deposits. The main findings of our study are the following: 
1) heparin increases DAß1-40 aggregation and inhibits DAß1-40 -mediated cytotoxicity of 
cultured cerebrovascular cells, 2) this effect is mainly mediated by the sulfate moieties in 
heparin, since desulfated forms of heparin are less active or even inactive, 3) heparan sul­
fate, but not dextran or chondroitin sulfate, also inhibits DAß1-40 -mediated cytotoxicity of 
cultured cerebrovascular cells, although it has less pronounced effects on DAß1-40 aggre­
gation, 4) GAGs with various sulfation motifs are closely associated with CAA in AD brains, 
supporting a biological role for sulfated GAGs in the pathology of CAA.
Previous studies, using a limited number of aggregation assays and wild type 
Aß40 or amylin, suggested that GAGs could affect amyloid formation [39, 40]. In the pre­
sent study, we found that several GAGs can affect aggregation of DAß1-40, a peptide that 
mainly deposits in the cerebral vasculature. In particular, the highly sulfated heparin and 
DxS stimulated Aß aggregation and fibrillization as visualized in the Thioflavin T assay 
(Fig. 1), CD spectroscopy (Fig. 3) and also by EM analysis (Fig. 2). The moderately sulfa­
ted CS and HS had a stimulatory effect on aggregation as observed in CD spectroscopy 
and EM analysis, but not in the Thioflavin T assay. Therefore, we demonstrated that sulfate 
moieties of GAGs, in particular those of heparin, influence Aß aggregation, apparently 
regardless of the level of sulfation. The effects of the various GAGs on Aß aggregation, 
however, are likely not completely attributable to sulfate modifications only. For example, 
the exact composition of the sugar chains themselves varies greatly between GAGs, with 
each GAG being characterized by a different disaccharide unit. These differences may 
therefore also influence Aß aggregation, although, as far as we know, this has not been 
investigated.
Our data suggested that sulfation of heparin, was critical in the effect of heparin 
on the aggregation of DAß1-40, which is in concurrence with previous observations [40]. 
Removal of N-sulfates from heparin showed the same prevention of aggregation in the 
Thioflavin-T analysis as completely desulfated heparin (Fig. 6), suggesting that N-sulfates 
are of predominant importance in Aß fibril formation. In contrast, in EM analysis (Fig. 7), 
which shows more details of the architecture of the aggregates and fibrils that are for­
med, De-N-sulfated heparin had some effect on the fibril formation of DAß1-40, whereas 
co-incubation of fully desulfated heparin with DAß1-40 resulted in compact aggregates in­
distinguishable from aggregates formed by DAß1-40 alone. This suggests that O-sulfation 
has a dominant effect over N-sulfation of heparin, which was supported by a similar ob­
servation in CD spectroscopy (Fig. 8). Our data are thus contradictory with respect to the 
specific and relative roles of N- and O-sulfation and are only partly in line with others [39, 
40], where it was suggested that O-sulfation is more important in enhancing fibril forma­
tion than N-sulfation. The limited availability of de-O sulfated heparin prevented us from 
specifically studying the effects of O-sulfation of heparin.
It has to be mentioned that we did find some discrepancies in determining Aß 
aggregation state since the Thioflavin T results for CS and HS did not match the results 
found with CD spectroscopy and EM. This may be explained by the fact that information 
on aggregation retrieved from the different assays is partly overlapping. For example, 
EM analysis reveals structural information, but is not sensitive enough to demonstrate 
ß-sheet formation in smaller peptide aggregates; CD spectroscopy results in spectra that
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are often reminiscent of mixed a-helix and ß-sheet conformations rather than the pure 
forms of protein folding and with the Thioflavin T assay protein the type of aggregation 
that is detected is not exactly defined.
When cerebrovascular cells are cultured with Aß, Aß accumulates at the cell surf­
ace and induces cellular degeneration over time [262]. Previous studies demonstrated 
that the cytotoxic interaction of Aß with the cell can be inhibited in several ways, e.g. 
by proteolytic breakdown of Aß [196], by binding to the Aß protein thereby blocking its 
interaction with binding sites [194, 279] or, finally, by blocking possible intracellular signa­
ling cascades [116]. In our case, the protective effect of heparin towards DAß1-40 -mediated 
cell death (Fig. 4 and Fig. 9) may be explained by the increased propensity of DAß1-40 to 
aggregate in solution when heparin is present. This could then prevent the interaction 
of toxic monomeric, oligomeric or prefibrillar species of DAß1-40 with the cell surface. Alt­
hough this may form a mechanistic explanation for our findings, our immunofluorescence 
experiments leave room for one of the alternative explanations, since we did not observe 
differences in the association of DAß1-40 with the cell surface under the influence of the 
various (desulfated) GAGs. Furthermore, HS inhibited DAß1-40-mediated cell death in the 
absence of an overt effect on DAß1-40 aggregation and DxS increased DAß1-40 aggrega­
tion and DAß1-40-mediated cell death. Therefore, it is possible that heparin and HS may 
also protect cells against DAß1-40 -mediated death in another way, for example by affecting 
intracellular signaling cascades that lead to cell death. Future studies will have to reveal if 
and how such pathways are affected by these GAGs. In any case, the pathological effect of 
heparin was abolished after (partial) desulfation of heparin, suggesting a crucial role for 
sulfate moieties of GAGs in their interaction with DAß1-40.
In previous studies we demonstrated the presence of HS GAGs in CAA of AD 
brains [255]. Furthermore, with antibodies directed against HS core proteins, we demon­
strated that the heparan sulfate proteoglycans agrin, glypican-1, syndecan-2 [255] and 
collagen XVIII [257] co-deposit with CAA. In the present study, we stained CAA vessels 
with antibodies directed against different motifs of sulfated HS (Table 2) and demonstra­
ted that the HS chains that are associated with Thioflavin-S-positive vessels are in fact 
sulfated (Fig. 10). Apparently, there is some variation in the sulfation and epimerization 
pattern of HS in CAA-vessels, since not all HS motifs were found in these vessels, but the 
relevance of this variation remains to be investigated. Unfortunately, we could not deter­
mine the level of sulfation (i.e. high vs. low) of HS near CAA vessels, although a previous 
study suggested that HS of AD patients are more sulfated than HS of controls [152]. Finally, 
it must be mentioned that only one patient was examined, therefore, in the future a more 
elaborate study of sulfation of CAA-associated HS should be performed to further sub­
stantiate our results.
Given the close association of cerebrovascular cells with the HS(PG) in CAA, the 
question arises if HSPG are produced locally by pericytes and smooth muscle cells or, like 
Aß itself, are produced by neurons and transported with the interstitial fluid to blood ves­
sel walls [275]. In line with the former possibility, our immunohistochemical stainings 
revealed the presence of sulfated HS in the entire vessel wall, suggesting production by 
vascular cells. Indeed, we recently demonstrated that cultured HBP can produce HSPG, in 
particular - but not restricted to - agrin and glypican-1, and its production is stimulated by 
DAß1-40 [244]. Furthermore, we showed that DAß1-40 also increased sulfate incorporation 
into GAG chains, suggesting that HSPG modifications are induced by DAß1-40. Therefore, 
these in vitro data may explain our immunohistochemical observations of the association
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of sulfated HS with CAA vessels.
In summary, our data show the importance of GAG sulfate moieties within hepa­
rin, and probably also in other GAGs, in regulating CAA-associated Aß aggregation and 
thus influencing Aß-induced cytotoxicity. Given the close association of sulfated GAGs in 
CAA, this may provide a mechanistic basis for the observation that Aß is highly aggrega­
ted in CAA.
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Abstract
Alzheimer's disease (AD) is characterized by deposition of the amyloid beta (Aß) pepti­
de in brain parenchyma and vasculature. Several proteins co-deposit with Aß, including 
heparan sulfate proteoglycans (HSPG). HSPG have been suggested to contribute to Aß 
aggregation and deposition, and may influence plaque formation and persistence by 
stimulating Aß fibrillization and by protecting Aß against degradation. Mouse models 
for AD, expressing the human amyloid precursor protein (APP), produce Aß deposits si­
milar to humans. These models may be used to study disease pathology and to develop 
new therapeutic interventions. We aimed to investigate whether co-deposition of HSPG 
in AD brains can be replicated in the APPswe/PS1dE9 mouse model for AD and if a tem­
poral association of HSPG with Aß exists. We studied the co-deposition of several HSPG 
and of the glycosaminoglycan (GAG) side-chains of HSPG in the APPswe/PS1dE9 model 
at different ages by immunohistochemistry. We found that, although APPswe/PS1dE9 
mice did develop severe Aß pathology with age, co-deposition of HS GAG chains and 
the various HSPG (agrin, perlecan and glypican-1) was scarce (<10-30% of the Aß de­
posits were stained). Therefore, our data suggest that the molecular composition of Aß 
deposits in the APPswe/PS1dE9 mouse, with respect to the several HSPG investigated 
in this study, does not accurately reflect the human situation. The near absence of HSPG 
in Aß deposits in this transgenic mouse model may, in turn, hinder the translation of 
preclinical intervention studies from mice to men.
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Introduction
In order to study Alzheimer's disease (AD) pathology, many different mouse models have 
been developed to test new therapeutic agents and to develop potentially new diagnos­
tic tools [49]. All these transgenic mice express one or more human proteins involved in 
AD pathology, usually (a mutant form of) the amyloid precursor protein (APP). In humans, 
APP cleavage may result in the production of the amyloid ß (Aß) peptide and, in turn, Aß 
fibrillizes and accumulates in AD brains. Aß deposits can be found in the brain parenchy­
ma as fibrillar or non-fibrillar senile plaques (SP) and in the vasculature as cerebral amyloid 
angiopathy (CAA). Transgenic expression of APP in mice leads to similar Aß depositions. In 
addition to human APP, some models express (mutant) human presenilin-1 (PS1), which 
is an essential component of the Y-secretase enzyme complex that mediates cleavage of 
APP [208], to accelerate development of Aß pathology.
In humans, Aß aggregation is thought to be facilitated by several co-depositing 
proteins, including apolipoprotein E [173], small heat shock proteins [280, 284] and hepa­
ran sulfate proteoglycans (HSPG). HSPG consist of a core protein with glycosaminoglycan 
(GAG) chains attached [256]. There are several different HSPG, some (perlecan, agrin and 
collagen XVIII) associated with the extracellular matrix, some (glypican and syndecan) as­
sociated with cell membranes. The co-deposition of HSPG with Aß has long been descri­
bed [220] as has the association of different subtypes of HSPG with Aß deposits [52, 254, 
255]. Remarkably, HSPG seem to be associated with virtually all types of human amyloido- 
ses, e.g. in amyloid A (AA) and amyloid light chain (AL) amyloidosis [225, 226].
The HSPG agrin and glypican-1 were strongly associated with almost all SP in 
cerebral cortex, cerebellum and hippocampus of AD patients [254, 263]. Syndecan ex­
pression, however, could only be observed in a minority of cortical and hippocampal SP. 
Glypican-1 was the most common HSPG in CAA, with some deposition of agrin and syn- 
decan-2 within vascular Aß deposits. Perlecan could neither be detected in SP nor in CAA, 
although this HSPG was previously thought to be most commonly associated with the 
pathological lesions of AD [222, 224].
The close association of HSPG with Aß in vivo suggests an important role for the­
se molecules in Aß deposition. Indeed, in vitro studies have shown that HSPG can regulate 
Aß production [17, 147, 204] and stimulate Aß aggregation [41, 52]. Furthermore, Aß pla­
ques may be protected from degradation by HSPG [87] and Aß, in turn, can protect HSPG 
from degradation [13]. We also recently demonstrated that mRNA expression of agrin and 
glypican-1 is induced by Aß in human brain pericytes [244]. Although Aß and HSPG mutu­
ally influence each other's production and degradation, and furthermore deposit simulta­
neously [222], it is yet unclear if HSPG are already associated with the earliest cerebral Aß 
depositions.
Since HSPG appear to be crucial in human Aß deposition, we aimed to inves­
tigate if transgenic mouse models for AD recapitulate the findings in AD brains. To this 
end, we used the frequently described transgenic APPswe/PS1dE9 mouse model, a well- 
characterized model [82] exhibiting a severe amyloid pathology starting from about 4-6 
months of age. Since transgenic mouse models allow for study of the temporal associa­
tion of HSPG with Aß, we investigated expression of several HSPG and of their GAG side- 
chains at different ages, in order to get a good understanding of the possible role of HSPG 
in the different stages of AD pathogenesis.
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Materials and Methods
APPswe/PS1dE9 mice
A colony of APPswe/PS1dE9 mice was established at the Central Animal Laboratory of the 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, after obtai­
ning founder animals from Johns Hopkins University, Baltimore (MA), USA. In short, this 
model was created by co-injecting the two transgenes with a prion protein promoter in 
the pronucleus of single cell C57Bl/6 embryos [112].
Female APPswe/PS1dE9 mice were group-housed in standard cages with nestlets 
and an igloo as cage enrichment. There was a 12 hour light-dark cycle (lights on at 7 am), 
with a constant temperature of 21±1°C, humidity control and background music during 
the light phase. Standard food pellets and acidified water (pH 2.5-3) were given ad libi­
tum. This study was approved by the Animal Care Committee of the Radboud University 
Nijmegen Medical Centre (RU-DEC) and was performed according to the guidelines of 
the Dutch Council for Animal Care and the European Communities Council Directive of 
24 November 1986 (86/609/EEC). Our study was also in concurrence with the European 
regulations on ethics and responsible conduct regarding scientific communication.
Transcardial perfusion
At 5 (n=5), 8 (n=5), 12 (n=4), 15 (n=3) and 18 months (n=4) of age, mice were anesthetized 
with 2-4% isoflurane and transcardially perfused with sterile phosphate buffered saline 
(PBS; Roche, Mannheim, Germany). After perfusion, mice were decapitated and brains 
were collected. One hemisphere was snap-frozen in liquid nitrogen and stored at -80°C 
until further analysis.
Immunohistochemical staining
Serial 5 ^m sagittal cryosections were stained for Aß and different HSPG (Table 1). In short, 
brain tissue was fixed with acetone and incubated with 20%  normal serum from the host 
species of the secondary antibody used. Sections were incubated with primary antibody 
overnight at 4°C and after which they were incubated with biotin-labeled secondary anti­
bodies for one hour at room temperature. As secondary antibody, horse-anti-mouse was 
used for 6C6, goat-anti-mouse IgM for JM403, goat-anti-rabbit for M95 and C40 and C42, 
horse-anti-goat for Bl31 and rabbit-anti-rat for MAB1948. Subsequently, sections were in­
cubated with an avidin-biotin complex (ABC) solution (Vector, CA, USA) for 45 minutes. 
Staining was developed using 5% diaminobenzidine (DAB) and 0.5% hydrogen peroxide. 
Copper sulfate (0.5% in saline) and haematoxylin were used to counterstain the surroun­
ding tissue. For each different HSPG staining, four sections of each mouse were used, se­
parated by 50 ^m (for Aß eight slices per mouse were stained). The number of Aß plaques 
and the number of HSPG-positive Aß plaques were counted manually. Two of the authors, 
who were blinded to the age of the mice, counted five microscopical fields (magnification 
200x) per randomized section. The number of HSPG-positive plaques is given as the per­
centage of Aß plaques that stained for a specific HSPG. Finally, percentages of co-deposi­
tion determined in the sections were averaged for each age group.
Statistical analysis
For the different age groups, the average number of Aß plaques and the percentage of 
plaques positive for HSPG were compared using One-way ANOVA with Bonferroni post 
hoc tests (SPSS).
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Table 1: Primary antibodies used to stain Aß and the different HSPG 
Antibody Antigen Dilution Source
6C6 Aß 1:1000 Elan pharmaceuticals, 
San Francisco, CA, USA
C40 Aß40 1:500 dr. T. Saido, Tokyo, Japan
C42 Aß42 1:500 dr. T. Saido, Tokyo, Japan
JM403 HS GAG 1:500 [248]
M-95 Glypican-1 1:50 Santa Cruz Biotechnology,
Santa Cruz, CA, USA
BI31 Agrin 1:750 [250]
MAB1948 Perlecan 1:500 Millipore, Billerica, MA, USA
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Results
Aß plaque number increases with age
The average number of plaques (Aß staining) increased with age (Fig. 1A), with a slight 
decrease at 18 months. At 12 months, plaque number was significantly (p<0.05) higher 
than at 5 months. At 15 and 18 months this number was significantly (p<0.05) higher than 
at 5 and 8 months. Aß-positive vessels were low in number or absent in mice between 5 
and 15 months old (Fig. 1B). At 18 months there was a significant (p<0.05) increase in the 
number of Aß-positive vessels compared to all other age groups. Because the number of 
Aß-positive vessels was very low, we did not quantify co-deposition of these vessels with 
the different HSPG.
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Figure 1: The average Aß plaque number (±S.E.M.) increased with age in the APPswe/PS1dE9 
mouse model (A), whereas the average number of Aß-positive blood vessels (±S.E.M.) was low 
(B), except in the 18-month-old mice. Sagittal sections (5 pm) of mice aged 5 months (C) or 15 
months (D) were stained for Aß using the 6C6 antibody and plaques and Aß-positive vessels 
were counted in 8 sections per mouse. (A) * p<0.05 compared to 5 months old. A p<0.05 com­
pared to 8 months old. (B) * p<0.05 compared to all other groups. Magnification 200x.
Expression of HS GAGs and the membrane-associated HSPG glypican-1 
To assess HS GAG deposition in APPswe/PS1dE9 mice, the JM403 antibody was used. At 
5 months of age, approximately 29% of Aß plaques were positive for GAG (Fig. 2A). This 
number decreased to 18% at 8 months and showed a steady incline to 34% at higher
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ages, but these changes were not significant (p>0.05). Both Aß-positive and Aß-negative 
cerebral vessels (Fig. 2D) were stained for GAG in all sections. Approximately 9% of Aß pla­
ques were positive for the glypican-1 antibody (M95) at all ages (Fig. 2B). Although some 
vessels were stained with M95 (Fig. 2E), vascular staining for glypican-1 was minimal. The 
immunohistochemical stainings did reveal staining of glial cells with the glypican-1 anti­
body (inset Fig. 2E).
Figure 2: Percentage of plaques positive for HS GAG (A) and glypican-1 (B). At and above the 
age of 8 months, the number of HS GAG-positive plaques increased with age (A). However, in 
5-month-old mice there was more HS GAG (29%) co-deposition with Aß than in 8-month-old 
mice (18%) but this was not significant (p>0.05). The number of glypican-1 positive plaques 
was low and remained constant with increasing age (B). Immunohistochemical analysis (C­
E) of a 15-month-old mouse demonstrated HS GAG and glypican-1 positive plaques (open 
arrows). An Aß-negative vessel was positive for HS-GAG (short closed arrow; D) and an Aß­
positive vessel (long closed arrow) was positive for both HS GAG (D) and glypican-1 (E). The 
inset (E) shows a glial cell positive for glypican-1 (arrowhead). Magnification 200x; magnifi­
cation inset 400x.
To assess HS GAG co-deposition with different Aß species, a serial staining for HS GAG, 
Aß40 and Aß42 was performed (Fig. 3). In 15-month-old APPswe/PS1dE9 mice, Aß42 pla­
ques were more numerous than Aß40 plaques, with all Aß40-positive deposits also being 
positive for Aß42 (Fig. 3A vs. 3B). Both Aß42- and Aß40- positive plaques were stained for 
HS GAG (Fig. 3B vs. 3C).
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Expression of the extracellular matrix-associated HSPG agrin and perlecan 
Staining of plaques with the agrin antibody (Bl31) was most frequent at 5 months of age 
with 11% of plaques being positive for this HSPG (Fig. 4A). Co-localization of agrin with 
Aß was not significantly lower (3-7%; p>0.05) at 8-18 months and, in general, staining was 
weak (Fig. 4D). Agrin staining was also detected in many cerebral blood vessels (Fig. 4G), 
including several Aß-positive vessels. Antibody MAB1948 for perlecan only weakly stained 
Aß plaques for all age groups tested (1-4%; Fig. 4B). However, strong staining for perlecan 
was detected in many cerebral blood vessels (Fig. 4E and H).
Figure 3: Aß40- (A) and Aß42-positive (B) plaques and co-deposition with HS GAG (C) in a 
15-month-old APPswe/PS1dE9 mouse. Aß42-positive plaques were more numerous than 
Aß40-positive plaques. All Aß40-positive plaques were positive for Aß42. HS GAG staining 
could be observed in both Aß42- and Aß40-containing plaques (open arrows).
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Figure 4: Percentage of plaques positive for agrin (A) and perlecan (B). The number of agrin and 
perlecan positive plaques is very low (<10%). Immunohistochemical analysis of an 18-month- 
old mouse (C-E) demonstrated agrin-positive (open arrows in D) and perlecan-negative pla­
ques (E). Aß-positive vessels (long closed arrows; F) were positive for agrin (G) and perlecan (H). 
Normal vessels unaffected by Aß deposition were also stained by antibodies against agrin and 
perlecan (short closed arrows in C-E). Magnification 200x.
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Discussion
Due to their close association with Aß deposits in humans, HSPG are thought to play a 
crucial role in Aß deposition. Using the APPswe/PS1dE9 mouse model for AD, we now 
establish that, although Aß deposits do contain HSPG as detected by the HS GAG anti­
body JM403, deposition of HSPG in plaques is less abundant in this mouse model than in 
humans [254, 255]. In fact, co-deposition of the different HSPG subtypes (i.e. glypican-1, 
agrin and perlecan) with Aß deposits was generally detected in less than 10% of the les­
ions. In contrast, agrin and glypican are present in virtually all cortical and hippocampal 
senile plaques of human AD patients [254, 263].
Deposition of Aß in mouse models morphologically resembles deposition in humans, but 
there are also many differences [129]. Due to overexpression of human APP, its deposition 
in mice is a much faster process than the natural deposition observed in humans [197]. 
Mouse Aß species often do not have the same posttranslational modifications as human 
Aß [136] and compact deposits are less dense in mice. While human Aß plaques can hard­
ly be dissolved, mouse plaques are soluble in most detergent-containing buffers [129]. It 
was suggested that the increased solubility of mouse plaques compared to human pla­
ques is due to the presence of glycoproteins in human, but not mouse, Aß deposits [129]. 
Our data support this idea as we could not detect co-deposition of HSPG at the same level 
as observed in humans.
There is great variation between different mouse models in terms of AD patho­
logy development. A previous study on HS co-deposition in sporadic AD patients and 
familiar PS1dE9 patients revealed that HS preferentially accumulated in Aß40 deposits 
and were absent in most Aß42 deposits [180]. Furthermore, in the Tg2576 model, that 
is known to accumulate substantially more Aß40 than Aß42 [122], more than 95% of Aß 
deposits were positive for HS [180], although most HS-positive deposits contained both 
Aß40 and Aß42. One characteristic of the APPswe/PS1dE9 mouse model is that it demon­
strates a shift in the Aß40:Aß42 ratio towards Aß42 due to expression of the mutated PS1 
gene [111]. Indeed, we found more abundant Aß42 than Aß40 staining in these mice. Ho­
wever, in contrast to the previous study on Tg2576 mice, in the APPswe/PS1dE9 model HS 
seem to preferentially, but not exclusively, accumulate in Aß42-positive plaques. Further 
study, using more AD mouse models and AD patients, will perhaps elucidate if HS prefe­
rentially co-deposit with one particular Aß species.
Previously, the membrane-bound HSPG glypican-1 and syndecan-3, but not 
agrin, perlecan or syndecans-1 and -2, were found co-deposited with Aß in the Tg2576 
mouse model [180], with these HSPG apparently expressed by astrocytes and microglia 
surrounding the Aß deposits. Using the APPswe/PS1dE9 model, we could detect several 
HSPG subtypes, albeit in only a low percentage of Aß plaques. Our glypican-1 antibody 
(M-95) also stained some astrocytes, suggesting that this cell type, along with other cells 
such as pericytes [244], may be responsible for expression of this HSPG.
As expected, in our APPswe/PS1dE9 mice we found an increase of Aß plaque 
number with age. The decrease in plaque number at 18 months of age was unexpected 
but may be the result of inter-animal variation. The number of cerebral Aß-positive ves­
sels in our mouse model was low. Only at 18 months of age did we detect a reasonable 
number of CAA vessels. Previous immunohistochemical studies in this model [154] also 
showed late development (i.e. after 16 months) of vascular amyloidosis in this model, 
although others, using alternative techniques, demonstrated that APPswe/PS1dE9 mice 
could develop CAA as early as 6 months of age [82]. In any case, due to the low number
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of CAA vessels, we could not reliably determine the co-deposition of the different HSPG 
species with vascular amyloidosis in the APPswe/PS1dE9 mouse model. Unlike glypican-1, 
agrin and perlecan were present in all cerebral blood vessels, a result that does reflect the 
human situation [255] and excludes the possibility that the antibodies used in this study 
did not detect murine HSPG.
In conclusion, we demonstrated minimal co-deposition of HSPG with Aß in the 
APPswe/PS1dE9 mouse model for AD. This mouse model did develop progressive Aß pa­
thology but we did not detect a temporal relation between HSPG and Aß deposition. Our 
data suggest that the molecular composition of Aß deposits in a transgenic mouse model, 
with respect to the HSPG studied here, does not accurately replicate the composition of 
human cerebral Aß deposits as commonly observed in AD brains. This may have impor­
tant consequences for preclinical intervention studies aimed at removal of Aß deposits 
from the brain, since the close interaction between HSPG and Aß may be crucial for the 
success of such depletion strategies. The relative absence of HSPG in Aß deposits in trans­
genic mouse models may therefore hinder the translation of intervention studies from 
mice to men. Future studies, using other models, may reveal whether our findings also 
apply to other transgenic mouse models of AD and to other Aß-associated factors that are 
commonly found in human Aß deposits.
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Abstract
Senile plaques and cerebral amyloid angiopathy in Alzheimer's disease (AD) patients 
not only consist of the amyloid ß protein (Aß), but also contain many different Aß- 
associated factors, such as heparan sulfate proteoglycans, apolipoproteins and comple­
ment factors. These factors may all influence Aß deposition, aggregation and clearance 
and therefore seem important in the development of human Aß deposits. To study AD 
pathology and test new therapeutic agents, many different mouse models have been 
created. By transgenic expression of the amyloid precursor protein, frequently in com­
bination with other transgenes, these animals develop Aß deposits that morphologi­
cally resemble their human counterparts. Whether this resemblance also applies to the 
presence of Aß-associated factors is largely unclear. In this review, the co-deposition of 
factors known to associate with human Aß deposits is summarized for several different 
AD mouse models.
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Introduction
To investigate disease mechanisms and test new therapeutic agents, animal models are 
necessary tools. Even though the use of animals is ethically controversial, there are no 
other models available that are capable of reproducing the complex nature of human 
physiology. However, mimicking disease is not easy in animal models, since the biological 
pathways in animals are often not identical to those in humans. Therefore, most models 
are created as transgenics, expressing (mutated) human proteins implicated in human 
disease. But even in transgenic models, it remains difficult to accurately model symptoms 
and pathology of a human disease.
Alzheimer's disease (AD) is pathologically characterized by accumulation of the 
amyloid ß (Aß) protein in senile plaques (SP) and cerebral amyloid angiopathy (CAA) [85, 
294] and by accumulation of hyperphosphorylated tau protein [12]. One of the earliest 
brain regions affected is the hippocampus, a brain region involved in memory formation. 
Indeed, memory impairment is one of the main symptoms of AD [24, 230]. The impor­
tance of Aß in the pathogenesis of AD, has been emphasized by the discovery of multiple 
causative mutations in Aß-related genes (amyloid precursor protein and presenilin genes) 
in familial AD [237].
Aß is a cleavage product of the amyloid precursor protein (APP) and generally 
comprises either 40 (Aß40) or 42 (Aß42) amino acids. APP is a transmembrane protein 
that can be cleaved by several different secretases to release Aß and a number of other 
cleavage products [45, 58, 288]. In the case of Aß, APP is first cleaved by a Y-secretase [31] 
and then by a ß- secretase [218, 260]. Many of the mutations in APP that cause the familial 
forms of AD are found close to these APP cleavage sites [237]. Aß is normally cleared from 
the brain, but when this clearance process becomes impaired, for example due to aging, 
Aß can start to oligomerize and eventually form fibrils. This fibrillization can then result in 
the formation of Aß deposits throughout the brain. Besides mutations in APP, pathogenic 
mutations have also been found in presenilin-1 (PS1) and, to a lesser extent, presenilin-2 
[29, 237]. Both these presenilins are part of the Y-secretase complex responsible for Aß 
cleavage from APP [31, 289]. These mutations increase Aß production, in particular of the 
more fibrillogenic Aß42 variant [25].
In more than 99% of AD cases ageing is the most important risk factor to deve­
lop AD, whereas in less than 1% of cases the disease can be related to gene mutations. 
However, there are only a few animal species, including dogs and primates, that naturally 
develop AD-like pathology with advanced age [202]. To create models for AD with a faster 
development of Aß pathology, transgenic (Tg) mouse models have been generated based 
on the introduction of human (mutated) APP, either alone or in combination with (muta­
ted) presenilin genes [80]. Mice are usually the animals of choice for creating transgenics, 
since they are not only very susceptible to genetic manipulation, but are also relatively 
easy and cheap to maintain.
The first AD mouse model that was developed was the PDAPP model [79]. In this 
model, starting at an age of 6-9 months immunohistochemically detectable Aß deposits 
developed, that become more dense upon ageing and finally morphologically resemble 
Aß deposits found in humans. Furthermore, as seen in humans, the Aß deposits in the 
PDAPP mice are surrounded by activated astrocytes and microglia and accompanied by 
a loss of synaptic density. PDAPP mice also develop cognitive deficits including memory 
impairment [68], further demonstrating their similarity to human AD patients.
Many more AD mouse models with Aß pathology have been created since this
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first model [80], all characterized by deposition of plaque-like Aß, and most of them de­
veloping cognitive impairment [80]. Due to the different gene combinations and mutati­
ons used to create these mice, there are, however, many differences between models. For 
example, the age of pathology onset in AD models varies greatly. In some mice, such as 
the TgCRND8 model, deposition starts at an age of 3-6 months [42], while in others, such 
as the Tg2576 model, it starts at an age of 9-12 months [106]. In general, co-expression of 
PS1 lowers the age of onset [111], because APP in these mice is more readily cleaved by 
the Y-secretase [101]. Plaque morphology can also vary greatly between different models. 
For example, APP23 mice accumulate mostly compact deposits [232], while parenchymal 
Aß deposits in TgSwDI mice are mostly diffuse [55]. Contrary to APP23 mice, that deve­
lop CAA next to parenchymal deposits [37], TgSwDI mice, but also for example APPDutch 
mice, accumulate Aß mainly in the brain vasculature with limited parenchymal deposition 
[55, 96]. This characteristic makes these latter models suitable models for familial and spo­
radic cases of vascular amyloid pathology. APP and APP/PS1 models do not develop tau 
pathology, but tau transgenic mice have been developed [86, 151]. There is also a triple 
transgenic mouse model available, overexpressing tau, APP and PS1 [181].
Even though most AD mouse models demonstrate Aß pathology that morpholo­
gically resembles human AD pathology, the Aß deposited in mice is chemically different 
from human Aß. In humans, Aß species undergo posttranslational modifications, such 
as N-terminal degradation, cross-linking and isomerization. These modifications are ei­
ther not found in AD mouse models or differ from the human situation [119, 136, 258]. 
Furthermore, Aß deposits in mice are usually less compact than in humans, allowing mild 
extraction buffers to more easily extract Aß from mouse brains relative to human brains. 
Finally, progressive AD pathology in humans is characterized by neurodegeneration, a 
characteristic that is rarely reproduced in AD mouse models [80]. Only the APP23 mouse 
model has been shown to have some neuronal loss in the CA1 region of the hippocampus 
[38].
In humans, Aß deposits not only contain the Aß protein, but immunohistoche­
mical analyses also demonstrated many other proteins [1, 264, 281]. It is thought that be­
cause of their close association, these co-deposited molecules contribute to Aß aggrega­
tion and deposition. Although this has not been proven for all co-depositing proteins, in 
vitro studies showed that heparan sulfate proteoglycans (HSPG), apolipoprotein E (apoE) 
and a1 chymotrypsin (a1-ACT), can indeed bind to Aß, affect its aggregation, stabilize Aß 
deposits and protect deposits against proteolytic degradation [156, 256, 286]. Because of 
their tight association with Aß, these (glyco-) proteins may greatly influence the outcome 
of therapeutic intervention in humans, aimed at reducing Aß aggregation and deposition. 
Since all new potential AD therapeutics are first tested in mouse models, it is important 
to know if these Aß-associated factors are present in the various mouse models. In this 
review, we aim to examine the validity of AD mouse models with respect to the presence 
of the main Aß co-depositing factors HSPG, apoE, complement factors, acute-phase pro­
teins, ICAM-1, cystatin C and CLAC. An overview of the co-deposition of these factors in 
transgenic AD models is shown in Table 1 and discussed below.
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Table 1 : Association of proteins that co-deposit with senile plaques in AD with Aß deposits in different mouse models for AD. 
Co-depositing AD mouse models Reference
factor Tg2576 PS/APP APP23a TgSwDIb APPswe/PS1dE9 APP-YAC
Heparan sulfate 
proteoglycans
HSGAG 
Perlecanc 
Glypican-1 
Agrin 
Syndecans
+ 
' 
+ 
' 
+i
+
+i +i +i
[26,180, 242]
ApoE
ApoJ
+ + + + +
+
[33,134, 135, 
206, 240, 258]
Complement [76, 78,162,
Clq + + ±/ + + 191,206, 300]
C3 + ±/ + +
C3d ±/ +
C4 + - +
C4d -
C7 -
C9 -/±
Acute phase [132,206]
proteinsd
Serum amyloid P
a2-macroglobulin +
ICAM-1 + [7]
Crystatin-c + [150]
CLAC + e [133]
( - no co-deposition; ± weak co-deposition; + strong co-deposition) 
a only compact Aß deposits visible 
k co-deposition with vascular Aß 
c expression in senile plaques in AD is controversial 
mice do not possess an a1-antichymotrypsin homologue [178] 
e co-deposition with Aß40- and Thioflavin S-negative plaques
Heparan sulfate proteoglycans (HSPG)
More than twenty years ago, close association of HSPG with Aß deposits in humans, both 
parenchymal and vascular, was first described [220]. HSPG consist of a protein core with 
several highly sulfated glycosaminoglycan chains attached. These glycosaminoglycan 
chains consist of repeating disaccharide units. There are several different HSPG species, 
some membrane-associated (glypicans and syndecans) and some associated with the ex­
tracellular matrix (agrin, collagen XVIII and perlecan). HSPG are thought to be involved in 
numerous (developmental) processes, including neurogenesis, angiogenesis and blood 
brain barrier permeability [256]. Of the different HSPG species, agrin and glypican-1 are 
the only two HSPG found in association with all different types of Aß deposits [52, 254, 
255]. The association of perlecan with Aß deposits is controversial, as one study described 
this HSPG to have the strongest association [220], whereas we have been unable to detect 
perlecan in CAA or SP [254, 255]. Overall though, HSPG are key components of human Aß 
deposits. Indeed, in vitro analysis has demonstrated that HSPG can bind Aß with high af­
finity, mainly through their glycosaminoglycan chains [219]. Through this binding, HSPG 
can enhance Aß deposition [41, 52, 256], a process that seems to involve HSPG sulfate 
moieties [40].
There are only a few studies describing co-deposition of HSPG with Aß depo­
sits in mouse models. In a characterization study of APP23 mice, it is very briefly menti­
oned that HSPG co-localize with Aß deposits [26]. A more elaborate study was done using 
20-month-old Tg2576 mice [180]. It was demonstrated that antibodies against heparan 
sulfate stained more than 95% of the "doughnut"-shaped Aß deposits visible in this mo­
del. Whereas in the APP23 mice no distinction was made between individual HSPG spe­
cies, in the Tg2576 mice it was discovered that glypican-1 and syndecan-3, but not agrin, 
perlecan, syndecan-1 and -2, were found in the Aß deposits. Therefore, in this mouse mo­
del the extensive co-deposition of HSPG seen in humans could only partly be reproduced. 
For example, agrin, a HSPG that is abundantly present in AD senile plaques, was absent 
from Aß deposits in mice, demonstrating that the association of individual HSPG species 
with Aß pathology may not always match the human situation.
We recently studied deposition of several HSPG species in the APPswe/PS1dE9 
mouse model [242]. In this model, in general HSPG were associated with approximately 
30% of Aß deposits. Furthermore, co-localization of the different HSPG species (agrin, 
glypican-1 and perlecan) occurred in less than 10% of Aß deposits for each of the spe­
cies. Therefore, HSPG co-deposition was much less pronounced in this model than in the 
Tg2576 model or in humans. Due to a low number of detectable vascular deposits, co­
deposition of HSPG with CAA vessels could not be determined in this model, nor was it 
investigated in the Tg2576 model.
Overall, the mouse models seem to differ from human AD pathology in either 
the type of HSPG species that co-deposit or the number of plaques in which HSPG co­
deposition is observed. As previously hypothesized [129], it may be that the lack of glyco­
proteins, like HSPG, in Aß deposits in mice is the reason that these deposits are generally 
less compact and more easily dissolved. It is important to note that HSPGs are an invari­
ant component of all known human amyloidoses, both cerebral and in peripheral organs, 
pointing to a very important role in amyloidosis in general [225], a property that is appa­
rently partly lacking in Tg mouse models for AD. As far as we know, co-deposition of HSPG 
has not been studied in mouse models for other types of amyloidosis.
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Apoliprotein E
Apolipoprotein E (apoE) is the most prominant apolipoprotein in the central nervous sys­
tem and mainly produced by astrocytes [27], although other cell types such as pericy­
tes and smooth muscle cells also contribute to cerebral levels [30, 282]. ApoE binds to li­
poproteins and mediates their interaction with lipoprotein receptors and endocytosis and 
in this manner regulates cholesterol homeostasis [185]. There are three isoforms of apoE 
(apoE2, 3 and 4), and the apoE4 isoform is a well-known risk factor for AD [231], whereas 
the apoE2 isoform seems to be protective for the development of AD. The exact role of 
apoE in AD, however, is still elusive [126]. In vitro studies have demonstrated a direct inter­
action between Aß and apoE [231] and it is suggested that through this interaction apoE 
can influence Aß aggregation and mediate Aß clearance [126, 156, 286].
The fact that apoE can bind Aß in vitro, suggests an interaction of these two 
proteins in vivo. Indeed, clear co-deposition of apoE with human Aß deposits has been 
shown. ApoE immunoreactivity is observed in all senile plaques in AD brains, including 
in diffuse plaques and in the core of amyloid plaques [173, 174, 264, 287], although some 
authors described the co-deposition with diffuse deposits to be minor [213]. In these stu­
dies, apoE was also found in CAA vessels [264] and in dystrophic neurites surrounding 
plaques.
Co-deposition of apoE with Aß deposits in mouse models has been well studied 
and in several models apoE was found co-localized with Aß. Immunohistochemical analy­
sis of deposits in Tg2576 [135, 240], APP23 [26, 206], PS/APP [33] and APP-YAC mice [134] 
revealed staining for apoE mostly in (Thioflavin-S positive) fibrillar deposits, with staining 
of some diffuse deposits. Furthermore, apoE colocalized with astrocyte markers [240], de­
monstrating that in mice, as in humans, astrocytes are likely responsible for apoE produc­
tion. In the TgSwDI mouse model, that specifically deposits Aß in the brain vasculature, 
apoE is found in close association with these vascular deposits [258]. All these findings in 
mice are therefore in concurrence with the apoE co-deposition found in humans.
Based on studies using brain material of Down-syndrome patients, it was sug­
gested that apoE contributes to plaque maturation [144]. In these patients, Aß42 was the 
first Aß species to accumulate and apoE co-localization could be detected in these de­
posits before Aß40 accumulates. In the Tg2576 model [240], Aß42 also seems to be the 
initial Aß species that deposits, with Aß40 only visible in more mature deposits. Using the 
Tg2576 model, it was found that all Aß deposits positive for apoE contained Aß42, with 
only some containing Aß40. Therefore, since apoE co-deposition in mice resembles that 
in humans, this suggests that apoE has a similar role in plaque maturation in mice as it has 
in humans. The function of apoE in Aß deposition has also been investigated using apoE 
knockout mouse models. By crossing these knockout mice with AD mouse models [11, 
103], it was discovered that apoE expression is key in developing Aß deposition.
Recently, an increased risk for AD was linked to another apolipoprotein, apoJ [93, 
142]. Indeed, this apolipoprotein, but also apoD, is known to co-deposit with Aß [43, 174] 
and furthermore apoJ could decrease Aß aggregation in vitro [161] and in vivo [64]. Co­
deposition of apoD has not been studied in AD mouse models. In contrast, in the APP-YAC 
mouse model [134] co-deposition of apoJ with Aß has been described. Therefore, in gene­
ral, it appears that co-deposition of apolipoproteins with Aß is well replicated in Tg mouse 
models for AD.
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Complement factors
The complement system consists of a cascade of factors that can become activated as 
part of the innate immune response of the body. Although the liver is the main source of 
complement, brain glial cells can also produce complement factors [171]. The cascade is 
triggered when either factor C1q (classical pathway), C3 (alternative pathway) or lectins 
become activated. Ultimately, a membrane attack complex (MAC), consisting of factor 
C5b-9, is formed that lyses cells by forming a membrane pore. Besides foreign intruders, 
the Aß protein is also known to trigger the complement system by binding to C1q or C3 
[28, 115]. Indeed, in AD brain, expression of the complement system is upregulated [298] 
and recently a complement component receptor (CR1) was identified as a risk factor for 
AD [142]. Furthermore, several components of the complement system, including C1q, 
C3 and C5b-9, can be found clearly associated with Aß deposits [73] and then mostly with 
fibrillar plaques [155]. Activation of the complement system in turn can stimulate Aß ag­
gregation [272]. Although the activated complement system can accelerate (Aß-induced) 
neurodegeneration [212], there is also evidence that it can protect the brain from Aß- 
induced damage [291].
Co-deposition of complement factors in mouse models has been well-studied. 
In two studies, C1q, C3 and C4 co-deposition in the Tg2576 model was investigated [78, 
300]. Strong co-deposition of these three complement factors was found with (Thioflavin-
S positive) Aß deposits. C1q was also strongly expressed in Aß deposits of PS/APP mice 
[162] and with the vascular deposits of TgSwDI mice [76]. In APP23 mice, not only was 
co-deposition of C1q studied, but also that of many more complement factors (C3, C3d, 
C4, C4d, C7, C9) [191, 206]. With the exception of C1q, C3 and C3d, co-deposition of these 
factors was weak, with co-deposition of complement factors further down in the cascade 
(C7, C9) being almost absent.
In summary, it appears that, unlike in human Aß deposits, only the early compo­
nents of the complement cascade (C1q, C3) can be detected in Aß deposits of Tg mouse 
models. Although these early complement factors co-deposit with Aß in mice, functional­
ly they differ from their human equivalents. For example, it is known that mouse C1q does 
not bind human Aß as efficiently as human C1q does [273] and that mouse C4 cannot acti­
vate C5 convertase [71]. Consequently, subsequent activation of the complement system 
in mice is also less efficient. Since complement can induce neurodegeneration [212], the 
less efficient activation of this system may explain the relatively low degree of neurodege­
neration seen in mouse models [80]. Furthermore, the difference in complement co-depo­
sition and activation between humans and mice may also provide some explanation for 
the different results that have been found in immunization studies in humans and mice 
aimed at finding new therapeutic agents [183, 203]. Despite the incomplete activation of 
the complement pathway in mice, it may still play a critical role in Aß pathology in mouse 
models as was demonstrated by a reduction of inflammation and neurodegeneration in 
an AD mouse model crossed with complement knockout mice [78].
Acute-phase proteins
In AD brains, several acute-phase proteins co-deposit with Aß, such as serum amyloid P 
(SAP), a2-macroglobulin (a2M) and a1-antichymotrypsin (a1-ACT) [2, 264]. Acute-phase 
proteins are proteins that become acutely upregulated in plasma in response to inflam­
mation.
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SAP is a glycoprotein that is closely associated with all Aß deposits in humans 
[118, 264]. The proposed role for SAP in senile plaques is to protect Aß fibrils from pro­
teolysis [166]. Besides, SAP may activate the complement system by binding C1q [299]. 
Only two studies on SAP co-deposition in mouse models have been performed. In one AD 
mouse model (C57B6/SJL overexpressing APP), SAP did not co-localize with amyloid de­
posits [214, 215]. It was postulated that SAP, with a molecular weight of ~250 kDa, failed to 
readily pass the blood brain barrier (BBB). Only when SAP was administered intranasally to 
transgenic APP mice, could SAP be detected in association with Aß deposits [215]. Since 
in humans, SAP can be detected in the AD brain and its production is exclusive to the liver, 
it was suggested that the integrity of the human BBB must be disturbed. In the APP23 
model [206], SAP was also not detected in Aß deposits, although staining in the periphery 
of deposits was visible. Therefore, functional disturbance of vessels of APP23 mice was 
apparently also not severe enough to allow BBB crossing of SAP into the brain [285]. The 
reduced transport of complement activator SAP into the brain may in turn contribute to 
the relative lack of complement activation in AD mouse models [206].
a2M, a protease inhibitor, co-localized with senile plaques in humans [252] and 
is thought to prevent accumulation of Aß [107]. In a study aimed at investigating the role 
of a2M in AD, the co-localization of this protein in the PS/APP mouse model was characte­
rized [132]. Starting from 3 months of age, these mice demonstrated Aß deposition, with 
some deposits positive for a2M. The number of a2M -positive plaques then increased 
with age, with a2M mainly depositing in Thioflavin-S positive fibrillar senile plaques. This 
demonstrates that a2M co-deposition resembles the human situation.
Finally, the acute-phase protein a1-ACT is a serine protease inhibitor that co­
deposits with human Aß deposits [2]. Whereas some describe a1-ACT to enhance Aß ag­
gregation [75], others demonstrated an inhibition of fibril formation [156], possibly re­
flecting different effects of a1-ACT depending on the molar ratio between a1-ACT and Aß 
[110]. However, as mice do not possess an a1-ACT homologue [178], co-deposition of this 
acute-phase protein in AD mouse models is not to be expected. Only by creating double 
transgenic mice for both human a1-ACT and APP, it was possible to study the in vivo role 
of a1-ACT on Aß aggregation [178]. Thus, it was demonstrated that a1-ACT increased Aß 
levels and plaque load in these mice.
Thus, co-deposition of acute-phase proteins has been studied in a few mouse mo­
dels only and in these models co-deposition with Aß was restricted to a2-macroglobulin.
ICAM-1, Cystatin C and CLAC
Besides the above mentioned factors, there are several more proteins that co-deposit 
with human Aß, including intercellular adhesion molecule (ICAM)-1, the cysteine prote­
ase inhibitor cystatin C and collagenous Alzheimer amyloid plaque component (CLAC). 
ICAM-1 is closely associated with Aß deposits in human AD brains, where it can be found 
in both classic and diffuse senile plaques in the cerebrum [267] and, specifically, in classic 
deposits in the cerebellum [266]. Similarly, co-deposition of ICAM-1 has been described 
in Tg2576 mice [7], although its expression is restricted to Thioflavin-S positive deposits.
Cystatin C has been found in both vascular and parenchymal Aß deposits in AD 
[150]. On its own, cystatin C can form vascular amyloid deposits, as demonstrated in Icel­
andic patients suffering from hereditary cerebral hemorrhage with amyloidosis (HCHWA) 
[182]. Immunohistochemical analysis of 2-year old Tg2576 mice revealed that, similar to 
the human situation, cystatin C was detected in Aß deposits of this model [150]. Other AD
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mouse models have not yet been investigated for the expression of cystatin C, but the 
role of cystatin C in Aß deposition has been studied by creating AD mouse models that 
overexpress human cystatin C. In these double transgenic mice, cystatin C reduced Aß 
deposition [117, 170]. However, a reduction was also found when cystatin C was ablated 
[233].
By raising antibodies against extracted amyloid deposits, the co-deposition of 
CLAC with Aß was discovered [95]. A subsequent in vitro study demonstrated that CLAC 
can bind Aß, but only when Aß is aggregated [95], making CLAC seemingly more selective 
in its binding than co-depositing proteins such as HSPG and apoE. In brain material of 
AD patients CLAC was found co-deposited with Aß42-positive, but not with Aß40- and 
Thioflavin S-positive plaques [133]. In the same study, a similar co-deposition of CLAC was 
found in PSAPP mice and it was suggested that CLAC co-deposited with Aß in more AD 
mouse models (unpublished data).
Concluding remarks
Some proteins known to co-deposit with human Aß also strongly associate with Aß in 
mice, with apoE being the most prominent. However, there are also many factors that only 
partly co-deposit with Aß in mice or that do not co-deposit at all, in contrast to the situa­
tion in AD brains (Table 1). For example, HSPG can be detected in Aß deposits in mice, but 
their expression in Tg mouse brains is much more restricted than in humans. Since HSPG 
are known to stimulate Aß aggregation and stabilize Aß deposits, it seems likely that their 
limited association with Aß deposits in mice is one of the reasons that these deposits are 
less compact and easier to dissolve than their human equivalents. Of the complement 
factors, only the early factors of the cascade co-deposit with Aß in mice, resulting in a less 
efficient activation of the complement system and the lack of formation of the membrane 
attack complex. The absence of a robust complement activation, in turn, may explain the 
relative absence of neurodegeneration in mouse models for AD. In conclusion, although 
several transgenic mouse models are far from extensively studied for the association of 
Aß-associated proteins with plaques, it appears that the composition of Aß deposits in 
transgenic mice is markedly different from human Aß deposits.
The less pronounced association of the above-mentioned factors may be a con­
sequence of the rapid development of AD pathology in mouse models as compared to 
human AD patients. Indeed in transgenic mice individual plaques can form within weeks 
[295] or even within 24 hours [169], therefore, there is probably simply not enough time 
to allow co-deposition of these Aß-associated proteins in the relatively constrained time 
period it takes for Aß to accumulate in mice. The incomplete replication of the expression 
of Aß-associated factors in mice and thus, the molecular composition of Aß deposits in 
mice, may in turn imply that the results of Aß-targeted therapeutics will likely be different 
in mice than in men. Indeed, there are many discrepancies in the outcomes of therapeutic 
interventions in mice and humans, with many human trials demonstrating side-effects 
not seen in mice [183]. Therefore, when using AD mouse models to study Aß deposition 
or the effects of therapeutic agents on Aß deposits, it is necessary to consider the diffe­
rences in Aß deposit composition between mice and humans when translating findings 
in mouse models to the human situation.
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Abstract
Enoxaparin (Enox), a low molecular weight heparin, has been shown to lower brain amy­
loid ß (Aß) load in a mouse model for Alzheimer's disease. However, the effect of Enox 
on cognition was not studied. Therefore, we examined the effect of peripheral Enox 
treatment on cognition and brain Aß levels in the APPswe/PS1dE9 mouse model by 
giving injections at an early (starting at 5 months of age) and late (starting at 10 and 12 
months of age) stage of Aß accumulation for three months. Although Enox had no ef­
fect on behaviour in the open field at any age, it improved spatial memory in the Morris 
water maze in 5-, 10- and 12-month-old mice. Furthermore, Enox treatment seemed to 
decrease guanidine HCl-extracted brain Aß levels at 5 months of age, but significantly 
increased guanidine HCl-extracted Aß42 and Aß40 levels in both 10- and 12-month-old 
mice. In vitro, Enox increased aggregation of Aß, even when Aß was pre-aggregated.
In conclusion, Enox treatment, either at an early or a late stage of Aß accumulation, 
could improve cognition in APPswe/PS1dE9 mice. However, since Enox treatment at an 
early stage of Aß accumulation decreased guanidine HCl-extracted Aß levels and Enox 
treatment at a late stage enhanced guanidine HCl-extracted Aß levels, it seems that 
Enox influences Aß deposition differently at different stages of Aß pathology. In any 
case, our study suggests that enoxaparin treatment has potential as a therapeutic agent 
for Alzheimer's disease.
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Introduction
Alzheimer's disease (AD) is characterized by atrophy of brain tissue caused by neuronal 
cell loss, particularly in regions involved in memory and learning [165]. Currently, only 
symptomatic treatment of AD is available and therefore, new therapeutic agents should 
be aimed at improving cognitive impairments by treating the underlying causes of the 
disease. One of the pathological hallmarks of AD is deposition of the amyloid ß (Aß) pro­
tein in the brain. Aß is a 4kDa cleavage product of the amyloid precursor protein (APP) and 
Aß aggregates, in particular soluble oligomeric aggregates, have been correlated to the 
extensive neuronal loss observed in AD patients [92, 128].
In the search for new therapeutic agents to prevent Aß toxicity, compounds that 
inhibit the production of Aß, reduce its aggregation or stimulate clearance of Aß from the 
brain are being investigated. The success of the latter option has been demonstrated in 
several vaccination studies where induction of an immune response against Aß resulted 
in cerebral Aß clearance in mice [203] and in humans [177]. Moreover, a reduction was ac­
companied by improvement of cognition [100, 113]. However, due to serious side-effects 
(i.e. meningoencephalitis) preclinical trials had to be ended [183] and therefore immune 
therapy still requires further optimization.
Even though immune therapy is not yet suitable as a therapeutic intervention, it 
did provide some clues for a possible mechanism of Aß clearance from the brain. Perip­
heral administration of Aß antibodies (m266) led to a decrease in brain Aß levels that was 
accompanied by an increase of plasma Aß levels [61]. It was assumed that by binding to 
plasma Aß, antibodies could trigger peripheral degradation of plasma Aß, leading to a 
subsequent efflux of Aß from the brain to reestablish the Aß equilibrium between brain 
and plasma (i.e. peripheral sink hypothesis). Binding to plasma Aß appears to be key, as 
other Aß-binding substances, such as gelsolin and GM1, also triggered an efflux of Aß 
from brain [163]. Proteins co-depositing with Aß and with high binding affinity to Aß are 
interesting candidates for (peripheral sink) clearance of Aß.
Several proteins co-deposit with Aß, such as small heat shock proteins [284] and 
heparan sulfate proteoglycans (HSPG) [254, 255]. HSPG are believed to play a key role in 
Aß deposition by stimulating Aß fibrillization and preventing Aß proteolysis [256]. In an 
effort to inhibit amyloidosis, it was discovered that small sulfated molecules [127] and he­
parin, a highly sulfated HSPG analogue, could interfere with endogenous HSPG-induced 
fibrillization of Aß. Even though heparin is a potential therapeutic agent, its use might 
lead to severe haemorrhages as it has anti-coagulant properties. Furthermore, because 
heparin is a mixture of polysaccharides with variable molecular weights ranging from 
3,000 to 30,000 kDa, finding an effective therapeutic dose is difficult. In vivo experiments 
therefore have mostly used low molecular weight heparins, one of which is enoxaparin 
(Enox).
Enox is currently being used as anti-coagulant treatment in cardiovascular 
disease and does not lead to severe hemorrhages, proving that it can be tolerated by pa­
tients without serious side-effects. A first in vivo experiment, testing the effect of Enox on 
amyloidosis, was performed using a mouse model for inflammation-associated amyloid 
(AA) formation in the spleen [301] where Enox reduced AA amyloidosis. Next, in 2004, 
using the APP23 mouse model for Alzheimer's disease, animals were prophylactically tre­
ated with Enox [20] and it was found that Aß levels had significantly lowered in Enox- 
treated mice compared to untreated mice. This lowering of Aß levels was accompanied by 
a reduction in astrocyte activation, suggesting that Enox attenuated the proinflammatory
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response of the brain. However, effects on cognition were not investigated in this mouse 
model and the exact mode of action of Enox remained unclear.
It was our aim to further investigate the effect of Enox, in both an early and late stage of 
the disease, on cognition and brain Aß levels. To this end, we used the APPswe/PS1dE9 
mouse model that develops Aß plaque pathology as early as 4-6 months of age [82, 253] 
and which is accompanied by severe exploration deficits and cognition impairment [104, 
139, 140].
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Materials and Methods
APPswe/PS1dE9 (APP/PS1) mice
A colony of APPswe/PS1dE9 (APP/PS1) mice was established at the conventional depart­
ment of the Central Animal Laboratory of the Radboud University Nijmegen Medical Cen­
tre, Nijmegen, The Netherlands, after obtaining the founder animals from Johns Hopkins 
University, Baltimore (MA), USA. In short, this model was created by co-injecting the two 
transgenes, with a prion protein promoter, in the pronucleus of single cell C57Bl/6 em­
bryos [112].
Female APP/PS1 mice and non-transgenic (NT) C57Bl/6 littermates were group- 
housed in standard cages with nestlets and an igloo as cage enrichment. There was a 12 
hour light-dark cycle (lights on at 7 am) with a constant temperature of 21±1°C, humidity 
control and background music during the light phase. Standard food pellets and acidi­
fied water (pH 2.5-3) were given ad libitum. This study was approved by the Animal Care 
Committee of the Radboud University Nijmegen Medical Centre (RU-DEC) and was perfor­
med according to the guidelines of the Dutch Council for Animal Care and the European 
Communities Council Directive of 24 November 1986 (86/609/EEC). Our study was also in 
concurrence with the European regulations on ethics and responsible conduct regarding 
scientific communication.
Treatment
Starting at either 5, 10 or 12 months of age, APP/PS1 mice received two (at 5 and 12 
months) or three (at 10 months) intraperitoneal injections per week (0.1 ml per injection) 
of saline (PBS) (n=10, n=14 and n=9 respectively) or 2.5 mg/kg Enox (n=10, n=14 and 
n=8 respectively) (Sanofi-Aventis, Gouda, The Netherlands) for 12 consecutive weeks. 
Age-matched NT mice were handled, but not injected, when APP/PS1 mice received their 
injections (n=8, n=8 and n=6 respectively). Mice were regularly weighed during the injec­
tion period and did not show weight loss.
Behavioural analyses
During the injection period, behavioural analyses were performed. On a test day injec­
tions were given after the behavioural experiment was performed. Mice were excluded 
from the behavioural experiments if their vision appeared to be impaired (i.e. clouded 
eyes), as was the case in 1 mouse (PBS-injected) from the 5-month-old group, 2 mice (PBS- 
injected) from the 10-month-old group and 2 mice (PBS-injected) from the 12-month-old 
group.
Rotarod analysis
To test motor skills, mice were individually placed on a rotarod when the rod visibly star­
ted to rotate. The time mice spent on the rotarod while it accelerated to about 38 rpm was 
recorded, with a maximum of 300 seconds. Each mouse performed four trials with a 30 
minute inter-trial rest period. Trial 1 was a pre-trial, trial 2 to 4 were averaged to determine 
the mean time (± standard error) spent on the rotarod.
Open Field
To analyze activity in a novel environment, open field behaviour was studied. The open 
field consisted of a 50 x 50 x 40 cm white Plexiglas box, placed below a video camera. Mice 
were placed in the centre of the box and were observed for 30 minutes each. They were
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scored for time spent on different types of passive (sitting, grooming) and active (rearing, 
wall leaning, walking) behaviour, as previously defined [10].
Morris water maze
To test spatial memory, the Morris water maze was performed. A circular pool (diameter 
of 120 cm) was filled with water of 21-22 °C, until a platform placed in the north-east qua­
drant was 1 cm below the water surface. The water was made opaque with milk powder 
and spatial cues were placed around the pool (distance ~ 0.5m). Mice were placed in the 
pool at different starting positions during four trials per day. Each trial lasted two minutes 
or until the mouse reached the platform, after which the mice had to stay on the platform 
for 30 seconds before being removed from the pool. The time needed to find the plat­
form (escape latency) was recorded for each trial. Each mouse performed four trials per 
day, with a 30-minute inter-trial rest period, for four days. Escape latencies of mice were 
averaged for each day. After 16 trials, a probe test was performed. In the probe test, the 
platform was removed and mice were allowed to swim for 2 minutes. DVD recordings of 
the probe trial were analysed using Ethovision® to score the number of crossings across 
the old platform location and the time they needed to first cross this location.
Reverse Morris water maze
Using the same pool and conditions as for the Morris water maze, mice again had to find a 
submerged platform in the reverse Morris water maze. This time the platform was moved 
to the south-west quadrant of the pool. The escape latency to find the new platform lo­
cation was measured for two days (four trials/day) and followed by the probe test. Again, 
using DVD recordings of the probe trial, the same parameters as for the Morris water maze 
were analysed using Ethovision®.
Transcardial perfusion
After the behavioural tasks, mice were weighed and anesthetized with 2-4% isoflurane 
and transcardially perfused with sterile PBS (Roche, Mannheim, Germany) to remove 
blood from the tissues. After the perfusion, mice were decapitated and brains were collec­
ted. One hemisphere was snap-frozen in liquid nitrogen and stored at -80°C until further 
analysis.
Aß extraction
A two-step extraction using carbonate buffer (soluble Aß) and guanidine HCl (insoluble 
Aß) was performed [55] on the frozen brain hemisphere. Prior to homogenization, the 
hemisphere was thawed on ice and the olfactory bulb and cerebellum were removed. 
Tissue was kept on ice until guanidine HCl was added. First, the hemisphere was weighed 
and homogenized in a tissue grinder with 10 l^/mg 1x carbonate buffer (0.1M carbonate, 
50mM NaCl, 0.5% sodium azide, pH 11.5) containing protease inhibitors (Complete, Ro­
che). To shear DNA, the carbonate extract was passed through a 21 gauge needle five 
times. The extract was then centrifuged for 20 min (4°C, 16,000 xg). The supernatant was 
collected and stored at -80°C (carbonate extract). The pellet was resuspended in 4 l^/mg 
of 5M guanidine HCl with protease inhibitors (Complete, Roche) and incubated for three 
hours on a rotamixer (room temperature). The extract was then centrifuged for 20 min 
(4°C, 16,000 xg) and the supernatant stored at -80°C (guanidine HCl extract).
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ELISA of brain Aß40 and Aß42
The carbonate and guanidine HCl extracts of one brain hemisphere were analysed for 
human Aß40 and Aß42 levels by ELISA (Invitrogen, Paisley, UK) according to the manufac­
turers protocol. A protein assay (Pierce BCA, Thermo Fisher Scientific Inc, Rockford, IL, USA) 
was performed to determine total protein levels in the different extracts and Aß levels 
were normalized to these total protein levels. In line with previous data [82], carbonate 
extracted (soluble) Aß levels were much lower (>50 times) than guanidine HCl-extracted 
(insoluble) Aß levels. Therefore, in the results we will only present guanidine HCl-extrac- 
ted Aß levels.
Thioflavin Tanalysis
For the Thioflavin-T assay, we used Aß containing the Dutch mutation (Glu22-->Gln22) 
as found in HCHWA-D (DAß1-40) as a model peptide, since this peptide has robust and 
reproducible aggregation and cytotoxic properties in vitro [54, 243]. DAß1-40 (QCB; Hop­
kinton, Massachusetts, USA, 96% pure) was incubated up to 48 hours at 37°C (50 ^M) with 
or without 250 ^g/ml heparin (Sigma-Aldrich, St. Louis, MO, USA) or 250 ^g/ml Enox in 
Tris/NaCl buffer (50 mM Tris, 150 mM NaCl, 0.01% sodium azide pH 7.4). In one sample, 
DAß1-40 was incubated for 24 hours at 37°C (pre-aggregated DAß1-40) before Enox was 
added for the remaining 24 hours. After various time intervals (1, 7, 24 and 48 hours), 
20 l^ samples were taken from the incubation mixture. These samples were added to 
980 l^ Thioflavin-T solution (50 mM glycine pH 9.2, 3 ^M Thioflavin-T). Samples were ex­
cited at 450 nm (slit width 5 nm) and emission fluorescence was measured twice for each 
sample at 482 nm (slid width 10 nm). Mean emission fluorescence ± standard error was 
plotted as a function of time.
Statistical analysis
In general, groups were compared using independent unpaired T-tests. Time spent on 
active/passive behaviour in the open field and escape latencies in (reverse) Morris wa­
ter maze were analyzed using a repeated measures analysis of variance (ANOVA). Lear­
ning curves of mice were also compared in this analysis. Results are presented as mean 
± standard error. At each time point measured in the Thioflavin-T assay an unpaired two­
sided t-test was performed to compare aggregation of DAß1-40 with and without heparin 
or Enox. Statistical significance was reached at p<0.05, with p<0.10 considered a trend.
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Results
Animals and body weight
During 12 weeks, three age groups of APP/PS1 mice received injections with either PBS or 
Enox. A non-transgenic (NT) group of C57Bl/6 mice served as a control. In both the 5- and 
10-month-old group, one PBS-treated APP/PS1 mouse was lost during the injection pe­
riod, but no Enox-treated APP/PS1 mice. In the 12-month-old group, one PBS-treated and 
two Enox-treated APP/PS1 mice were lost. No NT mice were lost during the injection pe­
riod at any age. There were no significant body weight differences within injection groups 
over time or between injection groups at any point during the injection period (data not 
shown).
Two injections of Enox per week improved cognition and altered brain Aß levels in 5- and 
12-month-old APP/PS1 mice
We observed no differences in time spent on the rotarod between transgenic (PBS-trea- 
ted) mice and NT mice or between injection groups at the ages tested (data not shown). 
The open field observations revealed that at 5 months of age, but not at 12 months of 
age, PBS-treated APP/PS1 mice tended to spend more time spent walking than NT mice 
and Enox-treated APP/PS1 mice (data not shown; F(1,14) = 3.48, p=0.08). There were no 
differences between NT, PBS-treated and Enox-treated mice in any of the other parame­
ters (data not shown).
Spatial memory of mice was tested in the Morris water maze (Fig. 1). Over the 
four trial days, NT mice of the 5-month-old group showed a decrease in escape latency 
from 80 s to 40 s (Fig. 1A). The PBS-treated APP/PS1 mice had a significantly higher escape 
latency (Fig. 1A; F(1,14) = 13.38, p=0.003). Enox treatment seemed to lower escape latency 
of APP/PS1 mice compared to PBS treatment at day 3 and day 4 (Fig. 1A; F(1,12) = 2.85, 
p=0.12). The 12-month-old NT mice also showed a decrease in escape latency (from 100 
s to 30 s) and PBS-treated APP/PS1 mice again had a significantly higher escape latency 
than NT mice (Fig. 1D; F(1,9) = 19.24, p=0.002). Enox-treated APP/PS1 mice had a signi­
ficantly lower escape latency compared to PBS-treated APP/PS1 mice (Fig. 1D; F(1,10) = 
5.22, p=0.045, day 2 until 4). Furthermore, PBS-treated APP/PS1 mice had a significantly 
less steeper slope of their learning curve than NT mice (F(1,9) = 7.0, p=0.027) and Enox- 
treated APP/PS1 mice (F(1,10) = 5.63, p=0.04) during the first three trial days (Fig. 1D).
In the probe test of the Morris water maze (Fig. 1 B, C, E and F), 5-month-old 
PBS-treated APP/PS1 mice had a seemingly lower number of platform crossings than age- 
matched NT mice (Fig. 1B; 2.0 ± 0.65 vs. 3.5 ± 1.25, p=0.30). In addition, PBS-treated ani­
mals needed near-significantly more time to cross the former platform location for the 
first time (Fig. 1C; 71.9 ± 18.0 sec vs. 31.0 ± 13.6 sec, p=0.09). Enox treatment of 5-month- 
old APP/PS1 mice seemed to increase the number of platform crossings (Fig. 1B; 4.2 ± 
1.3, p=0.14) and significantly lowered the time needed to first cross the platform location 
(Fig. 1C; 21.7 ± 7.1 sec, p=0.04) compared to PBS-treated APP/PS1 mice. The 12-month-old 
PBS-treated APP/PS1 mice had a significantly lower number of platform crossings (Fig. 1E; 
0.33 ± 0.21 vs. 3.80 ± 0.20, p<0.0001) and a significantly slower first crossing (Fig. 1F; 100.6 
± 14.7 sec vs. 17.8 ± 5.3 sec, p=0.0009) than NT mice. At this age, Enox treatment did not 
have an effect on the number of platform crossings (Fig. 1E) or on time-to-first-crossing 
(Fig. 1F) compared to PBS treatment.
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Figure 1: Performance of 5- and 12-month-old APP/PS1 mice in the Morris water maze. In the 
acquisition trials, 5- (A) and 12-month-old (D) PBS-treated APPswe/PS1dE9 mice (n=8 and 
n= 6 respectively) had a significantly higher escape latency over four trial days than NT mice 
(n=8 and n=5 respectively). Enox treatment seemed to lower escape latency of 5-month-old 
APP/PS1 mice (n=6) and significantly lowered escape latency of 12-month-old APP/PS1 mice 
(n=6). In the probe trial of the Morris water maze (B, C, E and F), 5-month-old PBS-treated 
APPswe/PS1dE9 mice crossed the former platform location less often than NT mice (B) and 
5-month-old PBS-treated APP/PS1 mice significantly less often than NT mice (E). At both ages, 
PBS-treated APP/PS1 mice needed (near-) significantly more time to first cross the old platform 
location (C and F respectively). Enox treatment increased the number of platform crossings (B) 
and significantly lowered the time needed to first cross the platform of 5-month-old PBS-trea- 
ted APP/PS1 (C). In 12-month-old APP/PS1 mice, Enox treatment had no effect on the number 
of platform crossings (E) or the time to the first crossing (F).
#p<0.10, *p<0.05, **p<0.01, ***p<0.001
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A reverse Morris water maze was performed for 2 days (four trials per day) to 
assess whether mice could unlearn irrelevant information and relearn a new platform lo­
cation at the opposite end of the pool. In both the 5-month-old and 12-month-old group, 
the escape latency of NT mice, PBS-treated and Enox-treated APP/PS1 mice did not differ 
(data not shown). Similarly, the probe test of the reverse Morris water maze revealed for 
both 5- and 12-month-old animals no differences in the number of platform crossings 
between NT mice, PBS-treated APP/PS1 mice or Enox-treated APP/PS1 mice (data not 
shown). Both 5- and 12-month-old PBS-treated APP/PS1 mice seemed to need more time 
to first cross the platform compared to NT mice (data not shown; p=0.15 at both ages). The 
values of the Enox-treated groups were in between those of the other two groups (data 
not shown).
Aß levels were determined in guanidine HCl extracts of one brain hemisphere 
(ng/mg total protein) (Fig. 2). Both brain Aß40 and Aß42 levels of 5- and 12-month-old NT 
mice were hardly detectable (<10 ng/mg). Enox treatment of 5- and 12-month-old APP/ 
PS1 mice did not alter guanidine HCl-extracted brain Aß42 level (Fig. 2C and D) compared 
to PBS-treated APP/PS1 mice. However, in 5-month-old Enox-treated APP/PS1 mice, the 
Aß40 level was near-significantly lower compared to PBS-treated APP/PS1 mice (Fig. 2A: 
0.76 ± 0.07 vs. 1.0 ± 0.10, p=0.07). Furthermore, Enox treatment significantly increased the 
Aß40 level of 12-month-old APP/PS1 mice (Fig. 2B: 1.48 ± 0.06 vs. 1.0 ± 0.14, p=0.02).
Three injections of Enox per week improved cognition and altered brain Aß levels of 10-month- 
old mice
Based on the above-described findings, we increased Enox treatment to three injections 
per week in APP/PS1 mice with an intermediary stage of disease (10-month-old). We ob­
served no differences in time spent on the rotarod between NT mice, PBS-treated or Enox- 
treated APP/PS1 mice (data not shown). Furthermore, in the open field, PBS-treated APP/ 
PS1 mice did not differ in activity from NT mice (data not shown) and Enox treatment did 
not alter the time spent any of the other parameters compared to PBS treatment (data not 
shown).
In the Morris water maze (Fig. 3), NT mice showed a decrease in escape latency 
from 110 s to 20 s over the four trial days (Fig. 3A). PBS-treated APP/PS1 mice had a signi­
ficantly higher escape latency than NT mice (F(1,16) = 16.76, p=0.001). Furthermore, the 
slope of their learning curves was near-significantly less steep (F(1,16) = 3.22, p=0.09). 
Enox treatment seemed to slightly lower the escape latency on day 3 and 4 compared to 
PBS treatment, but this did not reach significance (Fig. 3A; F(1,20) = 0.65, p=0.42). Further­
more, the slope of the learning curve of Enox-treated APP/PS1 mice did not differ from 
PBS-treated APP/PS1 mice (F(1,20) = 0.09, p=0.76).
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Figure 2: Guanidine HCl-extracted brain Aß40 levels (A and B) and Aß42 levels (C and D) of 
5- (A and C) and 12-month-old (B and D) APP/PS1 mice in ng/mg total protein. In 5-month- 
old APP/PS1 mice, Enox (n=10) had no effect on guanidine HCl-extracted Aß42 levels (C) but 
near-significantly lowered guanidine HCl-extracted Aß40 (A) levels compared to PBS (n=9). In 
12-month-old APP/PS1 mice, Enox (n=6) treatment again did not alter guanidine HCl-extrac- 
ted Aß42 levels (D) of APP/PS1 mice but significantly increased guanidine HCl-extracted Aß40 
levels (F) compared to PBS (n=8). At both ages, Aß levels of NT mice were hardly detectable. 
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In the probe test of the Morris water maze, PBS-treated APP/PS1 mice crossed 
the old platform location significantly less than NT mice (Fig. 3B: 2.1 ± 0.62 vs. 4.25 ± 0.53, 
p=0.02) and were significantly slower to first cross the platform (Fig. 3C: 52.4 ± 15.1 s vs. 
15.3 ± 4.3 s, p=0.05). For the Enox-treated APP/PS1 mice, the number of platform cros­
sings (Fig. 3B: 3.42 ± 0.70) was in between the values of the PBS and NT groups (p=0.18 
compared to PBS treatment). The time to first crossing the platform by Enox-treated APP/ 
PS1 mice was significantly reduced compared to PBS-treated APP/PS1 mice (Fig. 3C: 20.67 
± 4.87 s vs. 52.4 ± 15.1 s, p=0.04).
In the reverse Morris water maze, the escape latency of PBS-treated APP/PS1 
mice did not differ from NT mice or Enox-treated APP/PS1 mice (data not shown). Howe­
ver, in the probe trial of the reverse Morris water maze (Fig. 4), PBS-treated APP/PS1 mice 
crossed the old platform location significantly (p=0.04) less than NT mice (Fig. 4A; 2.55 
± 0.64 vs. 4.63 ± 0.65, p=0.04) and they seemed to take more time to first cross the old plat­
form location (Fig. 4B: 55.0 ± 14.5 sec vs. 26.1 ± 8.2 sec), although this was not significant 
(p=0.14). Enox treatment seemed to increase the number of platform crossings (Fig. 4A; 
3.75 ± 0.73, p=0.23) and significantly lowered the time needed to first cross the platform 
location (Fig. 4B; 18.75 ± 3.71 s, p=0.02) compared to PBS treatment.
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Figure 3: Performance of 10-month-old APP/PS1 mice in the Morris water maze. In the acqui­
sition trials, PBS-treated APP/PS1 mice (n=10) had a significantly higher escape latency over 
four trial days than NT mice (A). Treatment with Enox (n=12) had no effect on escape latency. 
In the probe trial of the Morris water maze (B and C), PBS-treated APP/PS1 mice crossed the 
former platform location significantly less often than NT mice (n=8) (B) and needed signifi­
cantly more time to first cross this location (C). Enox treatment slightly increased the number 
of platform crossings and significantly lowered the time needed to first cross the platform. 
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B
0
C
94
A 10-month-old
o
=t*
6 n
5 -
4 -
3 -
ra 2 
c i
1 -
PBS Enox NT
70 1 
60 - 
50 -
40 -
S£ 30 
«=
S  20
ai
. !  10
PBS Enox NT
Figure 4: Performance of 10-month-old APP/PS1 mice in the probe of the reverse Morris water 
maze. PBS-treated APP/PS1 mice (n=11) crossed the old platform location significantly less 
often than NT mice (n=8) (A) and seemed to need more time to first cross the location (B). Enox 
treatment (n=12) increased the number of platform crossings and significantly lowered the 
time needed to first cross the platform.* p<0.05
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In NT mice, guanidine HCl-extracted brain Aß40 levels and Aß42 levels were very 
low compared to PBS-treated APP/PS1 mice (Fig. 5). Enox treatment seemed to increase 
guanidine HCl-extracted Aß40 levels compared to PBS-treated APP/PS1 mice (Fig. 5A: 1.44 
± 0.28 vs. 1.0 ± 0.13, p=0.16) and significantly increased guanidine HCl-extracted Aß42 
levels (Fig. 5B: 1.23 ± 0.07 vs. 1.0 ± 0.05, p=0.01).
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Figure 5: Guanidine HCl-extracted brain Aß40 (A) and Aß42 (B) levels of 10-month-old APP/ 
PS1 mice in ng/mg total protein. Enox (n= 14) seemed to increase guanidine HCl-extracted 
Aß40 (A) and significantly increased guanidine HCl-extracted Aß42 levels (B) compared to PBS 
(n=12). **p=0.01
Enox stimulates Aß aggregation in vitro
To further investigate the effect of Enox on Aß aggregation, we performed a Thioflavin 
T assay (Fig. 6). We used heparin as a positive control, since it is known that heparin sti­
mulates Aß aggregation [243]. Indeed, heparin significantly increased DAß1-40 Thioflavin 
T fluorescence emission about two- to three-fold after 24 hours (p=0.02) and 48 hours 
(p=0.04) of incubation. Enox significantly increased DAß1-40 fluorescence emission, and 
thus aggregation, three- to four-fold after 7 hours (p=0.02), 24 hours (p=0.01) and 48 
hours of incubation (p=0.03). DAß1-40 was also pre-aggregated from 0 to 24 hours, with 
Enox added from 24 to 48 hours. At 48 hours, Enox significantly enhanced aggregation of 
pre-aggregated DAß1-40 compared to DAß1-40 pre-aggregated for 24 hours or aggregated 
for 48 hours without Enox (p=0.05 and p=0.04 respectively).
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Figure 6: Thioflavin-T analysis of DAß140 with heparin or Enox. DAß140 (black bars) was aggre­
gated up to 48 hours (37°C) with either heparin (dark grey bars) or Enox (white bars). Heparin 
treatment significantly increased Thioflavin-T fluorescence at 24 and 48 hours of incubation. 
Enox significantly increased fluorescence at 7, 24 and 48 hours of incubation. When DAß140 
was pre-aggregated for 24 hours (light grey bars), Enox also significantly increased fluorescen­
ce. * p<0.05 compared to DAß140; $ p<0.05 compared to pre-aggregated DAß140 (t=24 hours).
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Discussion
Previously it was demonstrated that enoxaparin, a low molecular weight heparin, was 
able to reduce brain Aß levels in the APP23 mouse model for Alzheimer's disease [20]. 
In our study, using three different age groups of the APPswe/PS1dE9 mouse model, we 
demonstrated that enoxaparin treatment can improve cognition in both an early and late 
stage of Aß pathology, but that 1) early treatment decreases (insoluble) brain Aß levels, 
whereas 2) late treatment increases (insoluble) brain Aß levels.
Since the APP23 model used in the previous study did not have significant cog­
nitive impairment at the age tested (12 months old) [123], we chose the APPswe/PS1dE9 
mouse model, a model with well-documented impairments in several behavioural tasks 
[104, 139, 140], to investigate the effect of enoxaparin on cognition. Indeed, we did find 
impaired spatial memory learning between non-transgenic mice and APPswe/PS1dE9 
mice that were not due to impaired motor functions. In the open field, APPswe/PS1dE9 
mice were hardly more active than non-transgenic mice, which was unexpected based 
on previous open field analyses of this model [104]. This finding is perhaps due to an 
age-related decrease in activity of C57Bl/6 NT mice [141]. Finally, Aß levels of 5-month- 
old APPswe/PS1dE9 mice were generally lower than that of 10- and 12-month-old mice, 
which was as expected [82]. Strikingly, Aß levels of our 12-month-old mice were generally 
lower than that of our 10-month-old mice, likely due to inter-assay differences.
In the different behavioural tests, the effects of Enox varied. For example, Enox 
treatment had no effect on open field activity of the APPswe/PS1dE9 mice tested in this 
study, neither when they received two injections per week nor when they received three 
injections per week. This may be the result of the absence of differences in activity levels 
between APPswe/PS1dE9 and NT mice or because the injection period or dose was insuf­
ficient to affect this type of behaviour. In the Morris water maze however, two injections of 
enoxaparin per week significantly improved spatial memory learning, as detected in the 
probe (5-month-old mice) and acquisition trial (12-month-old mice) of the Morris water 
maze. Following three injections per week, the 10-month-old group also demonstrated a 
significant improvement of cognition performance in the probe trials of both the Morris 
water maze and the reversal Morris water maze. It is known that mice can have great in­
tertrial variation in performance in the Morris water maze [153] which might explain why 
in one age-group improved cognition is seen in the acquisition trials and in others in the 
probe trials. Overall, we conclude that Enox, when administered early or when given at a 
later stage of Aß pathology, improves cognition in the APPswe/PS1dE9 mouse model.
We found that Enox seemed to decrease Aß40 and Aß42 levels in guanidine 
HCl extracts of 5-month-old APPswe/PS1dE9 mice. This result is similar to that previously 
found in APP23 mice treated early with Enox [20]. The effect of late administration of Enox 
has not yet been described, but we now observed that, unlike in the younger mice, Enox 
treatment enhanced guanidine HCl-extracted Aß42 and Aß40 levels of 12-month-old 
APP/PS1 mice compared to PBS treatment. A similar result was found when 10-month- 
old mice, that also have severe Aß pathology, were injected with enoxaparin three times 
a week. Therefore, we conclude that Enox influences early Aß pathology differently than 
late Aß pathology.
It is unclear if Enox acts directly in the brain. Indeed, it has been shown that Enox 
may reduce the Aß-induced activation of the complement and contact systems in blood 
[20]. To be able to act in the brain, Enox would have to cross the blood brain barrier (BBB), 
which appears to be unlikely considering its size (average 4500 dalton) and negative
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charge. A similarly sized heparin-like macromolecule, pentosan polysulfate, was unable 
to cross an in vitro model of the BBB, whereas heparin derivatives of 3 kDa or smaller 
did cross [148]. It may be that, at least in the younger mice, Enox acted in the peripheral 
circulation as a peripheral sink agent, lowering brain Aß levels by clearing Aß from the 
blood. However, since in older APPswe/PS1dE9 mice guanidine HCl-extracted Aß levels 
increased upon Enox treatment, an alternative mechanism may exist at a later stage of 
pathology.
It is known that transgenic models for AD can have a (age-dependent) disturban­
ce of BBB integrity [246]. However, as far as we know, BBB integrity of the APPswe/PS1dE9 
mouse model has not been investigated. Increased BBB permeability with age would al­
low easier passage of molecules like Enox across the BBB. As suggested by our in vitro ag­
gregation assay, after entering the brain, Enox may stimulate Aß aggregation, or enhance 
it when Aß is already aggregated. In a previous study it was found that in vitro, Enox had 
no effect on aggregation of Aß [20]. However, the time course for this study was only 30 
minutes at room temperature, whereas we allowed Aß to aggregate for a longer time and 
at physiological temperatures. Of course, the conditions of our in vitro aggregation assay 
may differ from in vivo conditions, since Aß usually does not contain the Dutch mutation 
and the absolute concentrations and ratio of Aß and Enox is likely different. Furthermore, 
in vivo other proteins may also influence the interaction between Aß and Enox.
Since Aß deposition is considered to be one of the major factors contributing 
to AD development [92, 165], most studies, aimed at finding new therapeutic agents, fo­
cus on improving cognition by decreasing Aß levels. Indeed, many studies, including this 
study on early Enox treatment of APPswe/PS1dE9 mice, show that decreased Aß levels are 
accompanied by improved cognition [167, 187]. However, our study now suggests that 
an improved cognition can also be accompanied by increased (guanidine HCl-extracted) 
brain Aß levels at a later stage of disease development. It is assumed that low-n oligo­
meric species of Aß (i.e. dimers and trimers) mediate neurotoxicity [269] and that these 
species are likely to be precursors of mature fibrils. Therefore, it may be that the increases 
in guanidine HCl-extracted Aß levels we found in the older mice, reflect decreases in these 
more toxic species. It should be mentioned that we did not inject our NT mice with Enox 
and therefore it cannot be excluded that Enox improved cognition independent of its ef­
fects on Aß levels.
In conclusion, our data confirm the previously demonstrated potency of enoxa­
parin as a therapeutic agent for Alzheimer's disease, although its exact effect on brain Aß 
levels and exact mechanism of action remains unknown. A preclinical prophylactic study 
of enoxaparin has already been started [21], which should further elucidate the effects of 
enoxaparin in human AD patients.
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Abstract
Amyloid ß (Aß) accumulation in Alzheimer's disease (AD) is aggravated by disturbed 
cerebral clearance. Currently, there is no curative treatment for AD. According to the 
peripheral sink hypothesis, peripheral administration of Aß-binding agents may reduce 
blood Aß levels and drain Aß from the brain across the blood-brain barrier. One small 
heat shock protein, aB-crystallin, binds Aß with high affinity. Therefore, we tested if aB- 
crystallin can act as a peripheral sink agent. We injected APPswe/PS1dE9 and TgSwDI 
mice with aB-crystallin for three months and investigated the effect on behaviour and 
brain Aß levels. In APPswe/PS1dE9 mice, aB-crystallin had no effect on activity or cogni­
tion and slightly increased Aß40 levels. In TgSwDI mice, aB-crystallin normalized activity 
(i.e. walking and sitting) to levels of controls and decreased brain Aß42 levels, without 
affecting cognition. Overall, we conclude that there is currently no evidence that aB- 
crystallin could serve as an effective therapeutic agent for AD.
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Introduction
Alzheimer's disease (AD) is pathologically characterized by accumulation of amyloid ß 
(Aß) protein in the brain. Aß is a 4kDa cleavage product of the amyloid precursor protein 
(APP) that is normally removed from the brain by degradation or clearance [149]. There are 
two peptidases involved in extracellular Aß degradation, insulin degrading enzyme (IDE) 
[188] and neprilysin (NEP) [109]. There is also evidence for phagocytosis of Aß by micro­
glia and subsequent intracellular degradation [16, 203]. Furthermore, Aß can be transpor­
ted across the blood brain barrier by, for instance, LDL-receptor-related protein 1 (LRP-1) 
[216]. With age, Aß removal from the brain becomes less efficient [149], Aß levels in brain 
rise and Aß starts to deposit, forming (senile) plaques in the parenchyma and accumula­
tions in the vascular walls. However, not the fibrillar deposits but soluble, oligomeric Aß 
species have been correlated to the extensive neuronal loss observed in AD patients [92, 
128]. Currently there is no cure for AD, only symptomatic treatment can be administered.
There is much interest in compounds that enhance removal of Aß from the brain. 
One extensively studied therapeutic approach is immune therapy that relies on the induc­
tion of an immune response against Aß to reduce brain Aß levels. Ideally, these reduced 
Aß levels should be accompanied by improvements in cognitive behaviour. Vaccination 
studies of mice [203] and humans [177] have indeed demonstrated a reduction in brain 
Aß levels as a result of cerebral Aß clearance, accompanied by improved cognition [100, 
113]. However, a follow-up study investigating long term effects of immunization did not 
demonstrate any effect on cognition, even though mean brain Aß levels were lower than 
unimmunized controls [102]. Furthermore, due to serious side-effects (i.e. meningoen­
cephalitis) preclinical trials had to be ended [183]. Therefore, immune therapy still requires 
further optimization before being applicable as a therapeutic intervention.
Even though immunization is not yet suitable for therapeutic intervention, it did 
provide some clues to a possible mechanism of Aß clearance from the brain. Peripheral 
administration of Aß antibodies (m266) led to a decrease in brain Aß levels that was ac­
companied by an increase in plasma Aß levels [61]. It was assumed that by binding to 
plasma Aß, antibodies could trigger peripheral degradation, leading to a subsequent ef­
flux of Aß from the brain to reestablish the Aß equilibrium between brain and plasma (i.e. 
peripheral sink hypothesis). Binding to plasma Aß appears to be key as other Aß-binding 
substances, such as gelsolin and GM1, also trigger an efflux of Aß from the brain [163]. 
Proteins co-depositing with Aß are likely to have high binding affinity to Aß and are less 
likely to generate the side-effects seen with antibody treatment, making these proteins 
interesting candidates for (peripheral sink) clearance of Aß.
Previously, we examined the interaction of small heat shock proteins (sHsp) with 
Aß. Small Hsp are chaperone proteins involved in proper folding of proteins [32]. In total, 
ten human sHsp have been described [121], all possessing an a-crystallin domain. Since 
misfolding of Aß is the main reason for its accumulation, it would be expected that sHsp 
are associated with Aß in the brain. Indeed, several members of the sHsp family can be 
detected in Aß deposits. Hsp20, Hsp27, HspB2/B3 and HspB8 can be found co-localized 
with senile plaques, with HspB2/B3 also co-localized with cerebral amyloid angiopathy 
(CAA) [284]. The only sHsp that is not co-localized with Aß deposits in vivo is aB-crystallin. 
However, in vitro aB-crystallin demonstrated the strongest association with Aß [279]. This 
sHsp strongly inhibited Aß-induced cellular toxicity, suppressed ß-sheet conformation of 
aggregating Aß and had the strongest binding affinity to Aß of all sHsp tested.
Since aB-crystallin can strongly bind Aß in vitro, we aimed to investigate if aB-
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crystallin can reduce brain Aß levels and act as a peripheral sink agent in vivo. To this end, 
we used two different mouse models for AD. The APPswe/PS1dE9 mouse model develops 
Aß plaque pathology as early as 4-6 months of age and has severely impaired cognition 
[82, 253]. The TgSwDI model accumulates Aß mainly in the vasculature, starting at an age 
of about 3 months [55]. This specific vascular accumulation of Aß is due to a reduced af­
finity of LRP-1 to Aß with Dutch and Iowa mutations [56], preventing this latter model to 
sustain a peripheral sink mechanism [259].
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Materials and Methods
APPswe/PS1dE9 and TgSwDI mice
A colony of APPswe/PS1dE9 (APP/PS1) mice was established at the conventional depart­
ment of the Central Animal Laboratory of the Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, after obtaining founder animals from Johns Hopkins 
University, Baltimore (MA), USA. In short, this model was created by co-injection of two 
transgenes for APP with the swedish mutation and PS1 with a deletion in exon 9, under 
control of a prion protein promoter, in the pronucleus of single cell C57Bl/6 embryos [112]. 
An additional colony of transgenic mice expressing human APP with the Swedish, Dutch 
and Iowa mutations (TgSwDI), under control of the Thy-1 promoter, was also established 
at the Central Animal Laboratory of the Radboud University Nijmegen Medical Centre. 
Founder animals of this transgenic line were obtained from Stony Brook University, Stony 
Brook (NY), USA [55].
Female APP/PS1 mice, TgSwDI mice and non-transgenic (WT) C57Bl/6 control 
mice were group-housed in standard cages with nestlets and an igloo as cage enrich­
ment. There was a 12 hour light-dark cycle (lights on at 7 am), with a constant tempera­
ture of 21±1°C, humidity control and background music during the light phase. Standard 
food pellets and acidified water (pH 2.5-3) were given ad libitum. This study was approved 
by the Animal Care Committee of the Radboud University Nijmegen Medical Centre (RU- 
DEC) and was performed according to the guidelines of the Dutch Council for Animal Care 
and the European Communities Council Directive of 24 November 1986 (86/609/EEC). Our 
study was also in concurrence with the European regulations on ethics and responsible 
conduct regarding scientific communication.
Recombinant mouse aB-crystallin production
To minimize the induction of an immune response, mouse aB-crystallin was used. Mouse 
aB-crystallin was either purified by column chromatography or by affinity chromato­
graphy using a histidine tag, generating mouse-aB-crystallin and mouse aB-crystallin- 
His respectively. For aB-crystallin without His-tag, the coding region was cloned into a 
pET16b vector. Subsequently, mouse aB-crystallin was expressed in Rosetta DE3 plysS 
competent cells (Invitrogen, Paisley, UK). A culture inoculated from a single colony was 
incubated for 3 hours at 37 °C. Production of mouse aB-crystallin was induced by addition 
of isopropyl-thio-ß-D-galactopyranoside (IPTG) at a final concentration of 0.37 mM. Cells 
were harvested in TEG (25 mM Tris pH 8.0, 2 mM EDTA, 50 mM glucose) with protease 
inhibitors (Complete mini EDTA-free, Roche, Mannheim, Germany) and lysed by sonica- 
tion. Purification of mouse aB-crystallin was performed using a DEAE-Sepharose Fast Flow 
column (Pharmacia, Freiburg, Germany) and a linear NaCl gradient from 0 up to 1M in 
TNE buffer (25 mM Tris pH 8.0, 1M NaCl, 2mM EDTA). For further purification a Source 15 
Q column (Amersham, Uppsala, Sweden) was used, again with a linear NaCl gradient in 
TNE buffer (0-1 M, pH 8.5). Finally, the buffer was exchanged to phosphate buffered saline 
(PBS) using iCon concentrator spin columns (9 kDa cut-off, Thermo Fisher Scientific, San 
Jose, CA, USA).
For the production of mouse aB-crystallin-His, the pET46EK vector was used to 
introduce a N-terminal His-tag sequence, was used. Again, mouse aB-crystallin was ex­
pressed in Bl21(DE3) plysS competent cells and production was induced by addition of
0.375 mM IPTG. Cells were lysed by sonication in native lysis buffer (NLB) (50 mM NaH- 
2PO4, 300 mM NaCl, pH 8.0) supplemented with EDTA-free protease inhibitors (Complete,
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Roche). For purification of the protein, Ni-NTA agarose beads (Qiagen, Hilden, Germany) 
were used. Mouse aB-crystallin-His was allowed to bind to the agarose beads for 1 hour 
(4°C), after which beads were brought into a polypropylene column (Qiagen) and washed 
and eluted with NLB supplemented with increasing amounts of imidazole (Sigma-Aldrich, 
St. Louis, MO, USA). Eluted fractions were collected and analyzed using 12% SDS-page 
gels, to determine which fraction contained the purified protein. An iCON concentrator 
spin column was used to concentrate mouse aB-crystallin-His and to exchange the buf­
fer to PBS. For both mouse aB-crystallin and mouse aB-crystallin-His, a BCA protein assay 
(Pierce BCA, Thermo Fisher Scientific Inc, Rockford, IL, USA) was performed to determine 
protein concentration. Purity of both mouse aB-crystallin and mouse aB-crystallin-His 
was >95%.
Treatment
Starting at an age of 12 months, APP/PS1 mice received two intraperitoneal injections per 
week (0.1 ml per injection) of PBS (n=9) or 750 ^g/kg mouse aB-crystallin in PBS (n=12) 
for 12 consecutive weeks. Age-matched WT mice (n=6) were handled similarly, but not 
injected, when the transgenic mice received their injections. Similarly, 9-month-old TgS­
wDI mice received three intraperitoneal injections per week of PBS (n=12) or 750 ^g/kg
■ mouse aB-crystallin-His (n=11). Again, age-matched WT mice (n=12) were handled when the transgenic mice received their injections. Mice were regularly weighed during the in­jection period.
Behavioural analyses
After 5 weeks of injections, behavioural analysis was started. Injections continued during 
the behavioural testing, but on a test day injections were given after the behavioural ex­
periment was performed. Mice were excluded from the behavioural experiments if they 
were blind (i.e. cloudy eyes) and therefore we excluded 2 animals (one in the PBS-group 
and one in the aB-crystallin-group) from the TgSwDI group. Because of the low number 
of surviving animals in the aB-crystallin-treated group of APP/PS1 mice, in this group we 
did not exclude data of mice that were blind in one eye (n=2). These blind mice performed 
similarly to non-blind aB-crystallin-treated mice in the behavioural analyses.
Rotarod analysis
To test motor skills, mice were individually placed on a rotarod, after the rod had started to 
visibly rotate. The time mice spent on the rotarod while it accelerated to about 38 rpm was 
recorded, with a maximum of 300 seconds. Each mouse performed four trials with a 30 
minute inter-trial rest period. Trial 1 was a pre-trial, trial 2 to 4 were averaged to determine 
the mean time (± standard error) spent on the rotarod.
Open Field
To analyze exploration and activity in a novel environment, open field behaviour was stu­
died. The open field consisted of a 50 x 50 x 40 cm white Plexiglas box, placed below a vi­
deo camera. Mice were placed in the centre of the box and were observed for 30 minutes 
each. They were scored for time spent on different types of passive (sitting, grooming) and 
active (rearing, wall leaning, walking) behaviours, as previously defined [10].
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Morris water maze
To test spatial memory, the Morris water maze was performed. A circular pool (diameter 
of 120 cm) was filled with water of 21-22 °C, until a platform placed in the north-east qua­
drant was 1 cm below the water surface. The water was made opaque with milk powder 
and spatial cues were placed around the pool (distance ~ 0.5m). Mice were placed in the 
pool at different starting positions during four trials per day. Each trial lasted two minutes 
or until the mouse reached the platform, after which the mouse had to stay on the plat­
form for 30 seconds before being removed from the pool. The time needed to find the 
platform (escape latency) was recorded for each trial. Each mouse performed four trials 
per day, with a 30-minute inter-trial rest period, for four days. Escape latencies of mice 
were averaged for each day. After 16 trials, a probe test was performed. In the probe test, 
the platform was removed and mice were allowed to swim for 2 minutes. DVD recordings 
of the probe trial were analysed using Ethovision®, to score the number of crossings across 
the old platform location and the time they needed to first cross this location.
Reverse Morris water maze
Using the same pool and conditions as for the Morris water maze, mice again had to find a 
submerged platform in the reverse Morris water maze. This time the platform was moved 
to the south-west quadrant of the pool. After two days (four trials/day), mice had to per­
form the probe test. Again, using DVD recordings of the probe trial, the same parameters 
as for the Morris water maze were analysed using Ethovision®.
Transcardial perfusion
After the behavioural tasks, mice were weighed, anesthetized with 2-4% isoflurane and 
transcardially perfused with sterile PBS (Roche, Mannheim, Germany). After the perfusion, 
mice were decapitated and brains were collected. One hemisphere was snap-frozen in 
liquid nitrogen and stored at -80°C until further analysis.
Aß extraction
A two-step extraction using carbonate buffer (soluble Aß) and guanidine-HCl (insoluble 
Aß) was performed on a frozen brain hemisphere. Prior to homogenization, the hemisp­
here was thawed on ice and the olfactory bulb and cerebellum were removed. Tissue was 
kept on ice extraction until guanidine-HCl was added. First, the hemisphere was weighed 
and homogenized in a tissue grinder with 10 l^/mg 1x carbonate buffer (0.1M carbona­
te, 50mM NaCl, 0.5% sodium azide, pH 11.5) containing protease inhibitors (Complete, 
Roche). To shear DNA, the carbonate extract was passed five times through a 21 gauge 
needle. The extract was then centrifuged for 20 min (4°C, 16.000 rcf). The supernatant was 
collected and stored at -80°C (carbonate extract). The pellet was resuspended in 4 l^/mg 
of 5M guanidine-HCl with protease inhibitors (Complete, Roche) and incubated for three 
hours on a rotamixer (room temperature). The extract was then centrifuged for 20 min 
(4°C, 16.000 rcf) and the supernatant was stored at -80°C (guanidine-HCl extract).
ELISA of brain Aß40 and Aß42
The carbonate and guanidine-HCl extracts of one brain hemisphere were analysed for hu­
man Aß40 and Aß42 levels by ELISA (Invitrogen, Paisley, UK). The ELISAs were performed 
according to the manufacturer's protocol. In short, extracts were diluted with diluent buf­
fer provided in the kit. Dilutions varied per model, and were therefore optimized for both
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models. To dilute the standards, 1x carbonate buffer or 5 M guanidine-HCl was added to 
the diluent buffer to create the same dilution and conditions as used for the samples. After 
incubating the extracts for 3 hours with detection antibody on a shaker (room temperatu­
re), plates were incubated for 30 minutes with anti-rabbit IgG-HRP diluted in HRP-diluent. 
Finally, stabilized chromogen (tetramethylbenzidine) was added to the wells and incuba­
ted for 30 minutes in the dark (room temperature), after which the reaction was stopped 
with stop solution from the kit. The O.D. was measured at 450 nm. Using the standard 
curve, the concentration of each mouse extract (in duplicate) could be determined (in pg/ 
ml) and averaged for each treatment group. A protein assay (Pierce BCA, Thermo Fisher 
Scientific Inc, Rockford, IL, USA) was performed to determine total protein levels in the 
different extracts. Aß levels were normalized to this protein level (ng/mg). In line with 
previous data [82], carbonate-extracted (soluble) Aß levels were much lower (>100 times) 
in both transgenic models than guanidine HCl-extracted (insoluble) Aß levels. Therefore, 
in the results we only present guanidine HCl-extracted Aß levels.
Statistical analysis
Injection groups were compared using independent unpaired T-tests. Time spent on ac­
tive/passive behaviour in the open field and escape latencies in (reverse) Morris water 
maze were analyzed using a repeated measures analysis of variance (ANOVA). Learning 
curves of mice were also compared in this analysis. Results are presented as mean ± 
standard error. Statistical significance was set at p<0.05, with p<0.10 considered a trend.
108
Results
Animals and body weight
During 12 weeks, 12-month old APP/PS1 and 9-month-old TgSwDI mice received injec­
tions with either PBS or aB-crystallin at an age when Aß deposition in these models was 
prominent (12 and 9 months of age respectively). Wildtype (WT) C57Bl/6 mice served as 
controls. There were no significant body weight differences in WT or PBS- or aB-crystallin- 
treated transgenic groups at any point during the injection period (data not shown). 
During the experiment with the APP/PS1 mice, 1 PBS-treated and 8 aB-crystallin-treated 
mice were lost (resp. n=8 and n=4 left). For the TgSwDI mice, 6 PBS-treated and 2 aB- 
crystallin-treated mice were lost (resp. n=6 and n=9 left). No WT mice were lost during the 
injection period of the APP/PS1 or TgSwDI mice.
aB-crystallin does not affect activity or cognition but increases brain Aß40 levels in 12-month- 
old APP/PS1 mice
The rotarod test was performed to test motor function of the mice. We observed no signi­
ficant differences in time spent on the rotarod between transgenic (PBS- or aB-crystallin 
treated) mice and WT mice (data not shown). The open field observations revealed that 
WT mice and APP/PS1 mice that were treated with PBS or aB-crystallin for 3 months did 
not differ in the time spent on walking, sitting rearing, wall leaning or grooming (data not 
shown).
Spatial memory of mice was tested in the Morris water maze (Fig. 1). Over the 
four trial days, WT mice showed a decrease in escape latency from 100 s to 30 s, with PBS- 
treated APP/PS1 mice having a significantly higher escape latency than WT mice (Fig. 1A; 
F(1,9) = 19.24, p=0.002). On average, treatment with aB-crystallin had no effect on escape 
latency compared to PBS treatment (Fig. 2A). Furthermore, PBS-treated APP/PS1 mice had 
a significantly less steep slope of their learning curve than WT mice (F(1,9) = 7.0, p=0.027) 
and a near-significantly less steep slope than aB-crystallin-treated APP/PS1 mice (F(1,7) = 
5.36, p=0.054) during the first three trial days (Fig. 1A) .
In the probe test of the Morris water maze, PBS-treated APP/PS1 mice had a signi­
ficantly lower number of platform crossings (Fig. 1B; 0.33 ± 0.21 vs. 3.80 ± 0.20, p<0.0001) 
and a significantly slower first crossing (Fig. 1C; 100.6 ± 14.7 sec vs. 17.8 ± 5.3 sec, p=0.0009) 
than WT mice. Treatment with aB-crystallin non-significantly (p=0.21) increased the num­
ber of platform crossings (Fig. 1B: 1.0 ± 0.56 vs. 0.33 ± 0.21) and non-significantly (p=0.26) 
decreased the time-to-first-crossing compared to PBS treatment (Fig. 1C: 66.0 ± 28.1 sec. 
vs. 100.6 ± 14.7 sec.).
A reverse Morris water maze was performed for 2 days (four trials per day) to 
assess whether mice could unlearn irrelevant information and relearn a new platform lo­
cation at the opposite side of the pool. In the acquisition trials of the reverse Morris water 
maze, the escape latency was not significantly different between the three treatments 
groups (data not shown). In the probe test of the reverse Morris water maze, the number 
of platform crossing was similar for WT mice, PBS-treated APP/PS1 mice or aB-crystallin- 
treated APP/PS1 mice (data not shown). PBS-treated APP/PS1 mice did seem to need 
more time to first cross the platform compared to WT mice, but these differences were 
not significant due to large variation in values (p=0.15). The aB-crystallin-treated group 
crossed the platform location a similar number of times as the PBS-treated group (data 
not shown) and needed a similar amount of time to first cross the platform location (data 
not shown).
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Figure 1: Performance of APPswe/PS1dE9 mice in the Morris water maze. In the acquisition 
trials (A), PBS-treated mice (n=6) had a significantly higher escape latency over four trial days 
than WT mice (n=5). Treatment with aB-crystallin (n=3) had no effect on escape latency. In 
the probe trial of the Morris water maze, PBS-treated APPswe/PS1dE9 mice crossed the former 
platform location significantly less often than WT mice (B) and needed significantly more time 
to first cross the old platform location (C). Treatment with aB-crystallin had no effect on the 
number of platform crossings (B) or the time to the first crossing (C).
**p<0.01, ***p<0.001
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Aß levels were determined in guanidine HCl extracts of one brain hemisphere 
(ng/mg total protein) (Fig. 2). Brain Aß40 and Aß42 levels of age-matched WT mice were 
hardly detectable (13.6 and 1.6 ng/mg respectively). Treatment with aB-crystallin did not 
alter the Aß42 (Fig. 2B) level in APP/PS1 mice compared to PBS treatment, but it near- 
significantly increased Aß40 (Fig. 2A: 434.1 ± 96.4 ng/mg vs. 266.6 ± 34.5 ng/mg, p=0.06).
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Figure 2: Guanidine HCl-extracted brain Aß levels (ng/mg total protein) of APPswe/PS1dE9 
mice. Treatment with aB-crystallin (n=4) did not alter Aß42 levels compared to PBS treatment 
(n=8) (B), but near-significantly increased Aß40 levels (A). #p<0.10
aB-crystallin affects activity, but not cognition, and lowers brain Aß42 levels of TgSwDI mice. 
When we used TgSwDI mice, we observed no differences in time spent on the rotarod 
between WT mice, PBS-treated or aB-crystallin-treated mice (data not shown). In the open 
field, PBS-treated TgSwDI mice were generally more active than WT mice, with significant­
ly more time spent on walking (Fig.3A: F(1,15) = 4.99, p=0.04) and wall leaning (Fig. 3C; 
F(1,15)=5.92, p=0.03) and significantly less time sitting (Fig. 3B: F(1,15) =11.34, p=0.004). 
There was no difference between these two groups in time spent on grooming (Fig.
A
0
B
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3D). Treatment with aB-crystallin non-significantly increased the time spent on walking 
(Fig. 3A: F(1,11) = 1.08, p=0.32) and decreased the time spent on sitting (Fig. 3B F(1,11) 
=2.11, p=0.17) compared to PBS treatment, although these effects were not significant. 
The time spent on wall leaning was significantly lowered with aB-crystallin treatment 
(Fig. 3C: F(1,11) =8.26, p=0.02) and the time spent on grooming was significantly incre­
ased compared to PBS treatment (Fig. 3D: F(1,11) = 8.93, p=0.01).
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Figure 3: The time TgSwDI and WT mice spent on the open field parameters walking (A), sit­
ting (B), wall leaning (C) and grooming (D) was recorded for 30 minutes and depicted in 3 
periods of 10 minutes. PBS-treated TgSwDI mice (n=5) spent significantly more time on wal­
king (A) and wall leaning (C) and significantly less time on sitting (B) than WT mice (n=12). 
Treatment with aB-crystallin (n=8) significantly reduced the time spent on wall leaning (C) 
and significantly increased the time spent on grooming (D) compared to PBS treatment. 
*p<0.05, **p<0.01
In the Morris water maze, WT mice showed a decrease in escape latency (Fig. 4), 
from 120 s to 70 s over the four trial days. PBS-treated TgSwDI mice had a significantly 
lower escape latency than WT mice (Fig. 4A: F(1,15) = 8.44, p=0.01), although the slope 
of their learning curve was not different (F(1,15) = 2.76, p=0.12). Overall, treatment with 
aB-crystallin had no effect on escape latency compared to PBS treatment or compared to 
WT mice (Fig. 4A). Only on the fourth trial day, the escape latency of aB-crystallin-treated 
TgSwDI mice was significantly lower than PBS-treated TgSwDI mice (18.6 ± 7.5 s vs. 71.75 
± 12.9 s, p=0.01). Furthermore, the slope of the learning curve of aB-crystallin-treated 
TgSwDI mice was significantly less steep than that of PBS-treated TgSwDI mice (Fig. 4A:
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F(1,11) = 20.53, p=0.01). In the probe test of the Morris water maze, PBS-treated TgSwDI 
mice had a non-significantly higher number of platform crossings than WT mice (Fig. 4B: 
2.2 ± 0.73 vs. 1.1 ± 0.33, p=0.13). The number of platform crossings of the aB-crystallin- 
treated TgSwDI mice were in between those of the other two groups (Fig. 4B). The time 
PBS-treated and aB-crystallin-treated TgSwDI mice needed to first cross the platform was 
not significantly different to the time WT mice needed (Fig.4C).
In the reverse Morris water maze, the escape latency of PBS-treated TgSwDI mice 
in the acquisition trials did not differ from WT mice or aB-crystallin-treated TgSwDI mice 
(data not shown). Furthermore, in the probe trial of the reverse Morris water maze, there 
were no significant differences between the treatment groups on the number of platform 
crossings and the time needed to first cross the old platform location (data not shown).
Finally, compared to PBS treatment, treatment with aB-crystallin non-significant- 
ly (p=0.32) increased guanidine HCl-extracted Aß40 levels compared to PBS-treated TgS­
wDI mice (Fig. 5A: 122.0 ± 19.8 ng/mg vs. 96.6 ± 4.2 ng/mg). Furthermore, aB-crystallin 
treatment significantly decreased Aß42 levels (Fig. 5B: 3.67 ± 0.60 vs. 2.43 ± 0.25, p=0.05). 
Guanidine HCl-extracted Aß levels of WT mice were too low to be detected.
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Figure 4: Performance of TgSwDI mice in the Morris water maze. In the acquisition trials (A), 
PBS-treated mice (n=5) had a significantly lower escape latency over four trial days than WT 
mice (n=12). Treatment with aB-crystallin (n=8) had no effect on escape latency. In the probe 
trial of the Morris water maze, PBS-treated TgSwDI mice non-significantly crossed the former 
platform location more often than WT mice (B) but needed a similar amount of time to first 
cross the old platform location (C). Treatment with aB-crystallin had no effect on the number 
of platform crossings (B) or the time to the first crossing (C). ** p<0.01
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Figure 5: Guanidine HCl-extracted brain Aß levels of TgSwDI mice (ng/mg total protein). Treat­
ment with aB-crystallin (n=6) slightly increased Aß40 levels (A) compared to PBS-treated mice 
(n=9), whereas it significantly decreased Aß42 levels (B). *p<0.05
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Discussion
Previously, we demonstrated that aB-crystallin can bind Aß and influence its aggregation
[279], making this small heat shock protein a candidate agent for therapeutic intervention 
in Alzheimer's disease. In the present study, using the APPswe/PS1dE9 and TgSwDI mouse 
model for AD, we demonstrated that aB-crystallin 1) had no effect on cognition in both 
models, 2) had some effect on activity levels in the TgSwDI model, 2) slightly increased gu­
anidine HCl-extracted brain Aß40 levels in the APP/PS1 model and 3) lowered guanidine 
HCl-extracted brain Aß42 levels in the TgSwDI model.
Both the APPswe/PS1dE9 and the TgSwDI mouse model have previously demon­
strated well-documented impairments in several behavioural tasks [104, 139, 140, 292]. 
We also found impaired spatial memory learning in our APPswe/PS1dE9 mice, but not in 
our TgSwDI mice. In the Morris water maze, APPswe/PS1dE9 mice needed significantly 
more time finding a hidden platform than WT mice, while TgSwDI mice performed similar 
to WT mice or even better. This latter result appears to be caused by the relatively weak 
performance of the WT mice in this behavioural test, although it is also important to men­
tion that 67% of our PBS-treated TgSwDI mice were lost during the injection period. The 
loss was likely not due to the PBS, as the same PBS solution was used to dilute the aB- 
crystallin and only 18% of the aB-crystallin-treated TgSwDI mice were lost. However, in 
this experiment the TgSwDI mice proved to be very sensitive to the combined stress of 
injections and behavioural testing, resulting in the death of many mice. It may be that 
aB-crystallin somehow lowered the stress response of these mice, thereby protecting 
them from stress-related death. In any case, because of this loss, the lack of a difference 
between TgSwDI and WT mice may also reflect a selection bias. As APPswe/PS1dE9 and 
TgSwDI mice performed equally well on the rotarod as their non-transgenic controls, any 
differences we found between non-transgenic mice and transgenic mice were not due to 
impaired motor functions.
In the open field, it was the APPswe/PS1dE9 model that hardly differed from 
non-transgenic controls, while the TgSwDI mice were (significantly) more active than WT 
mice. Both these results were unexpected. In a previous open field analysis of the APPswe/ 
PS1dE9 model, these mice were more active than non-transgenic controls [104]. And, pre­
viously, TgSwDI were similarly active to non-transgenic controls in an open field analysis, 
although the open field test was performed slightly different [292]. Again, it may be the 
increased sensitivity to stress that causes our TgSwDI mice to in this case be more active 
compared to wildtype controls. Finally, as expected from a previous characterization of 
the TgSwDI model [55], we found that Aß40 levels of this model were considerably higher 
than Aß42 levels. The APPswe/PS1dE9 model is known to have a higher amount of inso­
luble Aß42 compared to Aß40 [82], but in our hands Aß40 and Aß42 levels in 12-month- 
old APPswe/PS1dE9 mice were comparable. This latter discrepancy is perhaps due to the 
different extraction methods used in our study compared to the previous study.
In both mouse models, aB-crystallin had some effect on brain Aß levels; it near- 
significantly increased guanidine HCl-extracted Aß40 levels in APPswe/PS1dE9 mice and 
significantly lowered guanidine HCl-extracted Aß42 levels in TgSwDI mice. The fact that 
aB-crystallin could influence brain Aß levels in our TgSwDI mice, advocates against this 
sHsp acting as a peripheral sink agent, as it is known that TgSwDI mice cannot sustain a 
peripheral sink mechanism [259]. Therefore, our results suggest that aB-crystallin acted 
directly in the brain, although based on mere size, BBB crossing of this sHsp seems unli­
kely. Differential effects of aB-crystallin on brain Aß species may be due to the addition
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of a His-tag to the aB-crystallin injected in the TgSwDI mice or perhaps due to the larger 
number of injections received by the TgSwDI mice. Previously, it was demonstrated that 
addition of a His-tag to HSC70 altered the molecular state of this Hsp, because the His-tag 
stabilized the dimeric form of HSC70 [6]. However, we have previously found that this 
His-tagged sHsp had similar effects on protein aggregation and cellular toxicity as their 
untagged versions (unpublished data). It may be that differences in Aß accumulation of 
the two models used, provide an explanation to the differential result of aB-crystallin, as 
they have different types of Aß deposits and opposite Aß40:Aß42 ratios [55, 82].
Considering the Aß40:Aß42 ratios, it is striking that aB-crystallin affects concen­
trations of the Aß species that is less abundant in both models, i.e. Aß40 in APPswe/PS- 
1dE9 mice and Aß42 in TgSwDI mice. This result raises the question if aB-crystallin-induced 
changes in brain Aß levels are sufficient to affect cognitive function. Indeed, in our hands 
aB-crystallin injection hardly had an effect on cognition in any of the performed behavi­
oural tests; only in the TgSwDI mice, aB-crystallin restored parameters of the open field to 
WT levels. However, as with the comparison between the transgenic and non-transgenic 
mice, when interpreting the results of the aB-crystallin treatment, the substantial loss of 
mice in the aB-crystallin-treated APPswe/PS1dE9 mice and the PBS-treated TgSwDI mice 
should be taken into consideration. Again, this may have lead to selection biases and 
thereby influenced the interpretation of our experiments. Furthermore, since we did not 
include a control group injected with either a nonsense protein or a sHsp that did not in­
teract with Aß in vitro (e.g. Hsp27) [19], we cannot conclude that the observed effects on 
Aß levels are only the result of injection with the high affinity sHsp aB-crystallin. Finally, 
it should be mentioned that in this study only mice with severe Aß pathology were exa­
mined. It may be that administration of aB-crystallin at an earlier age, when more soluble 
Aß is present, can reveal stronger effects of aB-crystallin on cognition and brain Aß load 
and perhaps even demonstrate a peripheral sink action of aB-crystallin.
In conclusion, we have no indication that peripheral administration of aB- 
crystallin is a suitable treatment option for AD (mouse models), nor did our experiments 
reveal that aB-crystallin can act as a peripheral sink for Aß. Further investigation, using 
more mice at different stages of Aß pathology, may provide more conclusive evidence on 
a therapeutic action of aB-crystallin. Furthermore, (small) Hsp may also act as therapeutic 
agents in other ways than examined in our study. For example, it is known that Hsp not 
only bind the Aß protein, but are also highly immunogenic [304]. When Hsp form a com­
plex with Aß they may enhance the immune response against Aß, thereby enhancing Aß 
clearance. Indeed, immunization with an Aß/Hsp70 complex induced a markedly higher 
immune response in APPswe mice than immunization with Aß alone, although in this 
case the increased immune response was accompanied by an increase in brain Aß levels
[130]. Another approach to using Hsp as therapeutic agents is by pharmacologically indu­
cing their expression in the brain. For example, induction of Hsp70 by the plant-derived 
compound celastrol has neuroprotective effects in animal models for neurodegenerative 
diseases such as Parkinson's disease [48] and amyotrophic lateral sclerosis [125]. It is sug­
gested that a similar effect may occur in AD [3, 5]. As far as we know, the pharmacological 
induction of Hsp has not yet been tested in AD models. Therefore, even though adminis­
tration of Hsp such as aB-crystallin may not be effective, Hsp do have many characteristics 
making them interesting therapeutic targets and should therefore be further explored in 
the search for new therapeutic agents.
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Chapter 8
Summary and discussion
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Summary
Heparan sulfate proteoglycans and Aß
In humans suffering from Alzheimer's disease (AD), heparan sulfate proteoglycans (HSPG) 
are found in close association with amyloid ß (Aß) pathology [254, 255]. The extracellular 
matrix HSPG agrin and the cell surface HSPG glypican-1 seem to have a particularly strong 
association, as these are the only two HSPG that can be found in all the different types of 
AD lesions, i.e. parenchymal plaques and cerebral amyloid angiopathy (CAA). In vitro stu­
dies have demonstrated that HSPG affect Aß deposition at many levels, from regulating 
Aß cleavage [17, 204] to triggering Aß aggregation and maintaining Aß deposits [41, 52, 
87]. Vice versa, Aß can protect HSPG from proteolysis [13]. As it was known that Aß can 
induce the expression of a number of genes [195], we wanted to investigate if Aß could 
also influence production of HSPG such as agrin and glypican-1, as an explanation for the 
accumulation of HSPG species with Aß deposits. As we describe in Chapter 2, we found 
that Aß increased protein and mRNA production of the HSPG agrin and glypican-1 by 
human brain pericytes (HBP), suggesting a local production of HSPG by cerebrovascular 
cells in CAA. Furthermore, both HSPG accumulated at the cell surface of cerebrovascular 
cells, apparently retained there by the Aß fibrils attached to the cell membranes, which 
provides a plausible molecular basis of co-deposition of HSPG, and perhaps also of other 
co-depositing proteins (Chapter 5), with Aß.
After the initial production of core proteins, proteoglycan glycosaminoglycan 
(GAG) chains are stepwise attached to the protein core. Furthermore, the chains are en­
zymatically modified until they ultimately consist of both highly sulfated and relatively 
unmodified regions [22, 91, 256]. We have found evidence that Aß is involved in at least 
one of these modifications, as Aß can induce an increased sulfate incorporation into GAG 
chains (Chapter 2). These sulfate moieties in turn are essential in mediating the stimula­
tory effect of HSPG on Aß aggregation [40]. Indeed, in Chapter 3, we demonstrate that 
removal of O- and particularly N-sulfates from heparin, a HSPG analogue, could eliminate 
induction of Aß aggregation by heparin. Furthermore, whereas fully sulfated heparin inhi­
bited Aß-induced cellular toxicity, this effect was lost when heparin was (partially) desulfa­
ted. By immunohistochemistry we then determined that GAG chains near CAA vessels are 
differentially sulfated (Chapter 3), again suggesting that variation in sulfation patterns is 
relevant.
HSPG are part of a family of proteoglycans, including chondroitin sulfate, derma- 
tan sulfate and keratan sulfate [256], each characterized by the presence of different GAG 
chains with differing numbers of sulfate moieties. Although less abundant than HSPG, 
these different proteoglycans can be detected near Aß deposits as well [65, 221, 223], 
suggesting they may also influence Aß aggregation, perhaps dependent on their level of 
sulfation. When comparing the effects of different GAGs on Aß aggregation (Chapter 3) 
it seemed in general that highly sulfated GAGs (i.e. heparin and dextran sulfate, a GAG- 
related macromolecule) increased Aß aggregation most effectively. Furthermore, both 
heparin and heparan sulfate protected against Aß-induced toxicity of cerebrovascular 
cells, while the less sulfated chondroitin sulfate had no effect.
Aß-associated proteins in AD mouse models
In order to investigate pathology development and test new therapeutic agents, many 
transgenic mouse models for AD have been created by inserting human AD-related genes 
(i.e. amyloid precursor protein and presenilin) carrying one or more familial mutations
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into the mouse genome. For the experiments described in Chapters 4, 6 and 7, we used 
the APPswe/PS1dE9 mouse model. In this model, expression of human amyloid precursor 
protein (APP) with the Swedish mutation and presenilin-1 (PS1) with a deletion in exon 
9, leads to Aß deposition starting from 4-6 months of age [82, 253]. Furthermore, this 
Aß deposition is accompanied by severely impaired cognition [139, 140]. In Chapter 7 
we also describe experiments performed using the TgSwDI mouse model, a model that 
mainly accumulates vascular Aß deposits from about 3 months of age [55] and that also 
demonstrates robust cognitive impairment [292].
It is known that there are marked differences between human and mouse Aß 
deposits with regards to Aß modifications and compaction [119, 136, 258]. As HSPG are 
such an intrinsic part of Aß deposits in AD patients [254, 255, 257] and as they are clearly 
involved in Aß deposition in vitro (Chapters 2 and 3), we wanted to investigate if Aß de­
posits in a transgenic AD mouse model demonstrate a similar relation between Aß and 
HSPG. In Chapter 4, we describe that, unlike in humans, the co-deposition of HS GAG 
chains and the HSPG species perlecan, glypican-1 and agrin with Aß deposits in APPswe/ 
PS1dE9 mice was limited. Only about 30% of Aß deposits was positive for heparan sulfate 
(HS) GAG chains and less than 10% of deposits was positive for any of the different HSPG 
species. Furthermore, we could not find a temporal relation between the (limited) deposi­
tion of HSPG and the robust Aß deposition.
Besides HSPG, a whole number of other proteins, including apoliporotein E 
(apoE) [173], complement factors [73] and acute-phase proteins [264] are also found in or 
near Aß deposits. We therefore reviewed the literature on co-deposition of Aß-associated 
factors in different mouse models for AD (Chapter 5). We determined that only apoE co­
deposition was robustly modeled in many AD mouse models, while the other factors (i.e. 
HSPG, complement, acute phase proteins, ICAM-1, Cystatin C and CLAC) only partly co­
deposited or were not found co-localized with Aß at all. Therefore, it appears that the com­
position of Aß deposits in transgenic mice is very different from that of Aß deposits in hu­
mans, perhaps explaining why therapeutic agents proven to modulate brain Aß levels in 
mouse models often do not have a similar effect in patients. It should be mentioned that 
for many factors, the number of studies was limited to only one or two mouse models. As 
these factors appear crucial in human Aß deposition, we suggested that co-deposition of 
these factors should be studied in more mouse models.
New therapeutic agents
Until now, there are few options to treat AD. There are only a handful of approved agents 
and these merely treat the symptoms of the disease [175], but not the underlying patho­
logy. There are, however, many new therapeutic approaches under development. Many of 
these approaches target the Aß protein, as this protein appears to be a key player in AD 
pathology.
One new approach receiving much attention has been immune therapy, aimed 
at triggering an immune response against Aß. However, clinical trials revealed that im­
mune therapy is not suitable for treatment yet, as it was accompanied by serious nega­
tive side-effects [183]. As HSPG demonstrate such a clear affinity for Aß, a characteristic 
they share with many potential therapeutic agents including immune therapy, we wanted 
to investigate if HSPG could be used as therapeutic agents (Chapter 6). To this end, we 
used the low molecular weight heparin enoxaparin, that was previously shown to reduce 
brain Aß levels in the APP23 mouse model [20]. Furthermore, we previously demonstra-
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ted that several small heat shock proteins (sHsp) have affinity for Aß [279], many of which 
can be found co-deposited with Aß deposits [280, 284]. Of all sHsp, aB-crystallin had the 
strongest binding affinity with Aß and through this binding could reduce Aß aggregation 
and Aß-induced toxicity [279]. In Chapter 7, we investigated the potential of the small 
heat shock protein aB-crystallin to act as a therapeutic agent. Both enoxaparin and aB- 
crystallin were administered peripherally and we hypothesized that they may act as so- 
called peripheral sink agents, as both are considered too large (~4500 kDa and 22 kDa 
respectively) to cross the blood brain barrier (BBB). The peripheral sink hypothesis (Fig. 1) 
states that peripherally administered agents that bind Aß with high affinity can lower the 
plasma Aß pool when binding Aß in the peripheral circulation, as complexes of Aß and the 
peripheral sink agent become targeted for peripheral degradation. This then triggers an 
efflux of Aß from the brain to the blood in order to restore the equilibrium that is known 
to exist between brain and blood Aß pools [61].
Figure 1: The peripheral sink hypothesis. Peripherally administered Aß-binding agents bind 
Aß with high affinity in the plasma. These complexes, in turn, become targeted for degrada­
tion in organs such as the liver. This peripheral degradation depletes the plasma pool of Aß, 
triggering an efflux of Aß from the brain to the blood.
Using APPswe/PS1dE9 mice, we found that both enoxaparin (Chapter 6) and 
aB-crystallin (Chapter 7) altered brain Aß levels, although only enoxaparin could signifi­
cantly improve cognition, as measured in the Morris water maze. At an early stage of Aß 
deposition in APPswe/PS1dE9 mice (5 months of age), enoxaparin lowered guanidine-HCl 
extracted Aß40, which confirmed the results of the previous prophylactic enoxaparin tre­
atment of APP23 mice [20]. However, we found an opposite effect on Aß levels in APPswe/ 
PS1dE9 mice with intermediate to severe Aß pathology (10 and 12 months old respecti­
vely). At these stages, enoxaparin increased guanidine HCl-extractable Aß40 and Aß42 
levels. Although aB-crystallin could not improve cognition of APPswe/PS1dE9 mice, it did 
normalize activity levels of these mice as measured in the open field. Furthermore, aB- 
crystallin slightly increased guanidine HCl-extractable Aß40 levels (Chapter 7). Overall, 
we conclude that enoxaparin, but not aB-crystallin, may be a potential therapeutic agent.
The results of our experiments in APPswe/PS1dE9 mice did not provide us with 
clear evidence on a peripheral sink action of either protein. We also treated TgSwDI mice
EBB
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with aB-crystallin (Chapter 7). As Aß clearance from the brain by transport across the BBB 
is minimal in these mice [55], it is a suitable model to at least exclude a peripheral sink ac­
tion. In these mice, aB-crystallin had no effect on cognition or activity parameters, again 
demonstrating its unsuitability as a therapeutic agent. However, guanidine HCl-extracted 
Aß42 levels were reduced, suggesting that aB-crystallin possibly affects brain Aß levels 
independent of a peripheral sink function.
In summary, the main conclusions of our in vitro and in vivo experiments are that:
1. Aß can induce protein and mRNA expression of HSPG agrin and glypican-1
2. The molecular basis for HSPG co-deposition with Aß may be the retention of 
HSPG, such as agrin and glypican-1, by Aß fibrils e.g. on the cell surface.
3. Sulfate moieties of HSPG (i.e. heparin) modulate the influence of HSPG on Aß 
aggregation and their inhibitory effect on Aß-induced toxicity of 
cerebrovascular cells.
4. In the APPswe/PS1dE9 model, a robust Aß deposition with age (starting at 5 
months of age) is accompanied by limited co-deposition of HSPG species
(<30%).
5. In general, AD mouse models do not seem to co-deposit Aß-associated factors 
to the same extent as humans, limiting the translation of results of therapies 
aimed at Aß removal obtained in mouse models to the human situation.
6. aB-crystallin is not a suitable therapeutic agent, as it has no effect on cognition 
and only slightly influences brain Aß levels in APPswe/PS1dE9 and TgSwDI mice.
7. Enoxaparin may be a new therapeutic agent, improving cognitive impairment 
and altering brain Aß levels.
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Discussion
Aß-induced expression of co-depositing proteins
Previously it has been described that Aß is capable of inducing gene expression of a num­
ber of proteins [195]. Although there is no evidence that these proteins are involved in 
Aß aggregation, some of them could be detected in (vascular) Aß deposits. We have now 
demonstrated that Aß can also induce protein expression of the co-depositing heparan 
sulfate proteoglycans (HSPG) agrin and glypican-1 in cerebrovascular cells (Chapter 2). 
It would be interesting to investigate if Aß can also induce other co-depositing proteins, 
such as apoE and acute phase proteins.
As Aß can stimulate the expression of HSPG, it seems puzzling that co-deposition 
of HSPG in the APPswe/PS1dE9 mouse model was low (Chapter 4). It may simply be that 
in mouse cells, HSPG are not as easily induced as in human cells. However, it should be 
mentioned that the low detection of HSPG does not necessarily reflect low HSPG produc­
tion. Indeed, the APPswe/PS1dE9 model highly expresses Aß [112] and therefore enough 
Aß should be present to stimulate production of HSPG. It may be that due to the rapid 
deposition of Aß in mouse models [169, 295], HSPG are not able to co-deposit with Aß. 
Furthermore, HSPG may be more readily degraded in the brains of these mice. To deter­
mine if Aß can actually trigger the production of HSPG in APPswe/PS1dE9 mice, gene ex­
pression and mRNA production of HSPG should be analyzed in brain tissue of transgenic 
mice and wildtype controls. Analysis of expression and activity of HSPG-degrading hepa- 
rinases within mouse brains may reveal if HSPG are more easily degraded in the brains of 
our model compared to the brains of AD patients.
Finally, our in vitro analysis demonstrated that Aß fibrils can act as a HSPG 
reservoir (Chapter 2). As the APPswe/PS1dE9 model has a robust deposition of Aß 
(Chapter 4), it should be able to trap HSPG during deposition. Perhaps the chemical dif­
ferences between Aß expressed in humans and several mouse models [119, 136, 258] or 
the above-mentioned rapid deposition of Aß in mouse models compared to humans [169, 
295], can explain the fact that Aß hardly traps HSPG in APPswe/PS1dE9 mice. Furthermore, 
these explanations can perhaps also be extended to the co-deposition of other proteins, 
as our review summarizes that, in general, co-deposition of these proteins is different in 
transgenic mice compared to AD patients (Chapter 5).
Aß-induced modifications of GAG chains
Aß not only induces protein expression of agrin and glypican-1, it also triggers sul­
fate incorporation into GAG chains (Chapter 2). It was already described that the sul­
fate moieties of HSPG are necessary mediators of the HSPG-induced aggregation of 
Aß [40], a role that we have now further established for HSPG-induced aggregation 
of vascular Aß (Chapter 3). However, it remains to be investigated if Aß indeed trig­
gers sulfate incorporation of HS GAG chains, since sulfate could also have been incor­
porated into proteoglycans less involved in Aß deposition, such as chondroitin sulfate. 
There are enzymes that specifically degrade these other proteoglycans (i.e. chondroi- 
tinases), allowing for a more targeted study of HS GAG chain modulation by Aß.
The formation of HS GAG chains is a multi-step process, involving several diffe­
rent enzymatic modifications [256]. Even sulfation is not a one-step modification, as it 
involves sulfation of N- and (subsequently) O-glycans. Indeed, N- and O-sulfates each ap­
pear to have specific roles, as they do not have the same capability to induce Aß aggrega­
tion (Chapter 3). It may therefore be interesting to investigate if Aß can modulate any of
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these or other steps, e.g. affect enzyme levels involved in sulfation.
Risks of, and possible alternatives to, enoxaparin and aB-crystallin as therapeutic agents 
Of the two potential therapeutic agents we tested, only enoxaparin appeared to be a po­
tential therapeutic agent, as it not only altered brain Aß levels but improved cognition 
in several groups of APPswe/PS1dE9 mice (Chapter 6), although aB-crystallin also affec­
ted brain Aß levels (Chapter 7). However, aB-crystallin did not improve the symptoms of 
AD (e.g. cognitive impairment) and therefore it did not seem useful to further investigate 
peripheral aB-crystallin administration for future therapeutic use in AD patients. An al­
ternative strategy would be to administer aB-crystallin into the ventricles of the brain, 
assuming aB-crystallin can diffuse to areas rich in Aß deposits. However, when manipu­
lating brain protein levels of aB-crystallin it should be realized that aB-crystallin as a cha­
perone protein likely also affects proteins other than Aß. This may therefore prove more 
detrimental rather than any positive effects of intracerebroventricular administration of 
aB-crystallin on Aß deposition.
In our experiments, we could not detect any adverse effect of peripherally admi­
nistrated enoxaparin or aB-crystallin. If anything, aB-crystallin appeared to protect mice 
from (stress-induced) death during the experiments (Chapter 7). Enoxaparin is a known 
anti-coagulant and may therefore trigger (micro)hemorrhaging. However, we have no evi­
dence of hemorrhaging in our enoxaparin-treated APPswe/PS1dE9 mice. Furthermore, to 
anticipate to any future side-effects of enoxaparin treatment in humans, we used an enox­
aparin dose that has been demonstrated to be tolerated by humans. The use of even smal­
ler enoxaparin-related agents, such as Neuroparin, may reduce the risk of hemorrhaging 
even further. Neuroparin has already been proven to act as a neuroprotective agent [198] 
and is able to cross the BBB [157], although as far as we know, it has not been administered 
to transgenic Aß-depositing mice yet.
Finally, it remains to be established if enoxaparin has the same positive effects in 
AD patients. As we have described, there are marked differences between Aß deposits in 
transgenic mice and humans (Chapter 4 and 5). Mouse Aß deposits are known to be more 
easily dissolved in mild extraction buffers, perhaps explained by a relative lack of HSPG co­
deposition AD mouse models (Chapter 4), and this characteristic may make them more 
easily manipulated by exogenously administered proteins than human Aß deposits.
Peripheral sink or an alternative mechanism of action
Both enoxaparin and aB-crystallin influenced brain Aß levels of APP/PS1dE9 mice 
(Chapter 6 and 7), but the question remains how these proteins mediated this effect. 
Based on size, binding affinity and the chosen route of administration (i.e. intraperitone- 
ally), we assumed that enoxaparin and aB-crystallin should be able to act as peripheral 
sink agents. However, the results presented in this thesis gave us little evidence to con­
clude that enoxaparin and aB-crystallin indeed acted as peripheral sink agents. Genera­
lly, peripheral sink agents increase plasma Aß levels [61, 146] and lower brain Aß levels 
without entering the brain [163]. Therefore, to further investigate a potential peripheral 
sink action of enoxaparin or aB-crystallin, plasma Aß levels should be determined and/or 
mouse brains should be investigated for the presence of these agents. It should be noted 
that plasma Aß levels are not always altered when known peripheral sink agents are ad­
ministrated [163, 184], perhaps because effects on plasma Aß levels are transient, with a 
new equilibrium quickly establishing. Furthermore, it should be taken into consideration
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that antibodies that recognize peripherally administered proteins, will likely also detect 
endogenous proteins. To distinguish peripherally administered proteins from endoge­
nous proteins and easily track distribution of an agent within the body, labeled versions 
of enoxaparin or aB-crystallin may be administered to mice. For example, 125I-labeled 
heparins are available, suggesting a similar labeling should be possible for enoxaparin. 
Of course, the size of the label should be carefully chosen, as it should not hamper the 
potential entry of enoxaparin or aB-crystallin into the brain.
For enoxaparin, several other mechanisms of action could be considered. For 
example, enoxaparin may have protected the brain by its ability to reduce Aß-induced 
complement activation and thus detrimental brain inflammation [20]. In the present stu­
dy we did not investigate complement activation, but this could be considered for future 
experiments, keeping in mind that not all components of the complement system be­
have as they do in humans (Chapter 5). Furthermore, as an anti-coagulant, enoxaparin 
may have acted on Aß and mouse cognition by altering perfusion of the brain. It would 
therefore be interesting to investigate cerebral blood flow and cerebral blood volume in 
transgenic, but also wildtype, mice treated with enoxaparin.
In conclusion, we describe in this thesis that HSPG have an important role in Aß patho­
logy. Not only are several HSPG upregulated by Aß, HSPG also influence Aß aggregation 
and Aß-induced cellular toxicity, with an important function for their sulfate moieties. Alt­
hough an AD mouse model may not fully replicate the repertoire of Aß-associated pro­
teins, we demonstrated that HSPG analogues (i.e. enoxaparin) may be useful as potential 
therapeutic agents. The co-deposition of sHsp in AD mouse models remains to be investi­
gated, but in any case, the use of aB-crystallin as a peripherally administered therapeutic 
agent was unsuccessful.
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De ziekte van Alzheimer en het amyloid ß eiwit
De ziekte van Alzheimer is een ouderdomsgerelateerde aandoening die in Nederland 
130.000 patiënten kent en wordt gekenmerkt door symptomen als geheugenverlies, apa­
thie en depressie. Er wordt geschat dat met de vergrijzing het aantal patiënten de komen­
de jaren zal groeien naar zeker 300.000, waarbij er in 2050 wereldwijd zelfs 100 miljoen 
Alzheimer patiënten zullen zijn. Een juiste diagnose en effectieve behandeling zijn daar­
om zeer belangrijk. Echter, het stellen van met name een vroegtijdige diagnose is tot op 
heden niet mogelijk. Bovendien zijn er momenteel slechts vijf goedgekeurde medicijnen. 
De meeste van deze medicijnen zijn gericht zijn op het verhinderen van de afbraak van de 
neurotransmitter acetylcholine. Alzheimer patiënten hebben namelijk minder acetylcho­
line, omdat als gevolg van de ziekte met name de cholinerge neuronen, die normaliter de 
neurotransmitter acetylcholine afgeven, worden aangetast. Met deze medicijnen worden 
echter alleen de symptomen van de ziekte behandeld en niet de oorzaken van de ziekte. 
Daarom blijft het van groot belang meer inzicht te krijgen in de pathologie van de ziekte 
van Alzheimer en gaat de zoektocht naar nieuwe medicijnen nog altijd voort.
Kenmerkend voor de hersenen van Alzheimer patiënten zijn ophopingen van het 
eiwit amyloid bèta (Aß). Deze ophopingen bevinden zich niet alleen tussen zenuwcellen 
(neuronen), als zogenaamde seniele plaques (SP), maar zitten ook rondom bloedvaten als 
zogenaamd cerebraal amyloid angiopathie (CAA). Bij Alzheimer patiënten gaat er door 
ouderdom iets mis met het opruimen van het Aß eiwit. Normaliter wordt Aß namelijk 
opgeruimd na productie, enerzijds door enzymen in de hersenen, anderzijds door trans­
port van Aß uit de hersenen naar de bloedsomloop. Wanneer deze processen verstoord 
zijn, kan het Aß eiwit samenklonteren (aggregeren) en ophopen in de hersenen. Hierbij 
aggregeren afzonderlijke (monomere) Aß eiwitten samen tot zogenaamde oligomeren 
bestaande uit 2 tot 20 monomere Aß eiwitten. Vervolgens ontstaan protofibrillen en fi­
brillen, steeds langere ketens van Aß eiwitten. Uiteindelijk kunnen deze fibrillen plaques 
en CAA vormen. Aggregatie van Aß kan ook het gevolg zijn van genetische mutaties in 
bijvoorbeeld het amyloid precursor eiwit (APP), maar dit verklaard slechts een klein per­
centage patiënten (<1%).
Heparan sulfaat proteoglycanen
Eerdere studies hebben aangetoond dat in plaques en CAA ook andere eiwitten ophopen, 
waaronder heparan sulfaat proteoglycanen (HSPG). Proteoglycanen bestaan uit een eiwit 
met daaraan lange gesulfateerde suikergroepen. Naast HSPG zijn er ook chondroitine sul­
faat, keratan sulfaat en dermatan sulfaat proteoglycanen. De vier verschillende proteogly­
canen onderscheiden zich in de opbouw van hun suikerketen; elke proteoglycaan bevat 
een unieke (herhalende) disaccharide unit. Er zijn ook nog eens verschillende HSPG, elk 
met een ander eiwit. Drie van deze HSPG zijn geassocieerd met de extracellulaire matrix 
tussen cellen (perlecan, agrine en collageen VXIII) en twee HSPG bevinden zich op het 
celoppervlak (glypican en syndecan).
Omdat al deze HSPG, en dan met name agrine en glypican-1, samen worden ge­
vonden met Aß, wordt aangenomen dat ze een interactie aangaan met het laatstgenoem­
de eiwit en een rol spelen bij de aggregatie van Aß. Om te bepalen of het omgekeerde 
ook het geval is, namelijk dat Aß ook invloed heeft op het ophopen van HSPG in onder 
meer CAA, hebben wij in hoofdstuk 2 gekeken of Aß de productie en de cellulaire locatie 
van agrine en glypican-1 kan beïnvloeden. Hierbij is gebruik gemaakt van pericyten, cel­
len die zich rondom bloedvaten bevinden en daarom een mogelijke bron van HSPG kun­
128
nen zijn in CAA. Het bleek dat Aß de eiwit en mRNA expressie van agrine en glypican-1 
kon verhogen en dat de geproduceerde HSPG geassocieerd waren met Aß fibrillen op 
het celoppervlak van de pericyten. Bovendien werden onder invloed van Aß meer sul- 
faatgroepen ingebouwd in de suikerketens van proteoglycanen, wat suggereert dat ook 
de opbouw van de suikerketens van HSPG door Aß kan worden beïnvloed. Dit laatste is 
een interessante bevinding aangezien eerder is aangetoond dat de sulfaatgroepen van 
belang zijn bij de invloed die HSPG hebben op de ophoping van Aß. Dit blijkt ook uit 
de experimenten beschreven in hoofdstuk 3, waarbij (deels) desulfateren van HSPG de 
stimulerende werking van HSPG op Aß aggregatie en de bescherming van HSPG tegen 
Aß-gei'nduceerde cellulaire toxiciteit kon wegnemen.
In hoofdstuk 3 is bovendien onderzocht in welke mate andere proteoglycanen, 
zoals chondroitine sulfaat, Aß aggregatie beïnvloeden. Hierbij bleek nogmaals dat de sul­
faatgroepen een bepalende rol spelen in het stimuleren van Aß aggregatie, aangezien de 
sterker gesulfateerde proteoglycanen aggregatie sterker bevorderden dan minder gesul- 
fateerde proteoglycanen. Tenslotte is gevonden dat in CAA, HSPG terug te vinden waren 
met verschillende patronen van sulfatering, wat wederom aangeeft dat de sulfaatgroe­
pen een belangrijke component zijn van HSPG als het gaat om Aß aggregatie.
Muismodellen en amyloid ß-geassocieerde eiwitten
Om meer te weten te komen over de ziekte van Alzheimer en nieuwe therapieën te tes­
ten, wordt veel gebruik gemaakt van muismodellen. Het is namelijk mogelijk om ook in 
de hersenen van muizen het Aß eiwit te laten aggregeren. Hiervoor moet dan wel een 
menselijk gen voor APP, met één of meerdere van de in mensen beschreven mutaties, aan 
het genoom van de muis worden toegevoegd. Als gevolg van de Aß aggregaten in hun 
hersenen, verslechterd bij veel van deze muismodellen het geheugen van de muizen, wat 
zich uit in een verstoord leergedrag.
Omdat bij de mens HSPG zo'n belangrijk onderdeel zijn van Aß aggregaten, wil­
den wij onderzoeken of een soortgelijke relatie tussen HSPG en Aß bestaat in een muis- 
model (hoofdstuk 4). Als model hebben wij gekozen voor APPswe/PS1dE9 muizen. Deze 
muizen brengen APP tot expressie met daarin de zogenaamde Zweedse mutatie (Swe). 
Deze mutatie zorgt ervoor dat Aß makkelijker uit het gemuteerde APP wordt geknipt dan 
wanneer de mutatie afwezig zou zijn. Bovendien wordt ook humaan preseniline-1 (PS1) 
tot expressie gebracht in deze muis, met een deletie in exon 9 (dE9). Dit eiwit is onderdeel 
van één van de secretases die Aß uit APP knipt. Gecombineerd zorgen deze genen ervoor 
dat Aß al vanaf een leeftijd van 4-6 maanden oud gaat aggregeren in de hersenen van 
deze muizen.
In hoofdstuk 4 beschrijven we dat, in tegenstelling tot bij de mens de Aß depo­
sities in APPswe/PS1dE9 muizen slechts beperkt geassocieerd zijn met HSPG. Bij nadere 
bestudering van de literatuur (hoofdstuk 5) bleek dat ook veel andere eiwitten die in de 
mens samen met Aß terug te vinden zijn, zoals complement factoren en acute fase eiwit­
ten, in verschillende muismodellen in mindere mate of zelfs helemaal niet terug te vinden 
zijn. Deze resultaten geven duidelijk aan dat de samenstelling van Aß aggregaten in muis­
modellen zeer kan verschillen van menselijke Aß aggregaten. Aangezien de samenstel­
ling van een Aß aggregaat mede bepaald hoe makkelijk het aggregaat te verwijderen is, 
verklaart dit verschil tussen muis en mens mogelijk waarom een behandeling in mensen 
soms andere resultaten geeft dan dezelfde behandeling in een muismodel.
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HSPG en het kleine heat shock eiwit aB-crystalline als medicatie voor de ziekte van 
Alzheimer
Omdat HSPG een belangrijke rol spelen bij Aß aggregatie, is er in hoofdstuk 6 onder­
zocht of HSPG ook als medicijn kunnen dienen. Hierbij is voor de behandeling gekozen 
om gebruik te maken van enoxaparine, een heparine met een laag moleculair gewicht. 
Heparines op hun beurt zijn sterk gesulfateerde varianten van HSPG. Enoxaparine wordt 
al gebruikt bij de behandeling van hart- en vaatziekten en het is aangetoond dat het in 
een muismodel voor de ziekte van Alzheimer (APP23 muis), bij behandeling op jonge leef­
tijd, het Aß gehalte in de hersenen kon verlagen. Om het effect van enoxaparine op Aß 
verder te onderzoeken en bovendien het effect op het leergedrag van muizen te bestu­
deren, hebben wij APPswe/PS1dE9 muizen van verschillende leeftijden 3 maanden lang 
behandeld met enoxaparine (hoofdstuk 6).
Wij vonden dat bij APPswe/PS1dE9 muizen, waarbij de behandeling met enoxa­
parine vroeg in het aggregatie proces (leeftijd van 5 maanden oud) startte, de hoeveel­
heid Aß40 in de hersenen daalde, zoals ook al werd waargenomen in APP23 muizen. 
Echter, in een intermediair (10 maanden oud) en laat (12 maanden oud) stadium van ag­
gregatie verhoogde enoxaparine juist de hoeveelheid (geaggregeerd) Aß in de hersenen. 
Dit laatste resultaat komt overeen met onze bevinding dat enoxaparine, wanneer het in 
direct contact komt met Aß, de aggregatie van Aß bevordert (hoofdstuk 6). Er wordt ech­
ter aangenomen dat enoxaparine niet rechtstreeks in de hersenen zijn werking heeft; de 
barrière die bestaat tussen bloed en hersenen belemmert namelijk de doorgang van veel 
grote moleculen. Wellicht is de bloed-hersen barrière in de oudere muizen beschadigd, 
wat het voor enoxaparine mogelijk maakt om de hersenen in te komen en aggregatie van 
Aß te bevorderen.
In de jongere muizen heeft enoxaparine mogelijk gewerkt als een zogenaamde 
perifere sink. Een molecuul dat als perifere sink werkt, kan het Aß gehalte in de hersenen 
namelijk doen dalen door te binden aan Aß dat circuleert in de bloedsomloop (perifere 
circulatie). Aß dat in het bloed gebonden is aan een ander molecuul kan makkelijker wor­
den herkend voor afbraak in perifere organen zoals de lever of de nieren. Deze afbraak 
verstoort vervolgens het evenwicht dat bestaat tussen het Aß gehalte in de hersenen en 
het bloed. Om dit evenwicht te herstellen zal Aß vanuit de hersenen het Aß gehalte in het 
bloed weer aanvullen met als gevolg dat het Aß gehalte van het brein lager wordt. Om 
meer informatie te krijgen over de werking van enoxaparine, zou dus ook het Aß gehalte 
in het bloed gemeten moeten worden. Het labelen van enoxaparine zou bovendien mo­
gelijk kunnen uitwijzen of enoxaparine de bloed-hersen barrière passeert. Onafhankelijk 
van het precieze mechanisme waarmee enoxaparine het Aß gehalte in de hersenen be- 
invloedt, is het opvallend dat enoxaparine-geïnduceerde veranderingen van Aß gepaard 
gingen met een verbetering van het leergedrag van de muizen. Dit duidt erop dat enoxa­
parine potentie heeft als medicijn voor de ziekte van Alzheimer.
Uit eerdere studies is gebleken dat niet alleen HSPG, maar ook kleine heat shock 
eiwitten ophopen met het Aß eiwit. Heat shock eiwitten zijn stresseiwitten die betrokken 
zijn bij de juiste vouwing van eiwitten en het is dan ook niet verwonderlijk dat ze een 
interactie aangaan met Aß. Het is gebleken dat met name het kleine heat shock eiwit 
aB-crystalline een sterke binding heeft met Aß, wat kan betekenen dat het mogelijk als 
perifere sink kan dienen. In hoofdstuk 7 is daarom, op een vergelijkbare manier als in 
hoofdstuk 6 voor enoxaparine, onderzocht of aB-crystalline de hoeveelheid Aß in de her­
senen van APPswe/PS1dE9 muizen kan beïnvloeden en het leergedrag van de muizen kan
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verbeteren. Hierbij is ook een ander muismodel behandeld met aB-crystalline, het TgSwDI 
model. In dit model, dat APP tot expressie brengt met de Zweedse (Sw), Nederlandse (D; 
Dutch) en Iowa (I) mutatie, aggregeert Aß voornamelijk in de bloedvaten. Het bleek dat 
aB-crystalline een kleine verhoging gaf van Aß in de hersenen van APPswe/PS1dE9 mui­
zen en een verlaging in de TgSwDI muizen. Het is bekend dat TgSwDI muizen geen trans­
port van Aß over de bloed-hersen barrière toelaten. Dit laatste resultaat duidt erop dat 
aB-crystalline mogelijk niet als perifere sink heeft gewerkt. Het aB-crystalline zelf is echter 
ook te groot voor transport over deze barrière; kortom het exacte werkingsmechanisme 
is ook hier nog onduidelijk. Echter, aangezien aB-crystalline geen verbetering gaf van het 
leergedrag van de APPswe/PS1dE9 of de TgSwDI muizen, lijkt het erop dat dit klein heat 
shock eiwit, in tegenstelling tot enoxaparine, geen potentie heeft als medicijn tegen de 
ziekte van Alzheimer.
Conclusie
In dit proefschrift wordt de rol van HSPG bij Aß aggregatie beschreven. Het is gebleken 
dat Aß de expressie van enkele van deze HSPG reguleert. HSPG beïnvloeden op hun beurt 
weer de aggregatie van Aß en de Aß-gei'nduceerde cellulaire toxiciteit, waarbij de sulfaat- 
groepen van groot belang blijken. En hoewel er in dit proefschrift wordt beschreven dat 
een muismodel voor de ziekte van Alzheimer geen compleet model is als het gaat om de 
co-depositie van factoren zoals HSPG, is er met behulp van het APPswe/PS1dE9 model 
wel aangetoond dat een analoog van HSPG, enoxaparine, potentie heeft om als medicijn 
te dienen in de behandeling voor de ziekte van Alzheimer. Perifeer toedienen van een 
klein heat shock eiwit zoals aB crystalline daarentegen heeft nauwelijks effect op Aß de­
positie en cognitie.
N
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Biologie. Haar drie onderzoeksstages lagen vervolgens allen binnen de neurobiologie. Zo 
onderzocht zij tijdens haar eerste stage bij de afdeling Medische Fysiologie te Groningen, 
de mogelijkheid om neuronale stamcellen in vitro tot oligodendrocyten te differentiëren 
voor de behandeling van multiple sclerose (begeleider: Dr. J.C.V.M. Copray en Prof. Dr. 
H.W.G.M Boddeke). Tijdens haar tweede stage in Groningen bij de afdeling Moleculaire 
Neurobiologie (begeleider: Dr. K. van der Borght en Prof. Dr. P.G.M. Luiten) onderzocht zij 
of neuronale stamcellen getransplanteerd konden worden in de hersenen van muizen. 
Tenslotte vertrok zij voor een derde stage naar de universiteit van Szeged in Hongarije 
waar zij op de afdelingen Anatomie en Fysiologie onderzoek deed naar het effect van 
diazoxide op ischemie bij ratten met een operatief opgelegde chronische cerebrale hypo- 
perfusie (begeleider: Dr. E. Farkas en prof. dr. F. Bari). Tijdens haar opleiding heeft Nienke 
bovendien meerdere student-assistentschappen gedaan, waaronder de begeleiding van 
practica anatomie en histologie voor eerste- en tweedejaars biologie studenten.
In april 2005 studeerde Nienke af in de richting Medische Biologie, waarna zij in septem­
ber 2005 begon aan haar promotie op de afdeling Neurologie van het Universitair Me­
disch Centrum St. Radboud te Nijmegen onder supervisie van promotor Prof. Dr. H.P.H. 
Kremer (afd. Neurologie, Groningen) en copromotoren Dr. Ir. M.M Verbeek (afd. Neuro­
logie, Nijmegen) en Dr. R.M.W. de Waal (afd. Pathologie, Nijmegen). Tijdens haar promo­
tie, beschreven in dit proefschrift, begeleidde zij meerdere studenten tijdens hun stage. 
Daarnaast presenteerde zij haar onderzoeksresultaten op verschillende (internationale) 
bijeenkomsten, in de vorm van posters en mondelinge presentaties.
Vanaf december 2009 is zij werkzaam als postdoc op het LeARN project (CTMM) onder be­
geleiding van Dr. Ir. M.M. Verbeek. Binnen dit project doet zij onderzoek naar glutamaat- 
gerelateerde metabolieten als potentiële biomarkers voor de ziekte van Alzheimer.
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Dankwoord
Nu de wetenschappelijke inhoud van dit boekje afgerond (en gelezen?) is, is het tijd 
voor het dankwoord. Ik hoop natuurlijk dat ik niemand ben vergeten, zo ja, dan zal ik 
overwegen een beetje van mijn eigen medicijn te gebruiken...
Ik wil dit dankwoord beginnen met Marcel en Rob, mijn beide co-promotoren. Beiden 
waren aanwezig bij mijn allereerste stappen in het promotieonderzoek, oftewel de 
sollicitatie, en nu ook bij de uiteindelijke promotie.
Marcel, jij was de co-promotor die voor de dagelijkse begeleiding zorgde. Ik heb je leren 
kennen als een gedreven persoon die het serieuze werk van onderzoeker combineert met 
een flinke dosis humor en sarcasme. Met name de vrijheid die je mij tijdens het werk gaf, 
en nog steeds geeft, heb ik altijd als zeer fijn ervaren. Bovendien ben je, ondanks je drukke 
schema, altijd makkelijk benaderbaar. Bedankt voor de goede samenwerking de afgelo­
pen jaren, wat mij betreft gaan we nog even op dezelfde voet door.
Rob, waarschijnlijk met name door de wat grotere fysieke afstand van onze werkplekken, 
hebben wij de afgelopen jaren eigenlijk met name contact gehad tijdens de wekelijkse 
werkbesprekingen. Bij deze besprekingen blijkt telkens weer je grote interesse in een 
breed scala aan onderwerpen, zowel binnen als buiten de wetenschap, wat de werkbe­
sprekingen altijd weer net iets interessanter maakt. Ook wil ik je bedanken voor je nauw­
keurige nakijkwerk van mijn artikelen. Jij bent altijd degene die tekstueel letterlijk de 
'puntjes op de i' zet.
Beste Berry, als promotor bent u pas laat bij mijn promotie betrokken geraakt. Ik waardeer 
het dan ook zeer dat u, zelfs nu u in Groningen werkt, nog bereid was om mij tijdens de 
laatste loodjes van mijn promotie te begeleiden. Daarvoor dan ook mijn dank.
Ilona, al een half jaartje nadat ik was begonnen, kwam jij bij ons in de groep 
en sindsdien hebben wij eigenlijk al onze promotiebeslommeringen gedeeld. Bij jou vond 
ik een klankbord voor de experimenten die ik wilde uitvoeren en het is fijn om te weten 
dat ik altijd bij je kan komen emmeren over van alles en nog wat (en vice versa!). Laten we 
ook buiten het werk om veel contact houden, onze etentjes en tripjes, naar steden als Den 
Bosch en Groningen, zijn namelijk altijd zeer gezellig! Ik vond het niet meer dan logisch 
om jou bij mijn promotiedag te betrekken als paranimf en ben blij dat jij deze taak wilt 
vervullen. Kun je alvast een klein beetje oefenen voor je eigen promotie.
Toen ik bij Marcel op het toenmalige lab Kindergeneeskunde en Neurologie begon 
te werken, was ik naast Micha de enige promovendus binnen de "Alzheimer groep" 
Inmiddels is onze groep flink uitgebreid en dit is de sfeer op ons lab, wat mij betreft, zeer 
ten goede gekomen. Bea, van jouw kennis op onderzoeksgebied kan ik nog veel opsteken 
en ik hoop dat we nog vaak ook buiten het werk om samen gaan eten en kletsen. Ik meen 
dat we nog steeds een keertje sushi gaan maken, kan niet wachten!
Inge, Kim, Megan en Mareike, als "nieuwe" aio's binnen onze groep wil ik jullie 
bedanken voor de gezelligheid op het lab én in de kantoortuin en jullie heel veel succes 
wensen met jullie eigen promoties. Alexandra, bedankt voor je hulp met het zuiveren van 
aB-crystalline. Helaas is ons artikel (nog) niet gepubliceerd, maar je staat als co-auteur in 
ieder geval wel in dit boekje.
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Voor mijn onderzoek heb ik veel samengewerkt met andere onderzoekers. Amanda en 
Ineke, zonder jullie input zouden veel van mijn muizen studies niet zijn uitgevoerd. 
Kortom, bedankt voor jullie muizen(kennis) en bijdrages aan dit proefschrift.
Bill, I want to thank you and your colleagues for providing us with the TgSwDI mouse 
model and the occasional protocol and suggestion. In the end, we hardly used the TgSwDI 
mice for the publications in this thesis, but we will continue to work with this model and 
hopefully produce some interesting articles in the near future.
Ook al mijn andere co-auteurs wil ik hier natuurlijk bedanken. Micha, bedankt dat je 
me op weg hebt geholpen als aio en ik hoop dat we (wetenschappelijk) contact blijven 
houden. Aan jouw werk wordt in ieder geval nog steeds gerefereerd en dan niet alleen op 
wetenschappelijk gebied; gevleugelde uitspraken als "dat is flut" en "lekker bezig" komen 
nog steeds wel eens langs.
Jack en Irene, ik wil jullie beiden bedanken voor de samenwerking. Jack, veel van jouw 
werk was de basis voor dit proefschrift en Irene, van jouw expertise op het gebied van 
amyloid ß en electronen microscopie heb ik veel profijt gehad. Tenslotte wil ik ook Joyce 
van Beers, Wilbert Boelens, Guido David en Toin van Kuppevelt nog bedanken voor hun 
bijdrage aan mijn onderzoek en de tijd die ze hebben gestoken in mijn artikelen.
Hoewel ik hoofdzakelijk werkzaam was bij de afdeling Kindergeneeskunde en 
Neurologie, heb ik ook andere afdelingen bezocht tijdens mijn promotie. Ik wil 
hierbij vooral de afdeling pathologie, en dan met name Ine, Kiek, Cathy en Riki, 
bedanken voor de gastvrijheid de afgelopen jaren. Niet alleen heb ik veel celkweek en 
immunohistochemie bij jullie kunnen uitvoeren, ook veel van mijn studenten hebben 
hun werk bij pathologie kunnen uitvoeren.
Hierbij kom ik automatisch op de volgende groep die ik wil bedanken, namelijk de 
studenten die ik heb mogen begeleiden. In chronologische volgorde waren dit: Jelle, 
Wan Ying, Samantha, Laura, Niek, Tom, Sharon, Jan-Willem en Mieke. Slechts een aantal 
van jullie staat als co-auteur op mijn artikelen vermeld, maar jullie hebben allemaal een 
belangrijke bijdrage geleverd aan mijn onderzoek. Speciale dank ook aan de studenten 
die zich dagen achter elkaar hebben opgesloten in de "gedragskamer" om voor mij de 
muizen te testen.
Mijn muizenwerk is vrijwel allemaal uitgevoerd op het CDL en hier werken dan ook veel 
mensen die hebben bijgedragen aan mijn onderzoek. Zo hebben de dierverzorgers van 
de afdeling VGD mijn muizen de afgelopen jaren goed verzorgt. Hierbij wil ik met name 
Henk noemen, mijn contactpersoon binnen het CDL. Henk, bedankt voor je hulp bij 
vrijwel alle praktische, en vaak ook administratieve, aspecten van het muizenwerk. Ik 
hoop dat onze samenwerking ook de komende tijd op dezelfde gezellige en efficiënte 
manier kan worden voortgezet.
Van al mijn collega's heb ik buiten het werk om nog het meest contact met Herman. 
Herman, ik wil je dan ook bedanken voor je "opvang" hier in Nijmegen, samen met jou 
heb ik deze, voor mij eerst vreemde, stad goed leren kennen. Onze etentjes, concert- en 
filmbezoeken zijn altijd gezellig en wat mij betreft blijven we deze uitstapjes gewoon 
doen. En natuurlijk moeten we ook blijven borrelen in "stamkroeg" de Mug, al dan niet 
samen met collega's waaronder Inge K., Francien en Marijke. Ook alle overige (oud-) 
collega's van Q en P hebben natuurlijk bijgedragen aan de goede sfeer die ik heb ervaren 
tijdens het werk, de koffiepauzes en de vele uitjes, daarvoor mijn dank! Hierbij wil ik ook
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nog een tweetal oud-collega's bij naam noemen; Mieke en Suus, ik hoop dat we contact 
kunnen blijven houden!
Carlijn, jou wil ik, als oud-collega binnen het Alzheimer veld, bedanken voor je 
gezelligheid en kordaatheid tijdens het genotyperen van de muizen en tijdens onze 
congresavonturen! Inmiddels werk je al weer even op het CDL, waar ik je helaas veel te 
weinig tegenkom. Hopelijk kunnen we af een toe nog een lunch inplannen.
Naast alle collega's wil ik graag ook een heel aantal mensen bedanken die misschien niet 
direct naast mij aan de labtafel werken, maar wel veel ontspanning brengen na het werk. 
Marleen, onze vakanties (en reizen!) door heel Europa en inmiddels ook Amerika, zijn 
altijd supergezellig. Dit is eigenlijk al zo vanaf de eerste nacht dat we een tent deelden, 
toen we elkaar nog maar nauwelijks kenden. Jij hebt inmiddels, als vaste reisgenoot en 
goede vriendin, veel van mijn werkperikelen meegekregen en ik ben dan ook heel blij dat 
je bij mijn promotie aanwezig bent.
Al in mijn eerste week van de opleiding Biologie in Groningen, kreeg ik contact met de 
"biologievrienden" (en inmiddels ook de aanhang) die ik nu nog steeds met wisselende 
regelmatigheid zie. Ciska, Eva, Willemien en Sonja, samen met Marleen hebben we al 
menig gezellig weekendje gehad en ik hoop dat we dit de komende jaren kunnen 
voortzetten. Nu Willemien in New York zit, wordt het tijd ons "Landal" gebied uit te 
breiden. En Cis en Son, bij deze wil ik jullie alvast heel veel succes wensen met jullie 
promoties!
Ook Peter, Melian, Douwe Jaap, Carmen, Arjen, Marloes, Janneke en Sander wil ik 
bedanken voor de gezellige etentjes/logeerfeestjes/filmpjes de afgelopen jaren. Ons 
contact is misschien niet meer zo regelmatig, maar ik hoop dat jullie bij mijn promotie 
kunnen zijn. Marte en Hiltje, ik hoop ook dat wij de komende jaren ons contact kunnen 
blijven onderhouden.
En dan wil ik natuurlijk ook mijn familie bedanken. We zijn maar met een klein clubje, 
maar wat mij betreft daarom juist best hecht. Met alle onderwijzers, bèta's en zelfs 
een analiste in de familie, kon het haast niet missen dat ik ben gaan promoveren in de 
neurobiologie. Helaas kan niet iedereen van de familie mijn promotie meemaken. Met 
name Gerda zou ik graag nog bedanken voor de interesse die ze altijd toonde voor mijn 
werk en de adviezen die ze mij tijdens mijn promotietijd heeft gegeven. Ik ben in ieder 
geval trots mijn promotiedag met (een deel) van mijn familie te mogen delen, waaronder 
Joke, Marja, Minke, Johan, Tanja, Egbert en Rienk.
Tenslotte mijn lieve ouders, "broertje" en schoonzus. Jan-Rienk, we zien elkaar 
helaas niet zo veel meer nu we niet meer samen in één huis wonen, maar ik vind 
het erg leuk dat jij mijn paranimf wilt zijn en dat jij je bovendien ook op mijn lay-out 
wilde storten. Samen met Henk (bedankt Henk!) hebben we er een mooi boekje van 
gemaakt. Overigens zou je zelf ook makkelijk kunnen promoveren, het discussiëren 
en kritisch denken gaat jou veel makkelijker af dan mij! Je wordt zelfs al een beetje 
een filosoof, maar kijk uit, om met Theo Maassen te spreken, filosofen zijn mensen die 
de hele dag nadenken over de zin van het leven. Ik weet niet wat de zin van het leven 
is, maar volgens mij in ieder geval niet om daar de hele dag over na te lopen denken.
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Chantal, als wij aan de lijn hangen of als ik op bezoek kom, is het altijd gezellig. Ook onze 
bezoekjes aan "Jim" musicals zijn inmiddels een traditie geworden die ik er graag in wil 
houden. Bij ons in de familie sta je bekend om je brede en goede kledingsmaak en ik heb 
hier al veel van mogen profiteren. Ik denk dus dat ik je bij voorbaat alvast mag bedanken 
voor de hulp bij het uitzoeken van mijn promotie garderobe.
Pap en mam, last but definitely not least, het klinkt waarschijnlijk cliché, maar ik had 
volgens mij geen betere ouders kunnen hebben. Pap, het is altijd weer leuk om met 
jou op pad te gaan in de weekenden en ik wil je bedanken voor alle klusjes die je altijd 
(ongevraagd) voor mij uitvoert. Mam, jij zag al een onderzoeker in mij toen ik dat nog 
helemaal niet zag. Ik hoop dat jij de komende jaren veel rust en plezier vindt in je eigen 
werkzaamheden. In ieder geval is het fijn om te weten dat ik altijd bij jullie terecht kan 
voor een babbeltje, advies, gezelligheid en een dosis noordelijke nuchterheid. Bedankt 
dat jullie mij door dik en dun steunen, dit boekje is dan ook voor jullie!
Nienke
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Chapter 1: Figure 1
Figure 1: Amyloid precursor protein (APP) processing involves proteolytic cleavage by several 
secretases (A). The non-amyloidogenicpathway is initiated by a-secretase cleavage, which oc­
curs in the middle of the amyloid ß (Aß) sequence (red), and results in the release of several 
soluble APP fragments. The amyloidogenic pathway releases Aß peptides through cleavage 
by a- and ß-secretases. (B) Part of the APP amino-acid sequence; mutations associated with 
early-onset Alzheimer's disease have been highlighted. Most mutations are clustered in the 
close vicinity of secretase-cleavage sites, thereby influencing APP processing, and are named 
after the nationality or location of the first family in which that specific mutation was demon­
strated. The Aß sequence is indicated in red. Reprinted with permission from Macmillan Publis­
hers Ltd:[Nature Reviews Drug Discovery][247], copyright (2006)
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Chapter 1: Figure 2
Figure 2: Amyloid ß (Aß) can exist in multiple assembly states — monomers, oligomers, proto­
fibrils and fibrils. In its monomeric state, Aß does not appear to be neurotoxic. By contrast, oli­
gomeric and protofibrillar species are considered potent blockers of long-term potentiation, a 
form of synaptic plasticity. Reprinted with permission from Macmillan Publishers Ltd: [Nature 
Reviews Neuroscience] [138], copyright (2007).
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Chapter 1: Figure 3
a Microglia mediated b Direct resolution c Peripheral sink
Figure 3: Three biological mechanisms that are not mutually exclusive have been proposed. 
Small amounts of anti-amyloid antibodies reach amyloid deposits in the brain and trigger a 
phagocytic response by microglia (A). Anti-amyloid antibodies reach amyloid deposits in the 
brain and resolve them directly through interaction of the antibody with the amyloid depo­
sit (B). Anti-amyloid antibodies act as a peripheral sink for soluble amyloid ß species, leading 
ultimately to the resolution of brain deposits by mass action (B). BBB, blood-brain barrier. Re­
printed with permission from Macmillan Publishers Ltd: [Nature Reviews Neuroscience] [46], 
copyright (2004).
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Chapter 2: Figure 1
Figure 1: Immunofluorescence staining of untreated (A, C) and DAß140-treated (B, D) HBP for 
agrin (A, B) and glypican-1 (C, D). Protein expression of both agrin and glypican-1 was incre­
ased after treatment. Original magnification 630x.
Chapter 3: Figure 5
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Figure 5: Immunofluorescent staining of confluent cultures of HBP incubated with DAß140 al­
one (A) or in combination with heparin (B). No obvious change in the association of Aß (40-4; 
red) with the cultured cells (Topro-3; blue nuclei) was visible when DAß140 was incubated with 
heparin. Magnification 630x. Scale bar: 1 mm
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Figure 10: Immunofluorescent staining of Thioflavin-S positive cortical vessels of an 
AD patient (A-E) with different phage display antibodies that recognize different HS sul­
fate motives (F-J). In K-O, Thioflavin-S and HS staining is merged. Vessels with fibril­
lar Aß deposits were positive for most antibodies (K-N), but negative for RB4EA12 (O). 
Original magnification 630x.
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Chapter 4: Figures 1C and 1D
15 months
Figure 1: The average Aß plaque number (±S.E.M.) increased with age in the APPswe/PS1dE9 
mouse model (A), whereas the average number of Aß-positive blood vessels (±S.E.M.) was low 
(B), except in the 18-month-old mice. Sagittal sections (5 pm) of mice aged 5 months (C) or 15 
months (D) were stained for Aß using the 6C6 antibody and plaques and Aß-positive vessels 
were counted in 8 sections per mouse. (A) * p<0.05 compared to 5 months old. A p<0.05 com­
pared to 8 months old. (B) * p<0.05 compared to all other groups. Magnification 200x.
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Chapter 4: Figures 2C, 2D and 2E
Figure 2: Percentage of plaques positive for HS GAG (A) and glypican-1 (B). At and above the 
age of 8 months, the number of HS GAG-positive plaques increased with age (A). However, in 
5-month-old mice there was more HS GAG (29%) co-deposition with Aß than in 8-month-old 
mice (18%) but this was not significant (p>0.05). The number of glypican-1 positive plaques 
was low and remained constant with increasing age (B). Immunohistochemical analysis (C­
E) of a 15-month-old mouse demonstrated HS GAG and glypican-1 positive plaques (open 
arrows). An Aß-negative vessel was positive for HS-GAG (short closed arrow; D) and an Aß­
positive vessel (long closed arrow) was positive for both HS GAG (D) and glypican-1 (E). The 
inset (E) shows a glial cell positive for glypican-1 (arrowhead). Magnification 200x; magnifi­
cation inset 400x.
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Chapter 4: Figures 3A, 3B and 3C
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Figure 3: Aß40- (A) and Aß42-positive (B) plaques and co-deposition with HS GAG (C) in a 
15-month-old APPswe/PS1dE9 mouse. Aß42-positive plaques were more numerous than 
Aß40-positive plaques. All Aß40-positive plaques were positive for Aß42. HS GAG staining 
could be observed in both Aß42- and Aß40-containing plaques (open arrows).
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Chapter 4: Figures 4C, 4D, 4E, 4F, 4G and 4H
Figure 4: Percentage of plaques positive for agrin (A) and perlecan (B). The number of agrin and 
perlecan positive plaques is very low (<10%). Immunohistochemical analysis of an 18-month- 
old mouse (C-E) demonstrated agrin-positive (open arrows in D) and perlecan-negative pla­
ques (E). Aß-positive vessels (long closed arrows; F) were positive for agrin (G) and perlecan (H). 
Normal vessels unaffected by Aß deposition were also stained by antibodies against agrin and 
perlecan (short closed arrows in C-E). Magnification 200x.
Chapter 8: Figure 1
Figure 1: The peripheral sink hypothesis. Peripherally administered Aß-binding agents bind 
Aß with high affinity in the plasma. These complexes, in turn, become targeted for degrada­
tion in organs such as the liver. This peripheral degradation depletes the plasma pool of Aß, 
triggering an efflux of Aß from the brain to the blood.
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